To O
investigate O
whether O
the O
tumor O
expression O
of O
beta B
- I
2 I
- I
microglobulin I
( O
beta B
2 I
- I
M I
) O
could O
serve O
as O
a O
marker O
of O
tumor O
biologic O
behavior O
, O
the O
authors O
studied O
specimens O
of O
breast O
carcinomas O
from O
60 O
consecutive O
female O
patients O
. O

Presence O
of O
beta B
2 I
- I
M I
was O
analyzed O
by O
immunohistochemistry O
. O

Likewise O
, O
beta B
2 I
- I
M I
was O
not O
associated O
with O
markers O
of O
disease O
extension O
such O
as O
TNM O
, O
( O
UICC O
, O
classification O
of O
malignant O
tumors O
) O
staging O
and O
axillary O
lymph O
node O
involvement O
or O
with O
estrogen O
, O
progesterone O
, O
and O
glucocorticoid O
receptor O
levels O
. O

Beta B
2 I
- I
M I
serum O
levels O
were O
determined O
by O
an O
enzyme O
- O
linked O
immunosorbent O
assay O
in O
samples O
from O
22 O
of O
the O
above O
women O
. O

Although O
some O
of O
the O
highest O
values O
had O
been O
obtained O
in O
women O
with O
larger O
( O
T4 O
) O
primary O
tumors O
, O
the O
authors O
failed O
to O
detect O
any O
statistical O
relationship O
between O
beta B
2 I
- I
M I
expression O
in O
the O
tumor O
with O
serum O
levels O
or O
between O
serum B
beta I
2 I
- I
M I
and O
the O
above O
histologic O
, O
laboratory O
, O
and O
clinical O
factors O
. O

In O
137 O
cases O
of O
childbearing O
- O
aged O
and O
pregnant O
women O
, O
free B
form I
E I
receptor I
levels O
( O
sE B
) O
in O
serum O
were O
measured O
by O
ELISA O
. O

Mutation O
of O
a O
kappa B
B I
core I
sequence I
identified O
in O
the O
IL B
- I
2 I
promoter I
( O
- O
206 O
to O
- O
195 O
) O
partially O
inhibits O
both O
mitogen O
- O
and O
HTLV O
- O
I O
Tax O
- O
mediated O
activation O
of O
this O
transcription B
unit I
and O
blocks O
the O
specific O
binding O
of O
two O
inducible B
cellular I
factors I
. O

Mutation O
of O
a O
kappa B
B I
core I
sequence I
identified O
in O
the O
IL B
- I
2 I
promoter I
( O
- O
206 O
to O
- O
195 O
) O
partially O
inhibits O
both O
mitogen O
- O
and O
HTLV O
- O
I O
Tax O
- O
mediated O
activation O
of O
this O
transcription B
unit I
and O
blocks O
the O
specific O
binding O
of O
two O
inducible B
cellular I
factors I
. O

Novel O
region O
within O
the O
V B
kappa I
gene I
promoter I
is O
responsible O
for O
tissue O
and O
stage O
- O
specific O
expression O
of O
immunoglobulin B
genes I
in O
human O
lymphoid O
neoplasms O
. O

Different O
fragments O
of O
unrearranged B
human I
variable I
region I
of O
immunoglobulin B
kappa I
gene I
( O
V B
kappa I
) O
were O
used O
for O
cell O
- O
free O
in O
vitro O
transcription O
and O
DNA O
mobility O
shift O
assays O
. O

Previously O
described O
enhancement O
of O
in O
vitro O
transcription O
that O
was O
only O
seen O
with O
nuclear O
extracts O
derived O
from O
B O
- O
cell O
neoplasms O
corresponding O
to O
the O
late O
stages O
of O
B O
- O
cell O
differentiation O
was O
shown O
to O
be O
dependent O
on O
the O
actions O
of O
these O
factor O
( O
s O
) O
on O
the O
DNA O
region O
within O
the O
V B
kappa I
gene I
promoter I
. O

Octamer B
- I
binding I
proteins I
from O
B O
or O
HeLa O
cells O
stimulate O
transcription O
of O
the O
immunoglobulin B
heavy I
- I
chain I
promoter I
in O
vitro O
. O

The O
B O
- O
cell O
- O
type O
specificity O
of O
the O
immunoglobulin B
( O
Ig B
) O
heavy O
- O
chain O
and O
light O
- O
chain O
promoters O
is O
mediated O
by O
an O
octanucleotide B
( I
OCTA I
) I
element I
, O
ATGCAAAT O
, O
that O
is O
also O
a O
functional O
component O
of O
other O
RNA B
polymerase I
II I
promoters I
, O
such O
as O
snRNA O
and O
histone O
H2B O
promoters O
. O

This O
suggests O
that O
the O
constitutive O
OCTA B
- I
binding I
factor I
NF I
- I
A1 I
can O
activate O
transcription O
of O
the O
Ig B
promoter I
and O
that O
B O
- O
cell O
- O
specific O
transcription O
of O
this O
promoter O
, O
at O
least O
in O
vitro O
, O
is O
partially O
due O
to O
a O
quantitative O
difference O
in O
the O
amount O
of O
OCTA B
- I
binding I
protein I
. O

This O
complex O
appeared O
10 O
to O
25 O
minutes O
before O
the O
activation O
of O
the O
IL B
- I
2 I
gene I
. O

Studies O
with O
inhibitors O
of O
protein O
synthesis O
indicated O
that O
the O
time O
of O
synthesis O
of O
the O
activator O
of O
the O
IL B
- I
2 I
gene I
in O
Jurkat O
T O
cells O
corresponds O
to O
the O
time O
of O
appearance O
of O
NFAT B
- I
1 I
. O

These O
characteristics O
suggest O
that O
NFAT B
- I
1 I
transmits O
signals O
initiated O
at O
the O
T B
cell I
antigen I
receptor I
. O

In O
whole O
cell O
experiments O
at O
37 O
degrees O
C O
, O
nuclear O
binding O
of O
[ B
125I I
] I
T3 I
was O
saturable O
( O
Kd O
34 O
+ O
/ O
- O
6 O
pmol O
/ O
l O
) O
and O
of O
finite O
capacity O
( O
approximately O
equal O
to O
350 O
sites O
/ O
cell O
) O
. O

Separation O
of O
bound O
from O
free O
[ B
125I I
] I
T3 I
in O
the O
extracts O
was O
achieved O
using O
the O
calcium O
phosphate O
matrix O
, O
hydroxyapatite O
at O
a O
concentration O
of O
0 O
. O
3 O
ml O
of O
a O
150 O
g O
/ O
l O
slurry O
. O

Definition O
of O
T B
- I
cell I
specific I
DNA I
- I
binding I
factors I
that O
interact O
with O
a O
3 B
' I
- I
silencer I
in O
the O
CD4 B
+ I
T I
- I
cell I
gene I
Rpt I
- I
1 I
. O

Analysis O
of O
the O
region O
3 O
' O
to O
the O
CD4 B
+ I
T I
- I
cell I
gene I
Rpt I
- I
1 I
( O
encoding O
regulatory O
protein O
T B
- I
lymphocyte I
1 I
) O
led O
to O
the O
definition O
of O
a O
silencer B
element I
that O
inhibits O
heterologous B
gene I
expression O
in O
certain O
CD4 O
+ O
T O
- O
cell O
lines O
but O
not O
in O
B O
- O
cell O
or O
non O
- O
lymphoid O
cell O
lines O
. O

We O
discuss O
the O
possibility O
that O
DNA B
- I
binding I
factors I
may O
coregulate O
HIV O
- O
1 O
and O
Rpt O
- O
1 O
gene O
expression O
through O
a O
common O
transcriptional B
silencer I
element I
. O

Congenital O
immunodeficiencies O
associated O
with O
absence O
of O
HLA B
class I
II I
antigens I
on O
lymphocytes O
result O
from O
distinct O
mutations O
in O
trans B
- I
acting I
factors I
. O

Congenital O
immunodeficiencies O
associated O
with O
absence O
of O
HLA B
class I
II I
antigens I
on O
lymphocytes O
result O
from O
distinct O
mutations O
in O
trans B
- I
acting I
factors I
. O

Coordinate O
regulation O
of O
HLA B
class I
II I
gene I
expression O
during O
development O
and O
coinduction O
of O
class B
II I
genes I
by O
soluble B
factors I
suggests O
that O
common O
trans B
- I
acting I
factor I
( O
s O
) O
control O
expression O
of O
these O
genes O
. O

Coordinate O
regulation O
of O
HLA B
class I
II I
gene I
expression O
during O
development O
and O
coinduction O
of O
class B
II I
genes I
by O
soluble B
factors I
suggests O
that O
common O
trans B
- I
acting I
factor I
( O
s O
) O
control O
expression O
of O
these O
genes O
. O

In O
addition O
, O
we O
report O
the O
identification O
of O
two O
discrete O
complexes O
, O
NFX1 B
. I
1 I
and O
NFX1 B
. I
2 I
, O
that O
bind O
to O
the O
DRA B
X I
consensus I
element I
. O

Identification O
and O
purification O
of O
a O
human B
immunoglobulin I
- I
enhancer I
- I
binding I
protein I
( O
NF B
- I
kappa I
B I
) O
that O
activates O
transcription O
from O
a O
human B
immunodeficiency I
virus I
type I
1 I
promoter I
in O
vitro O
. O

The O
enhancer B
- I
binding I
factor I
NF I
- I
kappa I
B I
, O
which O
is O
found O
only O
in O
cells O
that O
transcribe O
immunoglobulin B
light I
chain I
genes I
, O
has O
been O
purified O
from O
nuclear O
extracts O
of O
Namalwa O
cells O
( O
human O
Burkitt O
lymphoma O
cells O
) O
by O
sequence O
- O
specific O
DNA O
affinity O
chromatography O
. O

The O
purified O
NF B
- I
kappa I
B I
has O
been O
identified O
as O
a O
51 B
- I
kDa I
polypeptide I
by O
UV O
- O
crosslinking O
analysis O
. O

The O
purified O
NF B
- I
kappa I
B I
has O
been O
identified O
as O
a O
51 B
- I
kDa I
polypeptide I
by O
UV O
- O
crosslinking O
analysis O
. O

` O
` O
Footprint O
' O
' O
and O
methylation O
- O
interference O
analyses O
have O
shown O
that O
purified O
NF B
- I
kappa I
B I
has O
a O
binding O
activity O
specific O
for O
the O
kappa B
light I
chain I
enhancer I
sequence I
. O

This O
B B
cell I
- I
specific I
octamer I
- I
binding I
factor I
, O
in O
pure O
form O
, O
activated O
transcription O
from O
a O
kappa B
light I
chain I
promoter I
in O
vitro O
, O
thus O
demonstrating O
that O
it O
is O
indeed O
a O
B B
cell I
- I
specific I
transcription I
factor I
for O
this O
gene O
. O

Decreased O
deoxyribonucleic O
acid O
binding O
of O
glucocorticoid B
- I
receptor I
complex I
in O
cultured O
skin O
fibroblasts O
from O
a O
patient O
with O
the O
glucocorticoid O
resistance O
syndrome O
. O

Data O
obtained O
with O
the O
use O
of O
antiglucocorticoids O
and O
the O
anti B
- I
CBG I
antibody I
are O
compatible O
with O
a O
role O
both O
of O
high O
- O
affinity O
glucocorticoid B
receptors I
and O
of O
CBG B
in O
mediating O
cortisol O
action O
on O
the O
human O
NK O
cell O
activity O
. O

Octamer B
- I
containing I
fragments I
have O
been O
reported O
to O
bind O
a O
factor O
present O
in O
nuclear O
extracts O
of O
human O
cell O
lines O
; O
however O
, O
identical O
binding O
activity O
was O
detected O
in O
both O
B O
lymphoid O
and O
non O
- O
lymphoid O
cells O
. O

Here O
we O
establish O
that O
nuclear O
extracts O
from O
distinct O
cell O
types O
differ O
in O
their O
ability O
to O
interact O
with O
octamer B
- I
containing I
fragments I
. O

Preferential O
transcription O
of O
HTLV B
- I
I I
LTR I
in O
cell O
- O
free O
extracts O
of O
human O
T O
cells O
producing O
HTLV B
- I
I I
viral I
proteins I
. O

The O
promoters B
of O
the O
adenovirus B
2 I
major I
late I
gene I
, O
the O
mouse B
beta I
- I
globin I
gene I
, O
the O
mouse B
immunoglobulin I
VH I
gene I
and O
the O
LTR B
of O
the O
human O
T O
- O
lymphotropic O
retrovirus O
type O
I O
were O
tested O
for O
their O
transcription O
activities O
in O
cell O
- O
free O
extracts O
of O
four O
cell O
lines O
; O
HeLa O
, O
CESS O
( O
Epstein O
- O
Barr O
virus O
- O
transformed O
human O
B O
cell O
line O
) O
, O
MT O
- O
1 O
( O
HTLV O
- O
I O
- O
infected O
human O
T O
cell O
line O
without O
viral O
protein O
synthesis O
) O
, O
and O
MT O
- O
2 O
( O
HTLV O
- O
I O
- O
infected O
human O

The O
results O
agree O
well O
with O
the O
previous O
in O
vivo O
studies O
on O
the O
promoter O
activity O
of O
HTLV B
- I
I I
LTR I
. O

Trans B
- I
acting I
factors I
that O
mediate O
B O
- O
cell O
specific O
transcription O
of O
immunoglobulin B
genes I
have O
been O
postulated O
based O
on O
an O
analysis O
of O
the O
expression O
of O
exogenously O
introduced O
immunoglobulin B
gene I
recombinants I
in O
lymphoid O
and O
non O
- O
lymphoid O
cells O
. O

EKLF B
is O
required O
for O
integrity O
of O
the O
chromatin O
structure O
at O
the O
beta B
- I
like I
globin I
locus I
, O
and O
it O
interacts O
with O
a O
positive B
- I
acting I
factor I
in O
vivo O
. O

The O
functional O
effects O
of O
these O
interactions O
are O
that O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
enhance O
EKLF B
' O
s O
transcriptional O
activation O
of O
the O
beta B
- I
globin I
promoter I
in O
erythroid O
cells O
. O

Expression O
cloning O
with O
this O
region O
of O
DNA O
now O
shows O
that O
tegument B
protein I
VP22 B
and O
the O
viral B
dUTPase I
, O
encoded O
by O
genes B
UL49 I
and I
UL50 I
, O
respectively O
, O
are O
T B
- I
cell I
antigens I
. O

Expression O
cloning O
with O
this O
region O
of O
DNA O
now O
shows O
that O
tegument B
protein I
VP22 B
and O
the O
viral B
dUTPase I
, O
encoded O
by O
genes B
UL49 I
and I
UL50 I
, O
respectively O
, O
are O
T B
- I
cell I
antigens I
. O

These O
results O
suggest O
that O
herpes B
simplex I
tegument I
proteins I
are O
processed O
for O
antigen O
presentation O
in O
vivo O
and O
are O
possible O
candidate O
compounds O
for O
herpes O
simplex O
vaccines O
. O

U937 O
cells O
differentiated O
with O
PMA O
in O
nonadherent O
culture O
were O
shown O
to O
express O
two O
fibrinogen B
- I
binding I
integrins I
, O
predominately O
CD11b B
/ I
CD18 I
, O
and O
to O
a O
lesser O
extent O
, O
CD11c B
/ I
CD18 I
. O

NF B
- I
kappa I
B I
activation O
, O
minimal O
in O
unstimulated O
cells O
, O
was O
substantially O
up O
- O
regulated O
by O
fibrinogen B
. O

Blocking O
mAbs B
against O
CD18 B
and O
CD11b B
abrogated O
fibrinogen B
- O
induced O
NF B
- I
kappa I
B I
activation O
. O

To O
determine O
the O
effects O
on O
transcriptional O
regulation O
, O
U937 O
cells O
were O
transfected O
with O
a O
plasmid O
containing O
the O
HIV B
- I
1 I
enhancer I
( O
bearing O
two O
NF B
- I
kappa I
B I
sites I
) O
coupled O
to O
a O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
reporter I
. O

We O
conclude O
that O
contact O
with O
fibrinogen B
- I
derived I
proteins I
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b B
/ I
CD18 I
, O
resulting O
in O
selective O
activation O
of O
transcriptional B
regulatory I
factors I
, O
including O
NF B
- I
kappa I
B I
. O

We O
conclude O
that O
contact O
with O
fibrinogen B
- I
derived I
proteins I
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b B
/ I
CD18 I
, O
resulting O
in O
selective O
activation O
of O
transcriptional B
regulatory I
factors I
, O
including O
NF B
- I
kappa I
B I
. O

Partial O
sequences O
from O
exons B
1 I
- I
8 I
were O
nearly O
identical O
to O
the O
published O
sequence O
of O
the O
human B
ER I
mRNA I
. O

CONCLUSION O
: O
Monocytes O
, O
T O
cells O
, O
and O
B O
cells O
in O
patients O
express O
transcripts O
of O
the O
normal O
wild B
type I
ER I
and O
the O
hormone B
binding I
domain I
variants I
in O
vivo O
. O

DNA O
damaging O
agents O
induce O
expression O
of O
Fas B
ligand I
and O
subsequent O
apoptosis O
in O
T O
lymphocytes O
via O
the O
activation O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
. O

Thus O
, O
activation O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
contributes O
to O
stress O
- O
induced O
apoptosis O
via O
the O
expression O
of O
FasL B
. O

Minimal O
residual O
disease O
in O
acute O
myelogenous O
leukemia O
with O
PML B
/ I
RAR I
alpha I
or O
AML1 B
/ I
ETO I
mRNA I
and O
phenotypic O
analysis O
of O
possible O
T O
and O
natural O
killer O
cells O
in O
bone O
marrow O
. O

Minimal O
residual O
disease O
in O
acute O
myelogenous O
leukemia O
with O
PML B
/ I
RAR I
alpha I
or O
AML1 B
/ I
ETO I
mRNA I
and O
phenotypic O
analysis O
of O
possible O
T O
and O
natural O
killer O
cells O
in O
bone O
marrow O
. O

Here O
we O
studied O
minimal O
residual O
disease O
( O
MRD O
) O
of O
patients O
with O
acute O
myeloid O
leukemia O
( O
AML O
) O
who O
have O
PML B
/ I
RAR I
alpha I
or O
AML1 B
/ I
ETO I
as O
well O
as O
the O
phenotypic O
analysis O
of O
lymphocyte O
subsets O
involved O
in O
antitumor O
immunity O
. O

Using O
the O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
( O
RT O
) O
assay O
, O
the O
limit O
of O
detection O
was O
10 O
( O
- O
5 O
) O
to O
10 O
( O
- O
6 O
) O
for O
PML B
/ I
RAR I
alpha I
transcript I
and O
10 O
( O
- O
4 O
) O
to O
10 O
( O
- O
5 O
) O
for O
the O
AML1 B
/ I
ETO I
transcript I
. O

Using O
the O
1G5 O
cell O
line O
harbouring O
the O
luciferase O
reporter O
gene O
under O
the O
control O
of O
the O
HIV B
- I
1 I
LTR I
, O
it O
was O
first O
found O
that O
culture O
protein O
filtrates O
( O
CFP O
) O
from O
M O
. O
tuberculosis O
or O
purified O
ManLAM O
could O
activate O
HIV B
- I
1 I
LTR I
- I
dependent I
gene I
expression O
unlike O
similarly O
prepared O
CFP O
extracts O
devoid O
of O
ManLAM O
. O

Finally O
, O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV O
- O
1 O
LTR O
transcription O
was O
found O
to O
be O
independent O
of O
the O
autocrine O
or O
paracrine O
action O
of O
endogenous B
TNF I
- I
alpha I
. O

To O
gain O
a O
better O
understanding O
of O
the O
impact O
of O
long B
terminal I
repeat I
( O
LTR B
) O
sequence O
diversity O
on O
LTR B
- I
directed I
gene I
expression O
in O
cells O
of O
the O
central O
nervous O
system O
( O
CNS O
) O
and O
immune O
system O
, O
we O
amplified O
and O
cloned O
LTRs B
from O
proviral O
DNA O
in O
HIV O
- O
1 O
- O
infected O
peripheral O
blood O
. O

Differences O
in O
LTR B
sequence I
also O
resulted O
in O
differences O
in O
transcription O
factor O
recruitment O
to O
cis B
- I
acting I
sites I
within O
the O
U3 B
region I
of O
the O
LTR B
, O
as O
demonstrated O
by O
electrophoretic O
mobility O
shift O
assays O
. O

In O
particular O
, O
naturally O
occurring O
sequence O
variation O
impacted O
transcription B
factor I
binding O
to O
an O
activating B
transcription I
factor I
/ O
cAMP B
response I
element I
binding I
( O
ATF B
/ O
CREB B
) O
binding O
site O
( O
located O
between O
the O
LEF B
- I
1 I
and I
distal I
NF I
- I
kappaB I
transcription I
factor I
binding I
sites I
) O
that O
we O
identified O
in O
previous O
studies O
of O
the O
HIV B
- I
1 I
LTR I
. O

In O
particular O
, O
naturally O
occurring O
sequence O
variation O
impacted O
transcription B
factor I
binding O
to O
an O
activating B
transcription I
factor I
/ O
cAMP B
response I
element I
binding I
( O
ATF B
/ O
CREB B
) O
binding O
site O
( O
located O
between O
the O
LEF B
- I
1 I
and I
distal I
NF I
- I
kappaB I
transcription I
factor I
binding I
sites I
) O
that O
we O
identified O
in O
previous O
studies O
of O
the O
HIV B
- I
1 I
LTR I
. O

TCF B
/ I
LEF I
proteins I
have O
recently O
been O
found O
to O
constitute O
a O
downstream O
component O
of O
the O
Wingless O
/ O
Wnt O
signal O
transduction O
pathway O
. O

Transcriptional O
regulation O
of O
the O
gene O
for O
the O
myeloid B
calcium I
binding I
protein I
, O
MRP14 B
, O
was O
investigated O
in O
human O
monocytic O
leukemia O
cell O
lines O
. O

Among O
several O
known O
transcription B
factor I
binding I
motifs I
, O
nuclear B
protein I
( I
s I
) I
of O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
bound O
to O
the O
CCAAT B
/ I
enhancer I
binding I
protein I
( I
C I
/ I
EBP I
) I
- I
binding I
motif I
that O
was O
located O
in O
the O
upstream B
region I
of O
the O
MRP14 B
gene I
( O
- O
81 O
) O
, O
as O
evidenced O
by O
the O
competitive O
gel O
mobility O
- O
shift O
assay O
. O

An O
antibody O
for O
C B
/ I
EBP I
alpha I
super O
- O
shifted O
the O
nucleoprotein B
complex I
in O
THP O
- O
1 O
cells O
but O
not O
in O
the O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
, O
whereas O
an O
antibody O
for O
C B
/ I
EBP I
beta I
blocked O
the O
formation O
of O
the O
complex O
with O
the O
nuclear B
factor I
of O
the O
HL O
- O
60 O
cells O
but O
not O
with O
that O
of O
THP O
- O
1 O
cells O
. O

An O
antibody O
for O
C B
/ I
EBP I
alpha I
super O
- O
shifted O
the O
nucleoprotein B
complex I
in O
THP O
- O
1 O
cells O
but O
not O
in O
the O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
, O
whereas O
an O
antibody O
for O
C B
/ I
EBP I
beta I
blocked O
the O
formation O
of O
the O
complex O
with O
the O
nuclear B
factor I
of O
the O
HL O
- O
60 O
cells O
but O
not O
with O
that O
of O
THP O
- O
1 O
cells O
. O

Thus O
, O
it O
was O
concluded O
that O
C B
/ I
EBP I
alpha I
and I
- I
beta I
were O
able O
to O
bind O
to O
the O
C B
/ I
EBP I
motif I
, O
and O
that O
C B
/ I
EBP I
alpha I
bound O
to O
the O
motif O
in O
THP O
- O
1 O
cells O
and O
C B
/ I
EBP I
beta I
bound O
to O
that O
in O
the O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
. O

Thus O
, O
it O
was O
concluded O
that O
C B
/ I
EBP I
alpha I
and I
- I
beta I
were O
able O
to O
bind O
to O
the O
C B
/ I
EBP I
motif I
, O
and O
that O
C B
/ I
EBP I
alpha I
bound O
to O
the O
motif O
in O
THP O
- O
1 O
cells O
and O
C B
/ I
EBP I
beta I
bound O
to O
that O
in O
the O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
. O

Thus O
, O
it O
was O
concluded O
that O
C B
/ I
EBP I
alpha I
and I
- I
beta I
were O
able O
to O
bind O
to O
the O
C B
/ I
EBP I
motif I
, O
and O
that O
C B
/ I
EBP I
alpha I
bound O
to O
the O
motif O
in O
THP O
- O
1 O
cells O
and O
C B
/ I
EBP I
beta I
bound O
to O
that O
in O
the O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
. O

Furthermore O
, O
to O
examine O
the O
transcriptional O
activity O
of O
the O
C B
/ I
EBP I
motif I
, O
we O
transfected O
several O
constructed O
luciferase B
reporter I
DNAs I
into O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
. O

The O
luciferase O
activity O
of O
the O
C B
/ I
EBP I
motif I
in O
HL O
- O
60 O
cells O
was O
increased O
by O
VD3 O
treatment O
. O

The O
C B
/ I
EBP I
motif I
in O
the O
MRP14 B
gene I
was O
confirmed O
to O
function O
as O
a O
regulatory O
region O
in O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
by O
the O
assay O
. O

Since O
C B
/ I
EBP I
beta I
was O
also O
detected O
in O
VD3 O
- O
untreated O
HL O
- O
60 O
cells O
by O
immunoblotting O
, O
VD3 O
activated O
C B
/ I
EBP I
beta I
to O
bind O
to O
the O
motif O
, O
probably O
through O
post O
- O
translational O
modification O
. O

Since O
C B
/ I
EBP I
beta I
was O
also O
detected O
in O
VD3 O
- O
untreated O
HL O
- O
60 O
cells O
by O
immunoblotting O
, O
VD3 O
activated O
C B
/ I
EBP I
beta I
to O
bind O
to O
the O
motif O
, O
probably O
through O
post O
- O
translational O
modification O
. O

Appropriate O
sized O
transcripts B
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A B
, O
CYP17 B
, O
HSD11L B
( O
11beta B
- I
hydroxysteroid I
dehydrogenase I
I I
) O
, O
HSD17B1 B
( O
17beta B
- I
hydroxysteroid I
dehydrogenase I
type I
I I
) O
and O
SRD5A1 B
( O
5alpha B
- I
reductase I
I I
) O
. O

Corresponding O
enzymatic O
activity O
was O
detectable O
only O
for O
17 B
- I
hydroxysteroid I
dehydrogenase I
and O
5alpha B
- I
reductase I
, O
respectively O
producing O
testosterone O
and O
5alpha O
- O
dihydrotestosterone O
. O

Here O
we O
report O
for O
the O
first O
time O
that O
the O
PCD B
/ I
DCoH I
mRNA I
is O
present O
in O
human O
white O
blood O
cells O
and O
hair O
follicles O
. O

The O
NF B
- I
Y I
complex I
derived O
from O
class O
II O
+ O
mature O
B O
- O
cells O
bound O
with O
high O
affinity O
to O
anion B
exchangers I
, O
and O
eluted O
as O
an O
intact O
trimeric B
complex I
, O
whereas O
, O
NF B
- I
Y I
derived O
from O
class O
II O
- O
plasma O
B O
- O
cells O
, O
and O
from O
bare O
lymphocyte O
syndrome O
group O
II O
cell O
lines O
, O
RJ2 O
. O
2 O
. O
5 O
and O
RM3 O
, O
dissociated O
into O
discrete O
NF B
- I
YA I
and O
NF B
- I
YB I
: I
C I
subunit B
fractions I
. O

Interaction O
between O
PC4 B
and O
NF B
- I
Y I
was O
mapped O
to O
the O
C B
- I
terminal I
region I
of O
PC4 B
, O
and O
the O
subunit B
interaction I
subdomain I
of O
the O
highly B
conserved I
DNA I
binding I
- I
subunit I
interaction I
domain I
( O
DBD B
) O
of O
NF B
- I
YA I
. O

At O
100 O
microM O
, O
LA O
did O
not O
but O
LA O
- O
Plus O
inhibited O
H2O2 O
induced O
NF B
- I
kappaB I
activation O
and O
NF B
- I
kappaB I
directed O
IL B
- I
2 I
receptor I
expression O
. O

METHODOLOGY O
: O
A O
polymerase O
chain O
reaction O
- O
based O
method O
was O
used O
to O
amplify O
a O
polymorphic O
CAG B
repeat I
in O
the O
first B
exon I
of O
the O
androgen B
receptor I
gene I
after O
selective O
digestion O
of O
the O
active B
X I
chromosome I
with O
a O
methylation B
- I
sensitive I
enzyme I
, O
HpaII B
to O
distinguish O
between O
the O
paternal B
and I
maternal I
alleles I
and O
to O
identify O
their O
methylation O
status O
. O

METHODOLOGY O
: O
A O
polymerase O
chain O
reaction O
- O
based O
method O
was O
used O
to O
amplify O
a O
polymorphic O
CAG B
repeat I
in O
the O
first B
exon I
of O
the O
androgen B
receptor I
gene I
after O
selective O
digestion O
of O
the O
active B
X I
chromosome I
with O
a O
methylation B
- I
sensitive I
enzyme I
, O
HpaII B
to O
distinguish O
between O
the O
paternal B
and I
maternal I
alleles I
and O
to O
identify O
their O
methylation O
status O
. O

Treatment O
of O
HUVEC O
exposed O
to O
high O
glucose O
with O
the O
NF B
- I
kB I
inhibitors I
pyrrolidinedithiocar O
( O
100 O
microM O
) O
and O
tosyl O
- O
phe O
- O
chloromethylketone O
( O
25 O
microM O
) O
significantly O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
leukocyte O
adhesion O
in O
respect O
to O
HUVEC O
treated O
with O
glucose O
alone O
. O

When O
HUVEC O
were O
treated O
with O
specific O
antisense O
oligodesoxynucleotid O
against O
PKCalpha B
and I
PKCepsilon I
isoforms I
before O
the O
addition O
of O
30 O
mM O
glucose O
, O
a O
significant O
( O
P O
< O
0 O
. O
05 O
) O
reduction O
in O
the O
adhesion O
was O
also O
seen O
. O

Here O
we O
review O
the O
role O
of O
Ikaros B
, O
the O
founding O
member O
of O
a O
unique O
family O
of O
zinc B
finger I
transcription I
factors I
in O
this O
developmental O
process O
. O

Induction O
of O
early B
B I
cell I
factor I
( O
EBF B
) O
and O
multiple B
B I
lineage I
genes I
by O
the O
basic B
helix I
- I
loop I
- I
helix I
transcription I
factor I
E12 B
. O

The O
transcription B
factors I
encoded O
by O
the O
E2A B
and O
early B
B I
cell I
factor I
( O
EBF B
) O
genes O
are O
required O
for O
the O
proper O
development O
of O
B O
lymphocytes O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B
protein O
E12 B
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many B
B I
lineage I
genes I
, O
including O
EBF B
, O
IL7Ralpha B
, O
lambda5 B
, O
and O
Rag O
- O
1 O
, O
and O
the O
ability O
to O
induce O
kappa B
light I
chain I
in O
response O
to O
mitogen O
. O

Here O
, O
we O
report O
the O
nucleotide O
sequence O
of O
3 B
. I
6 I
kilobases I
of O
this O
RNA O
, O
which O
represents O
the O
3 B
' I
end I
of O
RXRalpha B
mRNA I
, O
the O
sequence O
of O
which O
has O
not O
been O
previously O
described O
. O

Important O
in O
the O
development O
of O
HIV O
- O
associated O
NHL O
are O
cytokines B
and O
other O
factors O
that O
induce O
B O
- O
cell O
proliferation O
and O
increase O
the O
likelihood O
of O
mutations O
of O
c B
- I
myc I
, O
bcl B
- I
6 I
, O
and O
other O
tumor B
- I
suppressor I
genes I
with O
carcinogenic O
potential O
. O

Inactivation O
of O
the O
NF B
- I
kappaB I
and I
3 I
' I
NF I
- I
IL I
- I
6 I
DNA I
binding I
sites I
decreased O
IL B
- I
8 I
gene I
transcriptional O
activation O
in O
response O
to O
TNF B
while O
inactivation O
of O
the O
5 B
' I
NF I
- I
IL I
- I
6 I
binding I
site I
increased O
IL B
- I
8 I
gene I
transcriptional O
activity O
in O
response O
to O
TNF B
. O

Inactivation O
of O
the O
NF B
- I
kappaB I
and I
3 I
' I
NF I
- I
IL I
- I
6 I
DNA I
binding I
sites I
decreased O
IL B
- I
8 I
gene I
transcriptional O
activation O
in O
response O
to O
TNF B
while O
inactivation O
of O
the O
5 B
' I
NF I
- I
IL I
- I
6 I
binding I
site I
increased O
IL B
- I
8 I
gene I
transcriptional O
activity O
in O
response O
to O
TNF B
. O

Gel O
- O
shift O
analysis O
of O
nuclear O
extracts O
from O
hypoxic B
MPs I
and O
HeLa O
cells O
demonstrated O
increased O
DNA O
- O
binding O
activity O
at O
the O
serum B
response I
region I
( O
SRR O
; O
- O
111 O
/ O
+ O
14 O
bp O
) O
of O
the O
tissue B
factor I
promoter I
at O
Egr B
- I
1 I
motifs I
. O

Transient O
transfection O
of O
HeLa O
cells O
with O
chimeric B
plasmids I
containing O
wild B
- I
type I
or I
mutant I
SRR I
from O
the O
tissue B
factor I
promoter I
showed O
that O
intact B
Sp1 I
sites I
are O
necessary O
for O
basal O
promoter O
activity O
, O
whereas O
the O
integrity O
of O
Egr B
- I
1 I
sites I
was O
required O
for O
hypoxia O
- O
enhanced O
expression O
. O

Kinetics O
of O
cytokine O
and O
NFAT O
gene O
expression O
in O
human O
interleukin O
- O
2 O
- O
dependent O
T O
lymphoblasts O
stimulated O
via O
T B
- I
cell I
receptor I
. O

Here O
we O
have O
analysed O
the O
kinetics O
and O
nature O
of O
cytokine O
production O
in O
human O
peripheral O
blood O
- O
derived O
T O
lymphoblasts O
stimulated O
with O
anti B
- I
CD3 I
antibodies I
or O
Lens B
culinaris I
lectin I
( O
LCL B
) O
. O

T O
cells O
were O
purified O
from O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
and O
primarily O
activated O
with O
anti B
- I
CD3 I
antibodies I
and O
cultured O
in O
the O
presence O
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

No O
IL B
- I
6 I
gene I
expression O
was O
observed O
. O

The O
kinetics O
of O
TNF B
- I
alpha I
mRNA I
expression O
was O
faster O
, O
being O
at O
its O
peak O
level O
1 O
hr O
after O
stimulation O
. O

Anti O
- O
CD3 O
- O
stimulated O
IL B
- I
2 I
gene I
expression O
was O
down O
- O
regulated O
by O
protein O
synthesis O
inhibitor O
, O
whereas O
IL B
- I
10 I
, I
IFN I
- I
gamma I
and I
TNF I
- I
alpha I
genes I
were O
readily O
induced O
independent O
of O
ongoing O
protein O
synthesis O
. O

T B
- I
cell I
receptor I
stimulation O
also O
induced O
a O
very O
rapid O
expression O
of O
c B
- I
jun I
, I
c I
- I
fos I
and I
NFATc1 I
( I
NFATc I
) I
genes I
, O
the O
gene O
products O
of O
which O
are O
involved O
in O
cytokine O
gene O
expression O
. O

The O
presence O
of O
oxLDL O
is O
associated O
with O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
in O
the O
endothelium O
as O
well O
as O
endothelial O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
. O

gp34 B
is O
a O
type B
II I
transmembrane I
molecule I
belonging O
to O
the O
tumor O
necrosis O
factor O
family O
and O
is O
constitutively O
expressed O
on O
HTLV O
- O
I O
- O
producing O
cells O
but O
not O
normal O
resting O
T O
cells O
. O

Unlike O
typical O
NF B
- I
kappaB I
elements I
, O
the O
NF B
- I
kappaB I
- I
like I
elements I
in O
gp34 B
were O
not O
activated O
by O
treatment O
of O
Jurkat O
cells O
with O
phorbol O
ester O
despite O
induction O
of O
the O
NF B
- I
kappaB I
- O
like O
binding O
activity O
. O

beta B
- I
Amyloid I
fibrils I
activate O
parallel O
mitogen B
- I
activated I
protein I
kinase I
pathways O
in O
microglia O
and O
THP1 O
monocytes O
. O

Cellular B
retinoic I
acid I
binding I
proteins I
( O
CRABP B
) O
are O
low B
molecular I
weight I
proteins I
whose O
precise O
function O
remains O
unknown O
. O

The O
paired B
box I
containing I
gene I
PAX B
- I
5 I
encodes O
the O
transcription B
factor I
BSAP B
( O
B B
- I
cell I
- I
specific I
activator I
protein I
) O
, O
which O
plays O
a O
key O
role O
in O
B O
- O
lymphocyte O
development O
. O

Mitogen O
and O
growth O
factor O
- O
induced O
activation O
of O
a O
STAT B
- I
like I
molecule I
in O
channel O
catfish O
lymphoid O
cells O
. O

In O
driving O
T O
cell O
proliferation O
, O
IL B
- I
2 I
stimulates O
a O
new O
program O
of O
gene O
expression O
that O
includes O
proliferating B
cell I
nuclear I
antigen I
( O
PCNA B
) O
, O
a O
requisite O
processivity O
factor O
for O
DNA B
polymerase I
delta I
. O

The O
level O
of O
nm23 B
- I
H1 I
mRNA I
in O
CML O
cells O
at O
the O
chronic O
phase O
was O
as O
high O
as O
that O
in O
bone O
marrow O
cells O
from O
healthy O
volunteers O
. O

Proliferated O
blastic O
cells O
were O
positive O
for O
non B
- I
specific I
esterase I
, O
and O
the O
serum O
lysozyme O
level O
was O
elevated O
and O
diagnosed O
as O
monoblastic O
crisis O
. O

Mutation O
of O
BCL B
- I
6 I
gene I
in O
normal O
B O
cells O
by O
the O
process O
of O
somatic O
hypermutation O
of O
Ig B
genes I
. O

The O
mutations O
are O
linked O
to O
transcription O
initiation O
, O
but O
non B
- I
Ig I
promoters I
are O
permissible O
for O
the O
mutation O
process O
; O
thus O
, O
other O
genes O
expressed O
in O
mutating O
B O
cells O
may O
also O
be O
subject O
to O
somatic O
hypermutation O
. O

A O
family O
of O
hematopoietic B
specific I
transcription I
factors I
, O
MIP B
- I
1 I
alpha I
nuclear I
protein I
( I
MNP I
) I
family I
, O
has O
recently O
been O
identified O
. O

Overexpression O
of O
Bcl B
- I
3 I
in O
TF O
- O
1 O
cells O
by O
transient O
transfection O
along O
with O
the O
NF B
- I
kappaB I
factors I
p50 I
or I
p52 I
resulted O
in O
significant O
induction O
of O
an O
human B
immunodeficiency I
virus I
- I
type I
1 I
( I
HIV I
- I
1 I
) I
kappaB I
- I
TATA I
- I
luceriferase I
reporter I
plasmid I
, O
demonstrating O
that O
Bcl B
- I
3 I
has O
a O
positive O
role O
in O
transactivation O
of O
kappaB B
- I
containing I
genes I
in O
erythroid O
cells O
. O

Stimulation O
with O
GM B
- I
CSF I
enhanced O
c B
- I
myb I
mRNA I
expression O
in O
these O
cells O
. O

Bcl B
- I
3 I
in O
nuclear O
extracts O
of O
TF O
- O
1 O
cells O
bound O
to O
a O
kappaB B
enhancer I
in O
the O
c B
- I
myb I
promoter I
together O
with O
NF B
- I
kappaB2 I
/ I
p52 I
and O
this O
binding O
activity O
was O
enhanced O
by O
GM B
- I
CSF I
stimulation O
. O

These O
findings O
suggest O
that O
Bcl B
- I
3 I
may O
participate O
in O
the O
transcriptional O
regulation O
of O
certain O
kappaB B
- I
containing I
genes I
involved O
in O
hematopoiesis O
, O
including O
c B
- I
myb I
. O

A O
region O
of O
basic O
amino O
acids O
spanning O
residues B
639 I
- I
656 I
in O
the O
human B
5 I
- I
lipoxygenase I
sequence I
resembles O
a O
consensus B
bipartite I
nuclear I
localizing I
sequence I
. O

5 B
- I
Lipoxygenase I
protein I
was O
detected O
in O
nuclear B
factor I
kappaB I
( I
NF I
- I
kappaB I
) I
p65 I
subunit I
immunoprecipitate O
fractions O
prepared O
from O
HL O
- O
60 O
cell O
lysates O
. O

The O
amount O
of O
5 B
- I
lipoxygenase I
protein I
coimmunoprecipitated O
by O
NF O
- O
kappaB O
antiserum O
was O
increased O
following O
A23187 O
stimulation O
. O

A O
number O
of O
indirect O
methods O
have O
been O
utilized O
in O
demonstrating O
activator B
protein I
- I
1 I
transcription O
factor O
function O
in O
IL O
- O
2 O
promoter O
activity O
. O

However O
, O
there O
has O
been O
no O
direct O
demonstration O
that O
activator B
protein I
- I
1 I
is O
involved O
in O
CD28 O
- O
dependent O
costimulation O
of O
IL B
- I
2 I
gene I
transcription O
in O
freshly O
isolated O
naive O
and O
memory O
human O
T O
lymphocytes O
. O

However O
, O
there O
has O
been O
no O
direct O
demonstration O
that O
activator B
protein I
- I
1 I
is O
involved O
in O
CD28 O
- O
dependent O
costimulation O
of O
IL B
- I
2 I
gene I
transcription O
in O
freshly O
isolated O
naive O
and O
memory O
human O
T O
lymphocytes O
. O

Scrape O
loading O
thus O
provides O
an O
efficient O
mechanism O
for O
intracellular O
incorporation O
of O
macromolecules O
, O
and O
the O
first O
direct O
evidence O
that O
c B
- I
Fos I
and O
c B
- I
Jun I
are O
involved O
in O
transcription O
of O
the O
IL B
- I
2 I
gene I
within O
its O
correct O
chromosomal O
context O
, O
in O
resting O
human O
T O
lymphocyte O
subpopulations O
. O

Differential O
expression O
of O
Nur77 B
family I
members I
in O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
- O
infected O
cells O
: O
transactivation O
of O
the O
TR3 B
/ I
nur77 I
gene I
by O
Tax B
protein I
. O

We O
analyzed O
the O
differential O
expression O
and O
regulation O
of O
three O
members O
of O
the O
Nur77 B
transcription I
factor I
family I
by O
the O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax B
protein I
. O

Transient O
transfection O
analysis O
further O
confirmed O
the O
Tax B
transactivation O
of O
the O
TR3 B
/ I
nur77 I
promoter O
but O
not O
the O
NOR B
- I
1 I
promoter I
in O
different O
cell O
types O
. O

In O
response O
to O
stress O
, O
heat B
shock I
factor I
1 I
( O
HSF1 B
) O
acquires O
rapid O
DNA O
binding O
and O
transient O
transcriptional O
activity O
while O
undergoing O
conformational O
transition O
from O
an O
inert O
non B
- I
DNA I
- I
binding I
monomer I
to O
active O
functional O
trimers O
. O

Monocyte B
chemoattractant I
protein I
1 I
( O
MCP B
- I
1 I
) O
is O
likely O
to O
contribute O
to O
the O
macrophage O
infiltrate O
in O
human O
ovarian O
carcinomas O
. O

Tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
can O
stimulate O
MCP B
- I
1 I
production O
and O
is O
also O
present O
within O
ovarian O
carcinomas O
. O

Activation O
of O
nuclear B
factor I
kappa I
B I
inflammatory O
bowel O
disease O
[ O
see O
comments O
] O

BACKGROUND O
: O
Expression O
of O
pro B
- I
inflammatory I
cytokines I
is O
increased O
in O
the O
intestinal O
lamina O
propria O
of O
patients O
with O
inflammatory O
bowel O
disease O
( O
IBD O
) O
. O

Nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
controls O
transcription O
of O
inflammation B
genes I
. O

OBJECTIVE O
: O
The O
redox B
- I
sensitive I
transcription I
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
is O
believed O
to O
contribute O
to O
late O
diabetic O
complications O
. O

It O
is O
unknown O
whether O
NF B
- I
kappa I
B I
is O
influenced O
by O
glycemic O
control O
. O

RESEARCH O
DESIGN O
AND O
METHODS O
: O
To O
determine O
whether O
NF B
- I
kappa I
B I
is O
activated O
in O
patients O
with O
insufficient O
glycemic O
control O
( O
HbA1c O
> O
10 O
% O
) O
, O
we O
developed O
a O
tissue O
culture O
- O
independent O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
- O
based O
semiquantitative O
detection O
system O
that O
allowed O
us O
to O
determine O
NF B
- I
kappa I
B I
activation O
in O
ex O
vivo O
- O
isolated O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
. O

RESEARCH O
DESIGN O
AND O
METHODS O
: O
To O
determine O
whether O
NF B
- I
kappa I
B I
is O
activated O
in O
patients O
with O
insufficient O
glycemic O
control O
( O
HbA1c O
> O
10 O
% O
) O
, O
we O
developed O
a O
tissue O
culture O
- O
independent O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
- O
based O
semiquantitative O
detection O
system O
that O
allowed O
us O
to O
determine O
NF B
- I
kappa I
B I
activation O
in O
ex O
vivo O
- O
isolated O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
. O

RESULTS O
: O
Monocytes O
of O
patients O
with O
HbA1c O
levels O
> O
10 O
% O
demonstrated O
significantly O
higher O
NF B
- I
kappa I
B I
binding O
activity O
in O
an O
EMSA O
and O
a O
stronger O
NF B
- I
kappa I
B I
staining O
in O
immunohistochemistry O
than O
monocytes O
of O
patients O
with O
HbA1c O
levels O
of O
6 O
- O
8 O
% O
. O

RESULTS O
: O
Monocytes O
of O
patients O
with O
HbA1c O
levels O
> O
10 O
% O
demonstrated O
significantly O
higher O
NF B
- I
kappa I
B I
binding O
activity O
in O
an O
EMSA O
and O
a O
stronger O
NF B
- I
kappa I
B I
staining O
in O
immunohistochemistry O
than O
monocytes O
of O
patients O
with O
HbA1c O
levels O
of O
6 O
- O
8 O
% O
. O

The O
increase O
in O
NF B
- I
kappa I
B I
activation O
correlated O
with O
an O
increase O
in O
plasmatic O
markers O
of O
lipid O
peroxidation O
. O

Treatment O
with O
the O
antioxidant O
thioctic O
acid O
decreased O
NF B
- I
kappa I
B I
binding O
activity O
. O

CONCLUSIONS O
: O
Hyperglycemia O
induces O
activation O
of O
the O
transcription O
factor O
NF B
- I
kappa I
B I
in O
ex O
vivo O
- O
isolated O
PBMCs O
of O
patients O
with O
type O
1 O
diabetes O
. O

NF B
- I
kappa I
B I
activation O
is O
at O
least O
partially O
dependent O
on O
oxidative O
stress O
, O
since O
the O
antioxidant O
thioctic O
acid O
significantly O
lowered O
the O
extent O
of O
NF B
- I
kappa I
B I
binding O
activity O
. O

NF B
- I
kappa I
B I
activation O
is O
at O
least O
partially O
dependent O
on O
oxidative O
stress O
, O
since O
the O
antioxidant O
thioctic O
acid O
significantly O
lowered O
the O
extent O
of O
NF B
- I
kappa I
B I
binding O
activity O
. O

Treatment O
of O
the O
cells O
with O
PD98059 O
and O
wortmannin O
, O
inhibitors O
of O
MEK B
and O
PI B
- I
3 I
kinase I
, O
respectively O
, O
inhibited O
the O
synergistic O
activation O
of O
MAPK B
and O
also O
the O
cell O
growth O
, O
further O
supporting O
this O
conclusion O
. O

Expression O
of O
BCL B
- I
6 I
protein I
, O
which O
is O
restricted O
to O
GC O
B O
cells O
throughout O
physiologic O
B O
- O
cell O
maturation O
, O
was O
detected O
in O
100 O
% O
AIDS O
- O
unrelated O
PCNSL O
and O
in O
56 O
. O
2 O
% O
AIDS O
- O
related O
cases O
. O

Binding O
of O
human O
immunodeficiency O
virus O
type O
1 O
to O
CD4 B
and I
CXCR4 I
receptors I
differentially O
regulates O
expression O
of O
inflammatory B
genes I
and O
activates O
the O
MEK B
/ O
ERK O
signaling O
pathway O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
HIV B
- I
1 I
envelope I
glycoproteins I
of O
both O
T O
- O
cell O
- O
tropic O
and O
macrophagetropic O
strains O
rapidly O
activate O
the O
ERK O
/ O
mitogen O
- O
activated O
protein O
( O
MAP O
) O
kinase O
pathway O
and O
the O
binding O
of O
nuclear B
transcription I
factors I
( O
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
C B
/ I
EBP I
) O
and O
stimulate O
expression O
of O
cytokine B
and I
chemokine I
genes I
. O

However O
, O
SDF B
- I
1 I
did O
not O
affect O
the O
CD4 O
- O
mediated O
expression O
of O
cytokine B
and I
chemokine I
genes I
. O

To O
understand O
the O
molecular O
basis O
of O
the O
functional O
specificity O
between O
E2A B
and O
HEB B
/ O
E2 B
- I
2 I
in O
mammalian O
development O
, O
we O
generated O
and O
tested O
a O
panel O
of O
E2A B
knockin O
mutations O
including O
subtle O
mutations O
in O
the O
E12 B
and I
E47 I
exons I
and O
substitution O
of O
both O
E12 B
and I
E47 I
exons I
with O
a O
human B
HEB I
cDNA I
. O

To O
understand O
the O
molecular O
basis O
of O
the O
functional O
specificity O
between O
E2A B
and O
HEB B
/ O
E2 B
- I
2 I
in O
mammalian O
development O
, O
we O
generated O
and O
tested O
a O
panel O
of O
E2A B
knockin O
mutations O
including O
subtle O
mutations O
in O
the O
E12 B
and I
E47 I
exons I
and O
substitution O
of O
both O
E12 B
and I
E47 I
exons I
with O
a O
human B
HEB I
cDNA I
. O

To O
further O
characterize O
the O
consequences O
of O
this O
biased O
co O
- O
stimulatory O
dependency O
, O
we O
employed O
a O
well O
- O
defined O
system O
of O
transfected O
CHO O
cells O
expressing O
human B
MHC I
class I
II I
together O
with O
CD80 B
, O
CD86 B
or O
CD80 B
and O
CD86 B
. O

To O
analyze O
IL B
- I
2 I
transcriptional O
activity O
in O
CD80 B
and O
CD86 B
co O
- O
stimulated O
T O
cells O
we O
used O
Jurkat O
T O
cells O
transfected O
with O
luciferase B
reporter I
gene I
constructs I
. O

CD80 B
induced O
higher O
levels O
of O
IL B
- I
2 I
promoter I
- O
enhancer O
activity O
compared O
to O
CD86 B
. O

Furthermore O
, O
the O
activity O
of O
transcription B
factors I
regulating O
the O
IL B
- I
2 I
promoter I
- I
enhancer I
region I
including O
activation B
protein I
- I
1 I
, O
CD28 B
response I
element I
and O
nuclear B
factor I
kappaB I
were O
4 O
- O
8 O
times O
higher O
after O
CD80 B
compared O
to O
CD86 B
ligation O
. O

DR3 B
is O
capable O
of O
inducing O
both O
NF B
- I
kappa I
B I
activation O
and O
apoptosis O
when O
overexpressed O
in O
mammalian O
cells O
, O
although O
its O
ligand O
has O
not O
yet O
been O
identified O
. O

Duplication O
of O
at O
least O
a O
portion O
of O
the O
DR3 B
gene I
, O
including O
the O
extracellular B
and I
transmembrane I
regions I
but O
not O
the O
cytoplasmic B
domain I
, O
was O
demonstrated O
by O
both O
fluorescence O
in O
situ O
hybridization O
and O
genomic O
Southern O
blotting O
. O

It O
is O
suggested O
that O
the O
presence O
of O
steroid B
- I
inducible I
GS I
in O
ALL O
cells O
may O
prove O
to O
be O
a O
marker O
for O
functional B
receptor I
sites I
. O

These O
included O
inhibition O
of O
the O
proliferative O
responses O
to O
the O
T B
- I
cell I
mitogens I
concanavalin B
A I
and O
phytohaemagglutinin B
and O
an O
enhanced O
accumulation O
of O
immunoglobulin O
secreting O
cells O
in O
pokeweed O
mitogen O
- O
stimulated O
cultures O
. O

In O
Specimens O
of O
115 O
patients O
with O
breast O
cancer O
4 O
tumorparameters O
( O
tumorsize O
, O
tumorboder O
, O
nucleargrade O
, O
lymphocytic O
stromal O
reaction O
) O
3 O
features O
of O
regional O
lymphnodes O
( O
sinushistiocytosis O
, O
T O
- O
cellreaction O
, O
lymphnode O
metastases O
) O
and O
estrogen B
and I
progesteron I
receptors I
were O
determined O
. O

Mixing O
experiments O
using O
a O
UK O
standard O
and O
conditioned O
media O
from O
Dex O
- O
treated O
cells O
suggest O
an O
absence O
of O
glucocorticoid B
- I
inducible I
inhibitors I
to O
UK B
or O
plasmin B
in O
both O
cell O
types O
. O

Thus O
, O
low O
levels O
of O
glucocorticoid B
- I
inducible I
inhibitors I
may O
contribute O
to O
, O
but O
can O
not O
fully O
account O
for O
, O
Dex O
inhibition O
of O
GM4672A B
PA I
activity O
. O

Glucocorticoid B
- I
inducible I
inhibitors I
in O
HMy2 O
cells O
are O
either O
totally O
absent O
or O
are O
present O
at O
undetectable O
levels O
. O

Thus O
, O
regulation O
of O
UK B
- I
like I
PAs I
in O
HMy2 O
and O
GM4672A O
cells O
differs O
with O
respect O
to O
the O
extent O
to O
which O
glucocorticoids O
inhibit O
constitutively B
expressed I
activator I
levels O
, O
as O
well O
as O
the O
possible O
contribution O
of O
glucocorticoid B
- I
inducible I
inhibitors I
to O
the O
regulatory O
process O
in O
GM4672A O
cells O
. O

Thus O
, O
regulation O
of O
UK B
- I
like I
PAs I
in O
HMy2 O
and O
GM4672A O
cells O
differs O
with O
respect O
to O
the O
extent O
to O
which O
glucocorticoids O
inhibit O
constitutively B
expressed I
activator I
levels O
, O
as O
well O
as O
the O
possible O
contribution O
of O
glucocorticoid B
- I
inducible I
inhibitors I
to O
the O
regulatory O
process O
in O
GM4672A O
cells O
. O

Mineralocorticoid B
and I
glucocorticoid I
receptors I
in O
circulating O
mononuclear O
leukocytes O
of O
patients O
with O
primary O
hyperaldosteronism O
. O

Mineralocorticoid B
and I
glucocorticoid I
receptors I
were O
measured O
in O
circulating O
mononuclear O
leukocytes O
in O
5 O
patients O
affected O
by O
Conn O
' O
s O
syndrome O
( O
3 O
cases O
of O
bilateral O
adrenal O
hyperplasia O
and O
2 O
cases O
of O
adenoma O
plus O
unilateral O
hyperplasia O
) O
. O

Resting O
T O
- O
cells O
do O
not O
express O
IL B
- I
2 I
receptors I
, O
but O
receptors O
are O
rapidly O
expressed O
on O
T O
- O
cells O
following O
interaction O
of O
antigens O
, O
mitogens O
, O
or O
monoclonal B
antibodies I
with O
the O
antigen B
- I
specific I
T I
- I
cell I
receptor I
complex I
. O

Using O
anti B
- I
Tac I
, O
a O
monoclonal B
antibody I
that O
recognizes O
the O
IL B
- I
2 I
receptor I
, O
the O
receptor O
has O
been O
purified O
and O
shown O
to O
be O
a O
Mr O
33 O
, O
000 O
peptide O
that O
is O
posttranslationally O
glycosylated O
to O
a O
Mr O
55 O
, O
000 O
mature O
form O
. O

Normal O
resting O
T O
- O
cells O
and O
most O
leukemic O
T O
- O
cell O
populations O
do O
not O
express O
IL B
- I
2 I
receptors I
; O
however O
, O
the O
leukemic O
cells O
of O
the O
11 O
patients O
examined O
who O
had O
human O
T O
- O
cell O
lymphotropic O
virus O
- O
associated O
adult O
T O
- O
cell O
leukemia O
expressed O
the O
Tac B
antigen I
. O

In O
human O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infected O
cells O
, O
the O
Mr O
42 O
, O
000 O
long O
open B
reading I
frame I
protein I
encoded O
in O
part O
by O
the O
pX B
region I
of O
this O
virus O
may O
act O
as O
a O
transacting B
transcriptional I
activator I
that O
induces O
IL B
- I
2 I
receptor I
gene I
transcription O
, O
thus O
providing O
an O
explanation O
for O
the O
constant O
association O
of O
IL B
- I
2 I
receptor I
expression O
with O
adult O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infection O
of O
lymphoid O
cells O
. O

In O
human O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infected O
cells O
, O
the O
Mr O
42 O
, O
000 O
long O
open B
reading I
frame I
protein I
encoded O
in O
part O
by O
the O
pX B
region I
of O
this O
virus O
may O
act O
as O
a O
transacting B
transcriptional I
activator I
that O
induces O
IL B
- I
2 I
receptor I
gene I
transcription O
, O
thus O
providing O
an O
explanation O
for O
the O
constant O
association O
of O
IL B
- I
2 I
receptor I
expression O
with O
adult O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infection O
of O
lymphoid O
cells O
. O

The O
constant O
expression O
of O
large O
numbers O
of O
IL B
- I
2 I
receptors I
which O
may O
be O
aberrant O
may O
play O
a O
role O
in O
the O
uncontrolled O
growth O
of O
adult O
T O
- O
cell O
leukemia O
cells O
. O

The O
glucocorticoid B
receptor I
is O
an O
intracellular B
protein I
which O
possesses O
three O
distinct O
domains O
, O
one O
that O
binds O
agonist O
and O
antagonist O
steroids O
, O
one O
that O
binds O
DNA O
, O
and O
one O
that O
binds O
anti B
- I
receptor I
antibodies I
and O
is O
required O
for O
glucocorticoid O
modulation O
of O
gene O
expression O
. O

Some O
of O
these O
factors O
appear O
to O
exert O
their O
effect O
by O
controlling O
critical O
receptor O
properties O
such O
as O
ATP O
- O
dependent O
phosphorylation O
, O
integrity O
of O
thiol B
groups I
, O
and O
exposure O
of O
key B
amino I
acid I
residues I
. O

Glucocorticoid O
antagonists O
are O
steroids O
that O
interact O
with O
the O
receptor O
but O
either O
fail O
to O
produce O
a O
stable B
complex I
or O
produce O
a O
stable B
but I
inefficient I
complex I
. O

Cell O
cycle O
- O
related O
changes O
in O
number O
of O
T B
- I
lymphocyte I
receptors I
for O
glucocorticoids O
and O
insulin O
. O

DEX O
almost O
completely O
inhibited O
TPA O
activation O
of O
the O
following O
macrophage O
functions O
: O
adherency O
to O
the O
culture O
plate O
, O
expression O
of O
lysosomal B
enzymes I
, O
Fc B
and I
C3 I
receptors I
, O
and O
stimulation O
of O
phagocytosis O
. O

Identification O
of O
human B
leukemic I
glucocorticoid I
receptors I
using O
affinity O
labeling O
and O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
. O

Antisera O
raised O
against O
human B
lymphoid I
glucocorticoid I
receptors I
were O
used O
in O
combination O
with O
the O
glucocorticoid O
receptor O
affinity O
label O
[ O
3H O
] O
dexamethasone O
21 O
- O
mesylate O
[ O
( O
3H O
] O
DM O
) O
to O
identify O
the O
glucocorticoid B
receptors I
of O
the O
human O
B O
- O
lymphoblastoid O
cell O
line O
IM O
- O
9 O
and O
the O
human O
T O
- O
cell O
leukemic O
cell O
line O
CEM O
- O
C7 O
. O

Thus O
, O
the O
combination O
of O
affinity O
labeling O
and O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
is O
capable O
of O
providing O
direct O
physical O
identification O
of O
human B
lymphoid I
glucocorticoid I
receptors I
. O

The O
determination O
of O
estrogen B
and I
progesterone I
receptors I
in O
breast O
cancer O
has O
been O
shown O
to O
be O
useful O
in O
predicting O
the O
response O
to O
endocrine O
therapy O
. O

In O
cytosol O
from O
a O
glucocorticoid O
- O
resistant O
cell O
line O
with O
virtually O
no O
[ O
3H O
] O
DEX O
binding O
, O
[ O
3H O
] O
CVZ O
detected O
a O
single O
high B
affinity I
binding I
site I
that O
was O
similar O
in O
dissociation O
constant O
( O
0 O
. O
8 O
nM O
) O
and O
receptor O
concentration O
( O
0 O
. O
13 O
pmol O
/ O
mg O
protein O
) O
to O
the O
high B
affinity I
site I
detected O
in O
the O
glucocorticoid O
- O
sensitive O
cell O
line O
C7 O
. O

Excess O
labeled O
steroid O
as O
well O
as O
most O
non O
- O
specifically O
bound O
steroid O
is O
easily O
washed O
away O
, O
leaving O
the O
hormone B
- I
receptor I
complex I
retained O
by O
the O
beads O
. O

Evolution O
of O
a O
case O
of O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
into O
blast O
crisis O
was O
found O
to O
be O
characterized O
by O
three O
unusual O
features O
( O
1 O
) O
the O
phenotype O
of O
the O
emerging O
blast O
cells O
was O
that O
of O
pre O
- O
plasmacytoid O
cells O
as O
shown O
by O
plasma O
cell O
morphology O
and O
an O
immunological O
phenotype O
corresponding O
partially O
with O
CLL O
- O
or O
intermediate O
B O
- O
cells O
, O
partially O
with O
plasma O
cells O
( O
terminal B
transferase I
- O
, O
common O
acute B
lymphocytic I
leukemia I
antigen I
- O
, O
Ia B
+ I
, O
surface B
immunoglobulin I
heavy I
chains I
- O
, O
surface B
kappa I
light I
chains I
+ O
, O

Evolution O
of O
a O
case O
of O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
into O
blast O
crisis O
was O
found O
to O
be O
characterized O
by O
three O
unusual O
features O
( O
1 O
) O
the O
phenotype O
of O
the O
emerging O
blast O
cells O
was O
that O
of O
pre O
- O
plasmacytoid O
cells O
as O
shown O
by O
plasma O
cell O
morphology O
and O
an O
immunological O
phenotype O
corresponding O
partially O
with O
CLL O
- O
or O
intermediate O
B O
- O
cells O
, O
partially O
with O
plasma O
cells O
( O
terminal B
transferase I
- O
, O
common O
acute B
lymphocytic I
leukemia I
antigen I
- O
, O
Ia B
+ I
, O
surface B
immunoglobulin I
heavy I
chains I
- O
, O
surface B
kappa I
light I
chains I
+ O
, O

Evolution O
of O
a O
case O
of O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
into O
blast O
crisis O
was O
found O
to O
be O
characterized O
by O
three O
unusual O
features O
( O
1 O
) O
the O
phenotype O
of O
the O
emerging O
blast O
cells O
was O
that O
of O
pre O
- O
plasmacytoid O
cells O
as O
shown O
by O
plasma O
cell O
morphology O
and O
an O
immunological O
phenotype O
corresponding O
partially O
with O
CLL O
- O
or O
intermediate O
B O
- O
cells O
, O
partially O
with O
plasma O
cells O
( O
terminal B
transferase I
- O
, O
common O
acute B
lymphocytic I
leukemia I
antigen I
- O
, O
Ia B
+ I
, O
surface B
immunoglobulin I
heavy I
chains I
- O
, O
surface B
kappa I
light I
chains I
+ O
, O

intracytoplasmic B
immunoglobulin I
A I
+ I
and I
G I
+ I
, O
BA B
- I
1 I
+ I
, O
polyclonal O
gammaglobulin O
production O
) O
; O
( O
2 O
) O
cytogenetic O
analysis O
of O
spontaneous O
metaphases O
revealed O
that O
in O
addition O
to O
the O
typical O
CLL O
abnormality O
, O
trisomy O
12 O
, O
in O
all O
of O
the O
cells O
, O
an O
additional O
translocation O
between O
chromosomes B
14 I
and I
17 I
was O
present O
in O
40 O
% O
with O
a O
presumptive O
breakpoint O
on O
chromosome B
14 I
( O
q12 O
- O
3 O
) O
never O
described O
before O
( O
commonly O
q32 O
) O
and O
( O
3 O
) O
the O
progression O
of O
the O
disease O
was O
associated O
with O
a O

intracytoplasmic B
immunoglobulin I
A I
+ I
and I
G I
+ I
, O
BA B
- I
1 I
+ I
, O
polyclonal O
gammaglobulin O
production O
) O
; O
( O
2 O
) O
cytogenetic O
analysis O
of O
spontaneous O
metaphases O
revealed O
that O
in O
addition O
to O
the O
typical O
CLL O
abnormality O
, O
trisomy O
12 O
, O
in O
all O
of O
the O
cells O
, O
an O
additional O
translocation O
between O
chromosomes B
14 I
and I
17 I
was O
present O
in O
40 O
% O
with O
a O
presumptive O
breakpoint O
on O
chromosome B
14 I
( O
q12 O
- O
3 O
) O
never O
described O
before O
( O
commonly O
q32 O
) O
and O
( O
3 O
) O
the O
progression O
of O
the O
disease O
was O
associated O
with O
a O

Previous O
studies O
, O
however O
, O
have O
not O
revealed O
any O
consistent O
relationship O
between O
clinical O
responsiveness O
and O
the O
cellular O
or O
cytosolic O
concentration O
of O
glucocorticoid B
- I
binding I
sites I
. O

Covalent O
labeling O
of O
rat O
thymocyte O
and O
human B
lymphoid I
glucocorticoid I
receptor I
. O

The O
association O
of O
cytosol O
oestrogen B
and I
progesterone I
receptors I
with O
histological O
features O
of O
breast O
cancer O
and O
early O
recurrence O
of O
disease O
. O

Here O
we O
review O
the O
role O
of O
Ikaros B
, O
the O
founding O
member O
of O
a O
unique O
family O
of O
zinc B
finger I
transcription I
factors I
in O
this O
developmental O
process O
. O

Overexpression O
of O
p65 O
and O
c O
- O
Jun O
substitutes O
for O
B7 O
- O
1 O
costimulation O
by O
targeting O
the O
CD28RE B
within O
the O
IL B
- I
2 I
promoter I
. O

The O
role O
of O
Rel B
and O
activation B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
in O
IL B
- I
2 I
promoter I
activity O
in O
B7 O
- O
1 O
- O
and O
leukocyte O
function O
- O
associated O
Ag O
- O
3 O
( O
LFA O
. O
3 O
) O
- O
costimulated O
T O
cells O
has O
been O
evaluated O
. O

The O
role O
of O
Rel B
and O
activation B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
in O
IL B
- I
2 I
promoter I
activity O
in O
B7 O
- O
1 O
- O
and O
leukocyte O
function O
- O
associated O
Ag O
- O
3 O
( O
LFA O
. O
3 O
) O
- O
costimulated O
T O
cells O
has O
been O
evaluated O
. O

We O
demonstrate O
that O
overexpression O
of O
c B
- I
Jun I
but O
not O
c B
- I
Fos I
increases O
IL B
- I
2 I
promoter I
activity O
in O
both O
B7 O
- O
1 O
- O
and O
LFA O
- O
3 O
- O
costimulated O
Jurkat O
T O
cells O
. O

Cotransfection O
of O
both O
c O
- O
Jun O
and O
c O
- O
Fos O
substitutes O
for O
B7 O
- O
1 O
costimulation O
in O
driving O
an O
activation B
protein I
- I
1 I
response I
element I
but O
not O
for O
the O
IL B
- I
2 I
promoter I
. O

Overexpression O
of O
Rel B
proteins I
demonstrated O
that O
p65 O
- O
expressing O
Jurkat O
cells O
transcribed O
equally O
well O
a O
nuclear B
factor I
kappabeta I
reporter I
construct I
when O
costimulated O
with O
B7 B
- I
1 I
or O
LFA B
- I
3 I
, O
but O
transcription O
of O
IL B
- I
2 I
promoter I
or O
CD28 B
response I
element I
( I
CD28RE I
) I
- I
driven I
reporters I
was O
superior O
in O
B7 O
- O
1 O
- O
costimulated O
cells O
. O

Mutating O
the O
CD28RE B
but O
not O
the O
upstream B
nuclear I
factor I
kappabeta I
- I
binding I
site I
in O
the O
IL B
- I
2 I
promoter I
reduced O
B7 B
- I
1 I
- O
driven O
transcription O
> O
90 O
% O
. O

The O
results O
implicates O
a O
major O
role O
of O
the O
CD28RE B
in O
the O
integration O
of O
p65 B
/ O
c B
- I
Jun I
- O
mediated O
transcription O
within O
the O
IL B
- I
2 I
promoter I
. O

We O
suggest O
that O
the O
transition O
from O
an O
autocrine O
LFA B
- I
3 I
- O
driven O
immune O
response O
to O
a O
B7 O
- O
- O
induced O
paracrine O
immune O
response O
involves O
the O
activation O
of O
c B
- I
Jun I
and O
p65 B
, O
which O
target O
the O
CD28RE B
region O
of O
the O
IL B
- I
2 I
promoter I
. O

Activation O
of O
Jun B
N I
- I
terminal I
kinase I
or O
stress B
- I
activated I
kinase I
( O
JNK B
or O
SAPK B
) O
and O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
the O
induction O
of O
the O
transcription B
factor I
NF B
- I
ATc1 I
and I
egr I
- I
1 I
genes I
was O
normal O
. O

Despite O
the O
reduced O
Ca2 O
+ O
mobilization O
, O
translocation O
of O
cytoplasmic B
NF I
- I
ATc I
to O
the O
nucleus O
was O
normal O
, O
reflecting O
that O
the O
lower O
levels O
of O
Ca2 O
+ O
in O
vav O
- O
/ O
- O
cells O
were O
still O
sufficient O
to O
activate O
calcineurin B
. O

To O
assess O
HUVEC O
activation O
, O
E B
- I
selectin I
expression O
was O
measured O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
Northern O
blot O
analysis O
for O
E B
- I
selectin I
- I
specific I
mRNA I
, O
and O
electrophoretic O
gel O
mobility O
shift O
assay O
( O
EMSA O
) O
for O
NF B
- I
kappa I
B I
, O
a O
transcription B
factor I
necessary O
for O
E B
- I
selectin I
gene I
activation O
. O

To O
assess O
HUVEC O
activation O
, O
E B
- I
selectin I
expression O
was O
measured O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
Northern O
blot O
analysis O
for O
E B
- I
selectin I
- I
specific I
mRNA I
, O
and O
electrophoretic O
gel O
mobility O
shift O
assay O
( O
EMSA O
) O
for O
NF B
- I
kappa I
B I
, O
a O
transcription B
factor I
necessary O
for O
E B
- I
selectin I
gene I
activation O
. O

B O
. O
fragilis O
outer O
membranes O
induced O
translocation O
of O
NF B
- I
kappa I
B I
to O
HUVEC O
nuclei O
and O
accumulation O
of O
E B
- I
selectin I
mRNA I
in O
HUVEC O
cytoplasm O
. O

B O
. O
fragilis O
outer O
membranes O
induced O
translocation O
of O
NF B
- I
kappa I
B I
to O
HUVEC O
nuclei O
and O
accumulation O
of O
E B
- I
selectin I
mRNA I
in O
HUVEC O
cytoplasm O
. O

Two O
different O
monoclonal B
antibodies I
directed O
against O
human B
CD14 I
completely O
inhibited O
B O
. O
fragilis O
outer O
membrane O
- O
induced O
NF B
- I
kappa I
B I
activation O
, O
E O
- O
selectin O
transcription O
, O
and O
E O
- O
selectin O
surface O
expression O
. O

TNFalpha B
plus O
NAC O
treatment O
resulted O
in O
a O
marked O
decrease O
in O
Bcl B
- I
2 I
protein I
levels O
in O
HIV O
- O
1 O
- O
infected O
cells O
, O
coupled O
with O
an O
increase O
in O
Bax B
protein I
compared O
to O
uninfected O
cells O
, O
suggesting O
that O
the O
difference O
in O
susceptibility O
to O
TNFalpha B
- O
induced O
apoptosis O
may O
relate O
to O
the O
differences O
in O
relative O
levels O
of O
Bcl B
- I
2 I
and O
Bax B
. O

The O
protective O
role O
of O
NF B
- I
kappaB I
in O
blocking O
TNFalpha O
- O
and O
HIV O
- O
1 O
- O
induced O
apoptosis O
was O
supported O
by O
studies O
in O
Jurkat O
T O
cells O
engineered O
to O
express O
IkappaB B
alpha I
repressor I
mutants I
( O
TD B
- I
IkappaB I
) O
under O
the O
control O
of O
a O
tetracycline B
- I
responsive I
promoter I
. O

The O
protective O
role O
of O
NF B
- I
kappaB I
in O
blocking O
TNFalpha O
- O
and O
HIV O
- O
1 O
- O
induced O
apoptosis O
was O
supported O
by O
studies O
in O
Jurkat O
T O
cells O
engineered O
to O
express O
IkappaB B
alpha I
repressor I
mutants I
( O
TD B
- I
IkappaB I
) O
under O
the O
control O
of O
a O
tetracycline B
- I
responsive I
promoter I
. O

As O
was O
observed O
for O
the O
U9 O
- O
IIIB O
cells O
, O
TNFalpha B
treatment O
also O
induced O
a O
marked O
decrease O
in O
Bcl B
- I
2 I
protein I
levels O
in O
TD O
- O
IkappaB O
expressing O
cells O
. O

Ku B
is O
the O
DNA B
- I
targeting I
component I
of O
the O
large O
catalytic B
sub I
- I
unit I
of O
the O
DNA B
- I
dependent I
protein I
kinase I
complex I
( O
DNA B
- I
PK I
[ I
CS I
] I
) O
, O
that O
plays O
a O
critical O
role O
in O
mammalian O
double O
- O
strand O
break O
repair O
and O
lymphoid O
V O
( O
D O
) O
J O
recombination O
. O

Ku B
is O
the O
DNA B
- I
targeting I
component I
of O
the O
large O
catalytic B
sub I
- I
unit I
of O
the O
DNA B
- I
dependent I
protein I
kinase I
complex I
( O
DNA B
- I
PK I
[ I
CS I
] I
) O
, O
that O
plays O
a O
critical O
role O
in O
mammalian O
double O
- O
strand O
break O
repair O
and O
lymphoid O
V O
( O
D O
) O
J O
recombination O
. O

In O
contrast O
to O
previous O
studies O
performed O
in O
the O
absence O
of O
exogenous B
IL I
- I
2 I
, O
no O
increase O
in O
binding O
of O
CREB B
to O
a O
32P O
- O
labeled O
oligonucleotide O
probe O
was O
observed O
by O
electrophoretic O
mobility O
shift O
assay O
. O

Although O
all O
the O
cells O
in O
an O
organism O
contain O
the O
same O
genetic O
information O
, O
differences O
in O
the O
cell O
phenotype O
arise O
from O
the O
expression O
of O
lineage B
- I
specific I
genes I
. O

The O
combined O
action O
of O
these O
transcription B
factors I
subsequently O
determines O
the O
expression O
of O
myeloid B
- I
specific I
genes I
and O
the O
generation O
of O
monocytes O
and O
macrophages O
. O

Although O
p12 B
( I
I I
) I
contains O
4 O
minimal O
proline O
- O
rich O
, O
src B
homology I
3 I
- I
binding I
motifs I
( O
PXXP B
) O
, O
a O
characteristic O
commonly O
found O
in O
proteins O
involved O
in O
signaling O
pathways O
, O
it O
has O
not O
been O
known O
whether O
p12 B
( I
I I
) I
has O
a O
role O
in O
modulating O
intracellular O
signaling O
pathways O
. O

Although O
p12 B
( I
I I
) I
contains O
4 O
minimal O
proline O
- O
rich O
, O
src B
homology I
3 I
- I
binding I
motifs I
( O
PXXP B
) O
, O
a O
characteristic O
commonly O
found O
in O
proteins O
involved O
in O
signaling O
pathways O
, O
it O
has O
not O
been O
known O
whether O
p12 B
( I
I I
) I
has O
a O
role O
in O
modulating O
intracellular O
signaling O
pathways O
. O

This O
study O
demonstrated O
that O
p12 B
( I
I I
) I
binds O
to O
the O
cytoplasmic B
domain I
of O
the O
interleukin B
- I
2 I
receptor I
( I
IL I
- I
2R I
) I
beta I
chain I
that O
is O
involved O
in O
the O
recruitment O
of O
the O
Jak1 B
and I
Jak3 I
kinases I
. O

This O
study O
demonstrated O
that O
p12 B
( I
I I
) I
binds O
to O
the O
cytoplasmic B
domain I
of O
the O
interleukin B
- I
2 I
receptor I
( I
IL I
- I
2R I
) I
beta I
chain I
that O
is O
involved O
in O
the O
recruitment O
of O
the O
Jak1 B
and I
Jak3 I
kinases I
. O

As O
a O
result O
of O
this O
interaction O
, O
p12 B
( I
I I
) I
increases O
signal B
transducers I
and I
activators I
of I
transcription I
5 I
( O
STAT5 B
) O
DNA O
binding O
and O
transcriptional O
activity O
and O
this O
effect O
depends O
on O
the O
presence O
of O
both O
IL B
- I
2R I
beta I
and I
gamma I
( I
c I
) I
chains I
and O
Jak3 B
. O

Transduction O
of O
primary O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
with O
a O
human B
immunodeficiency I
virus I
type I
1 I
- I
based I
retroviral I
vector I
expressing O
p12 B
( I
I I
) I
also O
resulted O
in O
increased O
STAT5 B
phosphorylation O
and O
DNA O
binding O
. O

However O
, O
p12 B
( I
I I
) I
could O
increase O
proliferation O
of O
human O
PBMCs O
only O
after O
stimulation O
of O
T B
- I
cell I
receptors I
by O
treatment O
of O
cells O
with O
low O
concentrations O
of O
alphaCD3 B
and I
alphaCD28 I
antibodies I
. O

However O
, O
p12 B
( I
I I
) I
could O
increase O
proliferation O
of O
human O
PBMCs O
only O
after O
stimulation O
of O
T B
- I
cell I
receptors I
by O
treatment O
of O
cells O
with O
low O
concentrations O
of O
alphaCD3 B
and I
alphaCD28 I
antibodies I
. O

However O
, O
p12 B
( I
I I
) I
could O
increase O
proliferation O
of O
human O
PBMCs O
only O
after O
stimulation O
of O
T B
- I
cell I
receptors I
by O
treatment O
of O
cells O
with O
low O
concentrations O
of O
alphaCD3 B
and I
alphaCD28 I
antibodies I
. O

Together O
, O
these O
data O
indicate O
that O
p12 B
( I
I I
) I
may O
confer O
a O
proliferative O
advantage O
on O
HTLV O
- O
1 O
- O
infected O
cells O
in O
the O
presence O
of O
suboptimal O
antigen O
stimulation O
and O
that O
this O
event O
may O
account O
for O
the O
clonal O
proliferation O
of O
infected O
T O
cells O
in O
vivo O
. O

A O
sub O
- O
group O
of O
patients O
with O
glucocorticoid O
- O
insensitive O
asthma O
have O
an O
inability O
to O
induce O
histone O
acetylation O
in O
response O
to O
dexamethasone O
suggesting O
reduced O
expression O
of O
a O
GR B
- I
specific I
HAT I
. O

Lipopolysaccharide O
- O
stimulated O
tumor B
necrosis I
factor I
alpha I
and O
interleukin B
- I
10 I
production O
are O
significantly O
augmented O
in O
both O
XPA O
and O
CSB O
mice O
after O
ultraviolet O
B O
exposure O
. O

We O
tested O
the O
hypothesis O
that O
biomechanical O
strain O
can O
induce O
expression O
of O
the O
class B
A I
scavenger I
receptor I
( O
SRA B
) O
, O
an O
important O
lipoprotein B
receptor I
in O
atherogenesis O
. O

To O
examine O
the O
roles O
of O
the O
transcription B
factors I
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
and O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
was O
performed O
. O

To O
examine O
the O
roles O
of O
the O
transcription B
factors I
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
and O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
was O
performed O
. O

RESULTS O
: O
Glucose O
induced O
MCP B
- I
1 I
mRNA I
expression O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
. O

MCP B
- I
1 I
protein I
in O
cell O
culture O
supernant O
was O
also O
increased O
. O

Curcumin O
, O
an O
inhibitor O
of O
AP B
- I
1 I
, O
dose O
- O
dependently O
suppressed O
the O
induction O
of O
MCP B
- I
1 I
mRNA I
by O
high O
glucose O
. O

Tyrosine O
kinase O
inhibitors O
such O
as O
genistein O
( O
12 O
. O
5 O
to O
50 O
micromol O
/ O
L O
) O
and O
herbimycin O
A O
( O
0 O
. O
1 O
to O
1 O
micromol O
/ O
L O
) O
inhibited O
the O
high O
- O
glucose O
- O
induced O
MCP B
- I
1 I
mRNA I
expression O
in O
a O
dose O
- O
dependent O
manner O
, O
and O
also O
suppressed O
the O
high O
- O
glucose O
- O
induced O
AP B
- I
1 I
binding O
activity O
. O

Whereas O
B B
cell I
Ag I
receptor I
( O
BCR B
) O
cross O
- O
linking O
alone O
stimulated O
increased O
expression O
of O
CD86 B
, O
up O
- O
regulation O
of O
CD80 B
required O
dual O
stimulation O
with O
anti B
- I
IgM I
and O
anti B
- I
CD54 I
. O

Suppression O
of O
tumor B
necrosis I
factor I
alpha I
production O
by O
cAMP O
in O
human O
monocytes O
: O
dissociation O
with O
mRNA O
level O
and O
independent O
of O
interleukin B
- I
10 I
. O

BACKGROUND O
: O
Elevation O
of O
cellular O
cAMP O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
production O
and O
increases O
the O
expression O
of O
interleukin B
( I
IL I
) I
- I
10 I
in O
mononuclear O
cells O
. O

TNF B
- I
alpha I
gene I
expression O
obligates O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
. O

TNF B
- I
alpha I
mRNA I
was O
measured O
by O
reverse O
transcription O
polymerase O
chain O
reaction O
, O
and O
NF B
- I
kappaB I
DNA O
binding O
activity O
was O
assessed O
by O
gel O
mobility O
shift O
assay O
. O

Neither O
TNF B
- I
alpha I
mRNA I
expression O
nor O
NF B
- I
kappaB I
activation O
stimulated O
by O
LPS O
was O
inhibited O
by O
the O
cAMP O
- O
elevating O
agents O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP B
- I
2 I
activated O
the O
mouse O
p21 B
( I
CIP1 I
/ I
WAF1 I
) I
promoter I
in O
HS O
- O
72 O
cells O
, O
and O
that O
a O
29 B
- I
base I
pair I
( I
b I
) I
region I
of O
the O
promoter O
( O
- O
1928 O
/ O
- O
1900 O
relative O
to O
the O
TATA B
box I
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP B
- I
2 I
as O
well O
as O
expression O
of O
Smad1 B
, O
Smad4 B
, O
and O
constitutively O
active O
mutants O
of O
BMP B
type I
I I
receptors I
. O

Furthermore O
, O
an O
oligonucleotide O
containing O
the O
29 B
- I
b I
region I
was O
found O
to O
be O
associated O
with O
Smad4 B
and O
phosphorylated B
Smad1 I
in O
the O
nuclear O
extract O
of O
BMP B
- I
2 I
- O
stimulated O
HS O
- O
72 O
cells O
. O

These O
results O
suggested O
that O
BMP B
- I
2 I
might O
activate O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
transcription O
by O
inducing O
a O
binding O
of O
Smad4 B
and O
Smad1 B
to O
the O
29 B
- I
b I
region I
in O
HS O
- O
72 O
cells O
. O

We O
also O
examined O
whether O
signaling O
by O
muramyl O
peptides O
involves O
the O
use O
of O
cell B
surface I
receptors I
, O
including O
CD14 B
and O
Toll B
- I
like I
receptor I
2 I
( O
TLR2 B
) O
or O
TLR4 B
that O
are O
known O
to O
be O
signal B
- I
transducing I
receptors I
for O
other O
bacterial O
cell O
wall O
components O
. O

Long O
- O
term O
- O
impaired O
expression O
of O
nuclear B
factor I
- I
kappa I
B I
and O
I B
kappa I
B I
alpha I
in O
peripheral O
blood O
mononuclear O
cells O
of O
trauma O
patients O
. O

The O
ex O
vivo O
expression O
of O
I B
kappa I
B I
alpha I
was O
higher O
in O
PBMCs O
of O
controls O
than O
of O
trauma O
patients O
. O

Although O
no O
direct O
correlation O
was O
found O
between O
levels O
of O
interleukin B
- I
10 I
or O
transforming B
growth I
factor I
- I
beta I
and O
NF B
- I
kappa I
B I
, O
these O
immunosuppressive B
cytokines I
were O
significantly O
elevated O
in O
trauma O
patients O
by O
10 O
days O
after O
admission O
. O

The O
long O
- O
term O
low O
- O
basal O
and O
LPS O
- O
induced O
nuclear O
translocation O
of O
NF B
- I
kappa I
B I
recalled O
long O
- O
term O
immunoparalysis O
observed O
in O
patients O
with O
severe O
inflammatory O
stress O
such O
as O
trauma O
. O

The O
Friend B
of I
GATA I
proteins I
U O
- O
shaped O
, O
FOG B
- I
1 I
, O
and O
FOG B
- I
2 I
function O
as O
negative O
regulators O
of O
blood O
, O
heart O
, O
and O
eye O
development O
in O
Drosophila O
. O

During O
vertebrate O
hematopoiesis O
, O
FOG B
and I
GATA I
proteins I
cooperate O
to O
promote O
erythrocyte O
and O
megakaryocyte O
differentiation O
. O

When O
Ush B
, O
FOG B
- I
1 I
, O
FOG B
- I
2 I
, O
or O
mutant B
FOG I
- I
2 I
is O
coexpressed O
with O
Pnr B
during O
these O
developmental O
processes O
, O
severe O
eye O
and O
heart O
phenotypes O
result O
, O
consistent O
with O
a O
conserved O
negative O
regulation O
of O
Pnr B
function O
. O

Inhibition O
of O
the O
ubiquitin O
- O
proteasome O
pathway O
in O
B O
cells O
leads O
to O
elevated O
levels O
of O
OBF B
- I
1 I
protein I
. O

Furthermore O
, O
in O
immunized O
mice O
, O
OBF B
- I
1 I
protein I
amounts O
are O
dramatically O
increased O
in O
primary O
activated O
B O
cells O
, O
without O
concomitant O
increase O
in O
OBF B
- I
1 I
mRNA I
. O

Furthermore O
, O
in O
immunized O
mice O
, O
OBF B
- I
1 I
protein I
amounts O
are O
dramatically O
increased O
in O
primary O
activated O
B O
cells O
, O
without O
concomitant O
increase O
in O
OBF B
- I
1 I
mRNA I
. O

These O
data O
suggest O
that O
Siah B
- I
1 I
is O
part O
of O
a O
novel O
regulatory O
loop O
controlling O
the O
level O
of O
OBF B
- I
1 I
protein I
in O
B O
cells O
. O

The O
association O
of O
trans B
- I
acting I
T I
cell I
factors I
( O
TCFs B
) O
or O
lymphoid B
enhancer I
factor I
1 I
( O
LEF B
- I
1 I
) O
with O
their O
coactivator O
beta O
- O
catenin O
mediates O
transient O
transcriptional O
responses O
to O
extracellular O
Wnt O
signals O
. O

Accelerated O
spontaneous O
thymocyte O
death O
in O
the O
absence O
of O
TCF B
- I
1 I
correlates O
with O
aberrantly O
low O
expression O
of O
the O
anti B
- I
apoptotic I
protein I
Bcl B
- I
x I
( I
L I
) I
. O

Increasing O
anti O
- O
apoptotic O
effectors O
in O
thymocytes O
by O
the O
use O
of O
a O
Bcl B
- I
2 I
transgene I
rescued O
TCF O
- O
1 O
- O
deficient O
DP O
thymocytes O
from O
apoptosis O
. O

TRAIL B
/ I
Apo2L I
ligand I
selectively O
induces O
apoptosis O
and O
overcomes O
drug O
resistance O
in O
multiple O
myeloma O
: O
therapeutic O
applications O
. O

CD28 B
costimulation O
is O
required O
not O
only O
to O
induce O
IL B
- I
12 I
receptor I
but O
also O
to O
render O
janus B
kinases I
/ I
STAT4 I
responsive O
to O
IL B
- I
12 I
stimulation O
in O
TCR O
- O
triggered O
T O
cells O
. O

CD28 B
costimulation O
is O
required O
not O
only O
to O
induce O
IL B
- I
12 I
receptor I
but O
also O
to O
render O
janus B
kinases I
/ I
STAT4 I
responsive O
to O
IL B
- I
12 I
stimulation O
in O
TCR O
- O
triggered O
T O
cells O
. O

When O
T O
cells O
are O
stimulated O
with O
low O
doses O
of O
anti B
- I
CD3 I
mAb I
, O
CD28 O
costimulation O
was O
required O
for O
the O
optimal O
levels O
of O
IL B
- I
12 I
receptor I
( O
IL B
- I
12R I
) O
expression O
. O

When O
T O
cells O
are O
stimulated O
with O
low O
doses O
of O
anti B
- I
CD3 I
mAb I
, O
CD28 O
costimulation O
was O
required O
for O
the O
optimal O
levels O
of O
IL B
- I
12 I
receptor I
( O
IL B
- I
12R I
) O
expression O
. O

Recent O
data O
from O
mice O
deficient O
for O
phosphatase B
and O
tensin B
homologue I
deleted O
from O
chromosome B
10 I
or O
src B
homology I
2 I
domain I
- I
containing I
5 I
' I
inositol I
phosphatase I
, O
phosphatases B
that O
negatively O
regulate O
the O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI3K B
) O
pathway O
, O
revealed O
an O
increased O
number O
of O
macrophages O
in O
these O
animals O
, O
suggesting O
an O
essential O
role O
for O
the O
PI3K B
pathway O
for O
macro O
- O
phage O
survival O
. O

Inhibition O
of O
PI3K B
/ O
Akt O
- O
1 O
pathway O
either O
by O
LY294002 O
or O
DN B
Akt I
- I
1 I
had O
no O
effect O
on O
the O
constitutive O
or O
inducible O
activation O
of O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
in O
human O
macrophages O
. O

Recent O
evidence O
suggests O
that O
overexpression O
of O
the O
glucocorticoid B
receptor I
splice I
variant I
GRbeta B
in O
inflammatory O
cells O
might O
contribute O
to O
steroid O
insensitivity O
in O
diseases O
such O
as O
asthma O
. O

Analysis O
of O
the O
minimal B
promoter I
revealed O
nine O
consensus B
- I
binding I
sites I
for O
transcription B
factors I
, O
including O
several O
that O
are O
also O
found O
in O
the O
minimal B
promoters I
of O
galectins B
- I
1 I
, I
- I
2 I
, I
and I
- I
3 I
. O

The O
decrease O
in O
gal O
- O
10 O
promoter O
activity O
after O
disruption O
of O
either O
the O
GC B
box I
( O
- O
44 O
to O
- O
50 O
) O
or O
the O
Oct B
site I
( O
- O
255 O
to O
- O
261 O
) O
suggests O
that O
these O
sites O
, O
along O
with O
the O
previously O
characterized O
GATA B
and I
EoTF I
sites I
, O
are O
necessary O
for O
full O
promoter O
activity O
. O

Additionally O
, O
we O
demonstrate O
AML3 O
binding O
to O
the O
consensus B
AML I
site I
and O
YY1 B
binding I
to O
the O
Inr B
sequence I
, O
both O
elements O
functioning O
as O
silencers O
in O
the O
gal B
- I
10 I
promoter I
. O

Although O
the O
signals O
governing O
fibrotic O
induction O
, O
ductal O
morphogenesis O
, O
and O
growth O
inhibition O
are O
unknown O
, O
a O
role O
for O
transforming O
growth B
factor I
- I
beta I
is O
highly O
likely O
and O
is O
discussed O
. O

Constitutive O
expression O
of O
MHC B
class I
II I
genes I
in O
melanoma O
cell O
lines O
results O
from O
the O
transcription O
of O
class B
II I
transactivator I
abnormally O
initiated O
from O
its O
B B
cell I
- I
specific I
promoter I
. O

In O
melanoma O
cell O
lines O
, O
two O
different O
patterns O
of O
MHC O
class O
II O
expression O
have O
been O
described O
, O
either O
an O
IFN O
gamma O
- O
inducible O
expression O
of O
HLA B
- I
DR I
and O
HLA B
- I
DP I
, O
with O
a O
faint O
or O
null O
expression O
of O
HLA B
- I
DQ I
, O
resembling O
that O
described O
for O
melanocytes O
, O
or O
a O
constitutive O
expression O
, O
i O
. O
e O
. O
, O
IFN O
- O
gamma O
independent O
, O
of O
all O
three O
HLA B
- I
D I
isotypes I
. O

In O
agreement O
with O
the O
evidence O
of O
a O
coordinate O
transcription O
of O
the O
HLA B
- I
D I
genes I
in O
these O
cell O
lines O
, O
we O
have O
shown O
the O
constitutive O
expression O
of O
CIITA B
( I
class I
II I
transactivator I
) I
transcripts I
, O
CIITA B
being O
known O
as O
the O
master O
switch O
of O
MHC O
class O
II O
expression O
. O

In O
parallel O
, O
proteolytic O
activation O
of O
upstream O
caspases B
( O
caspase O
- O
8 O
and O
- O
9 O
) O
as O
well O
as O
effector B
caspase I
- I
3 I
was O
also O
observed O
. O

Furthermore O
, O
in O
PHA O
or O
P O
+ O
I O
- O
activated O
Jurkat O
cells O
, O
dephosphorylation O
of O
calcineurin B
substrate O
NFATc B
( O
a O
transcription B
factor I
known O
to O
be O
involved O
in O
transactivation O
of O
the O
IL B
- I
2 I
gene I
) O
, O
was O
also O
suppressed O
by O
Z O
- O
D O
- O
DCB O
. O

The O
cells O
were O
matured O
by O
addition O
of O
tumor B
necrosis I
factor I
( I
TNF I
) I
- I
a I
, O
IL B
- I
1 I
beta I
, O
and O
prostaglandin B
E2 I
in O
the O
presence O
of O
sulfasalazine O
or O
its O
metabolites O
- O
- O
aminosalicylate O
and O
sulfapyridine O
, O
or O
their O
combinations O
. O

Current O
models O
propose O
that O
the O
functions O
of O
Ikaros B
should O
be O
disrupted O
by O
a O
small O
isoform B
that O
retains O
the O
dimerization B
domain I
and O
lacks O
the O
DNA B
- I
binding I
domain I
. O

Rather O
, O
the O
small O
isoform B
assembled O
into O
multimeric B
complexes I
with O
DNA B
- I
bound I
Ikaros I
at O
the O
pericentromeric O
foci O
. O

The O
underlying O
mechanism O
involves O
transcriptional O
inhibition O
of O
the O
IL B
- I
12p40 I
gene I
, O
marked O
by O
down O
- O
regulation O
of O
PU O
. O
1 O
binding O
activity O
at O
the O
upstream B
Ets I
site I
of O
the O
IL B
- I
12p40 I
promoter I
. O

The O
underlying O
mechanism O
involves O
transcriptional O
inhibition O
of O
the O
IL B
- I
12p40 I
gene I
, O
marked O
by O
down O
- O
regulation O
of O
PU O
. O
1 O
binding O
activity O
at O
the O
upstream B
Ets I
site I
of O
the O
IL B
- I
12p40 I
promoter I
. O

Nuclear B
factor I
- I
kappaB I
suppressive O
and O
inhibitor B
- I
kappaB I
stimulatory O
effects O
of O
troglitazone O
in O
obese O
patients O
with O
type O
2 O
diabetes O
: O
evidence O
of O
an O
antiinflammatory O
action O
? O

To O
test O
these O
properties O
in O
humans O
, O
we O
investigated O
the O
effect O
of O
troglitazone O
on O
the O
proinflammatory B
transcription I
factor I
nuclear I
factor I
- I
kappaB I
and O
its O
inhibitory B
protein I
IkappaB I
in O
mononuclear O
cells O
( O
MNC O
) O
and O
plasma B
soluble I
intracellular I
adhesion I
molecule I
- I
1 I
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
plasminogen B
activator I
inhibitor I
- I
1 I
, O
and O
C B
- I
reactive I
protein I
. O

Nuclear B
factor I
- I
kappaB I
binding O
activity O
in O
MNC O
nuclear O
extracts O
was O
significantly O
inhibited O
after O
troglitazone O
treatment O
at O
week O
1 O
and O
continued O
to O
be O
inhibited O
up O
to O
week O
4 O
. O

Reactive O
oxygen O
species O
generation O
by O
polymorphonuclear O
cells O
and O
MNC O
, O
p47 B
( I
phox I
) I
subunit I
protein I
quantities O
, O
plasminogen B
activator I
inhibitor I
- I
1 I
, O
and O
C B
- I
reactive I
protein I
levels O
decreased O
significantly O
after O
troglitazone O
intake O
. O

OX40 O
stimulation O
by O
gp34 B
/ I
OX40 I
ligand I
enhances O
productive O
human O
immunodeficiency O
virus O
type O
1 O
infection O
. O

This O
was O
followed O
by O
apparent O
apoptosis O
, O
and O
both O
processes O
were O
specifically O
inhibited O
by O
the O
gp34 B
- O
specific O
neutralizing B
monoclonal I
antibody I
5A8 I
. O

Furthermore O
, O
enhanced O
HIV O
- O
1 O
transcription O
in O
gp34 B
- O
stimulated O
ACH O
- O
2 O
/ O
OX40 O
cells O
was O
dependent O
on O
the O
kappa B
B I
site I
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
, O
and O
the O
OX40 O
- O
gp34 O
interaction O
activated O
NF B
- I
kappa I
B I
consisting O
of O
p50 B
and I
p65 I
subunits I
. O

Furthermore O
, O
enhanced O
HIV O
- O
1 O
transcription O
in O
gp34 B
- O
stimulated O
ACH O
- O
2 O
/ O
OX40 O
cells O
was O
dependent O
on O
the O
kappa B
B I
site I
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
, O
and O
the O
OX40 O
- O
gp34 O
interaction O
activated O
NF B
- I
kappa I
B I
consisting O
of O
p50 B
and I
p65 I
subunits I
. O

The O
tissue O
- O
and O
stage O
- O
specific O
assembly O
of O
Ig B
and I
TCR I
genes I
is O
mediated O
by O
a O
common O
V B
( I
D I
) I
J I
recombinase I
complex I
in O
precursor O
lymphocytes O
. O

In O
pull O
- O
down O
experiments O
, O
only O
full B
- I
length I
BTK I
and O
its O
SH1 B
/ I
kinase I
domain I
( O
but O
not O
the O
pleckstrin O
homology O
, O
SH2 B
, I
or I
SH3 I
domains I
) O
were O
capable O
of O
binding O
STAT5A B
. O

In O
pull O
- O
down O
experiments O
, O
only O
full B
- I
length I
BTK I
and O
its O
SH1 B
/ I
kinase I
domain I
( O
but O
not O
the O
pleckstrin O
homology O
, O
SH2 B
, I
or I
SH3 I
domains I
) O
were O
capable O
of O
binding O
STAT5A B
. O

B O
cell O
antigen O
receptor O
ligation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5 B
in O
BTK B
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
wild B
type I
human I
BTK I
but O
not O
in O
BTK B
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
kinase B
- I
inactive I
mutant I
BTK I
. O

Subsequently O
, O
it O
appears O
that O
IL B
- I
12 I
/ O
STAT4 B
serves O
two O
essential O
functions O
in O
the O
development O
of O
TH1 O
cells O
: O
as O
growth B
signal I
, O
inducing O
survival O
and O
cell O
division O
; O
and O
as O
trans B
- I
activator I
, O
prolonging O
IFN B
- I
gamma I
synthesis O
through O
a O
genetic O
interaction O
with O
the O
coactivator B
, O
CREB B
- I
binding I
protein I
. O

The O
mutant B
hIL I
- I
4Ralpha I
, O
as O
well O
as O
the O
wild B
- I
type I
( I
WT I
) I
hIL I
- I
4Ralpha I
, O
was O
introduced O
into O
naive O
CD4 O
T O
cells O
. O

Upon O
hIL O
- O
4 O
stimulation O
, O
Y497F B
worked O
as O
well O
as O
the O
WT B
hIL I
- I
4Ralpha I
in O
driving O
Th2 O
differentiation O
, O
as O
measured O
by O
Gata3 O
up O
- O
regulation O
and O
IL O
- O
4 O
production O
. O

Furthermore O
, O
IL O
- O
4 O
- O
driven O
cell O
expansion O
was O
also O
normal O
in O
the O
cells O
infected O
with O
Y497F B
, O
although O
cells O
infected O
with O
Y497F B
were O
not O
capable O
of O
phosphorylating O
insulin B
receptor I
substrate I
2 I
. O

The O
effect O
of O
HIV B
- I
1 I
regulatory I
proteins I
on O
cellular O
genes O
: O
derepression O
of O
the O
IL B
- I
2 I
promoter I
by O
Tat B
. O

We O
demonstrate O
that O
increased O
IL O
- O
2 O
secretion O
is O
due O
to O
Tat B
- O
enhanced O
IL B
- I
2 I
promoter I
activation O
. O

Tat B
derepresses O
and O
activates O
the O
distal B
AP I
- I
1 I
site I
( O
position B
- I
185 I
to I
- I
177 I
) O
in O
the O
IL B
- I
2 I
promoter I
. O

In O
nonstimulated O
T O
cells O
a O
repressor O
complex O
containing O
NF B
- I
IL6 I
, O
JunB B
, O
c B
- I
Fos I
and O
Fra B
- I
1 I
is O
formed O
on O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
and O
represses O
IL B
- I
2 I
promoter I
activity O
. O

TPO B
- O
induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathway O
( O
PD098059 O
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK B
extracellular I
signal I
- I
regulated I
kinases I
( O
ERK B
) O
ERK1 B
and O
ERK2 B
, O
and O
AG490 O
, O
an O
inhibitor O
of O
Janus B
kinase I
- I
2 I
, O
which O
completely O
blocked O
TPO B
- O
induced O
proliferation O
. O

The O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
, O
a O
member O
of O
the O
nuclear B
hormone I
receptor I
superfamily I
, O
is O
essential O
for O
adipocyte O
differentiation O
and O
glucose O
homeostasis O
. O

A O
prominent O
role O
for O
activator B
protein I
- I
1 I
in O
the O
transcription O
of O
the O
human B
2B4 I
( I
CD244 I
) I
gene I
in O
NK O
cells O
. O

The O
cell B
surface I
glycoprotein I
2B4 I
( O
CD244 B
) O
of O
the O
Ig B
superfamily I
is O
involved O
in O
the O
regulation O
of O
NK O
and O
T O
lymphocyte O
functions O
. O

We O
isolated O
h2B4 B
genomic I
clones I
and O
PCR O
amplified O
the O
5 B
' I
untranslated I
region I
containing O
the O
promoter B
elements I
. O

We O
have O
identified O
a O
functional O
AP B
- I
1 I
site I
that O
lies O
between O
( O
- O
106 O
to O
- O
100 O
) O
through O
transient O
transfection O
analysis O
in O
YT O
cells O
, O
a O
human O
NK O
cell O
line O
. O

EMSAs O
with O
Abs B
specific O
for O
various O
protein B
factors I
of O
the O
AP B
- I
1 I
family I
revealed O
that O
multiple O
members O
of O
the O
Jun B
family I
are O
involved O
in O
the O
regulation O
of O
the O
h2B4 B
gene I
. O

Mutation O
of O
the O
AP B
- I
1 I
site I
not O
only O
abolishes O
protein O
/ O
DNA O
interactions O
but O
also O
promoter O
activity O
. O

Because O
hematopoietic O
cells O
derived O
from O
Fanconi O
anemia O
( O
FA O
) O
patients O
of O
the O
C O
- O
complementation O
group O
( O
FA O
- O
C O
) O
are O
hypersensitive O
to O
the O
inhibitory O
effects O
of O
interferon B
gamma I
( O
IFNgamma B
) O
, O
the O
products O
of O
certain O
IFNgamma B
- I
inducible I
genes I
known O
to O
influence O
hematopoietic O
cell O
survival O
were O
quantified O
. O

High O
constitutive O
expression O
of O
the O
IFNgamma B
- I
inducible I
genes I
, O
IFN B
- I
stimulated I
gene I
factor I
3 I
gamma I
subunit I
( O
ISGF3gamma B
) O
, O
IFN B
regulatory I
factor I
- I
1 I
( O
IRF B
- I
1 I
) O
, O
and O
the O
cyclin B
- I
dependent I
kinase I
inhibitor I
p21 I
( O
WAF1 B
) O
was O
found O
in O
FANCC B
mutant O
B O
lymphoblasts O
, O
low O
- O
density O
bone O
marrow O
cells O
, O
and O
murine O
embryonic O
fibroblasts O
. O

In O
an O
attempt O
to O
clarify O
mechanisms O
by O
which O
FA O
- O
C O
cells O
overexpress O
IFNgamma B
- I
inducible I
genes I
in O
the O
face O
of O
defective O
STAT1 O
phosphorylation O
, O
it O
was O
reasoned O
that O
decreased O
levels O
of O
activated B
STAT1 I
might O
result O
in O
reduced O
expression O
of O
a O
hematopoietic B
IFNgamma I
- I
responsive I
protein I
that O
normally O
modulates O
expression O
of O
other O
IFNgamma B
- I
responsive I
genes I
. O

In O
an O
attempt O
to O
clarify O
mechanisms O
by O
which O
FA O
- O
C O
cells O
overexpress O
IFNgamma B
- I
inducible I
genes I
in O
the O
face O
of O
defective O
STAT1 O
phosphorylation O
, O
it O
was O
reasoned O
that O
decreased O
levels O
of O
activated B
STAT1 I
might O
result O
in O
reduced O
expression O
of O
a O
hematopoietic B
IFNgamma I
- I
responsive I
protein I
that O
normally O
modulates O
expression O
of O
other O
IFNgamma B
- I
responsive I
genes I
. O

Levels O
of O
the O
IFNgamma B
- O
inducible O
factor O
IFN B
consensus I
sequence I
binding I
protein I
( O
ICSBP B
) O
, O
a O
negative B
trans I
- I
acting I
regulator I
of O
some O
IFNgamma B
- I
inducible I
genes I
, O
were O
quantified O
. O

However O
, O
enforced O
expression O
of O
ICSBP B
failed O
to O
down O
- O
regulate O
IRF B
- I
1 I
, O
ISGF3gamma B
, O
and O
p21 B
( I
WAF1 I
) I
. O

Furthermore O
, O
preincubation O
of O
lymphocytes O
with O
D609 O
resulted O
in O
a O
significant O
diminution O
of O
ionizing O
radiation O
( O
IR O
) O
- O
induced O
1 O
) O
production O
of O
reactive O
oxygen O
species O
; O
2 O
) O
decrease O
in O
intracellular O
reduced O
glutathione O
; O
3 O
) O
oxidative O
damage O
to O
proteins O
and O
lipids O
; O
and O
4 O
) O
activation O
of O
nuclear B
factor I
- I
kappaB I
. O

The O
immunosuppressive O
effects O
of O
glucocorticoids O
arise O
largely O
by O
inhibition O
of O
cytokine O
gene O
expression O
, O
which O
has O
been O
ascribed O
to O
interference O
between O
the O
glucocorticoid B
receptor I
and O
transcription B
factors I
such O
as O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
as O
well O
as O
by O
competition O
for O
common O
coactivators O
. O

GILZ B
also O
potently O
inhibited O
AP B
- I
1 I
- I
driven I
and I
IL I
- I
2 I
promoter I
- I
driven I
reporter I
constructs I
, O
and O
recombinant O
GILZ B
specifically O
interacted O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
in O
vitro O
and O
inhibited O
the O
binding O
of O
active B
AP I
- I
1 I
to O
its O
target O
DNA O
. O

Transforming B
growth I
factor I
( I
TGF I
) I
- I
beta1 I
is O
well O
established O
as O
a O
critical O
IgA B
isotype I
switching I
factor I
and O
Smad B
molecules I
have O
been O
reported O
to O
act O
as O
transducers B
and O
transcriptional B
factors I
in O
the O
expression O
of O
TGF B
- I
beta1 I
- O
targeted O
genes B
. O

The O
results O
from O
the O
present O
study O
indicate O
that O
Smad3 B
, O
Smad4 B
, O
and O
Smad7 B
, O
at O
least O
in O
part O
, O
serve O
as O
mediators O
linking O
TGF B
- I
beta1 I
to O
transcriptional O
regulation O
of O
IgA B
switching I
related I
gene I
and O
regulation O
of O
IgA O
class O
switching O
. O

The O
translesion B
DNA I
polymerase I
zeta I
plays O
a O
major O
role O
in O
Ig O
and O
bcl O
- O
6 O
somatic O
hypermutation O
. O

Introduction O
of O
Tax B
into O
resting O
Kit O
225 O
cells O
induced O
activation O
of O
the O
G1 O
/ O
S O
transition O
regulation O
cascade O
consisting O
of O
activation O
of O
cyclin B
dependent I
kinase I
2 I
( O
CDK2 B
) O
and O
CDK4 B
, O
phosphorylation O
of O
the O
Rb B
family I
proteins I
and O
an O
increase O
in O
free O
E2F B
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

These O
results O
indicate O
the O
important O
role O
of O
Tax B
- O
mediated O
trans O
- O
activation O
of O
the O
genes O
for O
cell B
cycle I
regulatory I
molecules I
in O
Tax B
- O
induced O
cell O
cycle O
progression O
. O

Here O
we O
report O
that O
Cot B
kinase I
, O
a O
mitogen B
- I
activated I
protein I
kinase I
kinase I
kinase I
involved O
in O
T O
cell O
activation O
, O
up O
- O
regulates O
COX B
- I
2 I
gene I
expression O
in O
Jurkat O
T O
cells O
. O

Mutation O
of O
the O
distal B
( I
- I
105 I
/ I
- I
97 I
) I
and O
proximal B
( I
- I
76 I
/ I
- I
61 I
) I
NFAT B
response I
elements I
in O
the O
COX B
- I
2 I
promoter I
abolished O
the O
activation O
induced O
by O
Cot B
kinase I
. O

Even O
more O
, O
coexpression O
of O
a O
dominant O
negative O
version O
of O
NFAT B
inhibited O
Cot B
kinase I
- O
mediated O
COX B
- I
2 I
promoter I
activation O
, O
whereas O
cotransfection O
of O
a O
constitutively O
active O
version O
of O
the O
calcium B
- I
dependent I
phosphatase I
calcineurin I
synergizes O
with O
Cot B
kinase I
in O
the O
up O
- O
regulation O
of O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
. O

Even O
more O
, O
coexpression O
of O
a O
dominant O
negative O
version O
of O
NFAT B
inhibited O
Cot B
kinase I
- O
mediated O
COX B
- I
2 I
promoter I
activation O
, O
whereas O
cotransfection O
of O
a O
constitutively O
active O
version O
of O
the O
calcium B
- I
dependent I
phosphatase I
calcineurin I
synergizes O
with O
Cot B
kinase I
in O
the O
up O
- O
regulation O
of O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
. O

In O
contrast O
to O
phorbol O
ester O
plus O
calcium O
ionophore O
A23187 O
, O
Cot B
kinase I
increases O
both O
COX B
- I
2 I
promoter I
activity O
and O
NFAT B
- O
mediated O
transactivation O
in O
a O
cyclosporin O
A O
- O
independent O
manner O
. O

These O
data O
indicate O
that O
Cot B
kinase I
up O
- O
regulates O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
through O
the O
NFAT B
response I
elements I
, O
being O
the O
Cot B
kinase I
- O
induced O
NFAT B
- O
dependent O
transactivation O
presumably O
implicated O
in O
this O
up O
- O
regulation O
. O

Due O
to O
a O
combinatorial O
distribution O
of O
Ly B
- I
49 I
receptors I
, O
NK O
cells O
display O
considerable O
clonal O
heterogeneity O
. O

The O
acquisition O
of O
one O
Ly B
- I
49 I
receptor I
, O
Ly B
- I
49A I
is O
strictly O
dependent O
on O
the O
transcriptional B
trans I
- I
acting I
factor I
T B
cell I
- I
specific I
factor I
- I
1 I
( O
TCF B
- I
1 I
) O
. O

Indeed O
, O
TCF B
- I
1 I
binds O
to O
two O
sites O
in O
the O
Ly B
- I
49a I
promoter I
and O
regulates O
its O
activity O
, O
suggesting O
that O
the O
Ly B
- I
49a I
gene I
is O
a O
direct O
TCF B
- I
1 I
target O
. O

Indeed O
, O
TCF B
- I
1 I
binds O
to O
two O
sites O
in O
the O
Ly B
- I
49a I
promoter I
and O
regulates O
its O
activity O
, O
suggesting O
that O
the O
Ly B
- I
49a I
gene I
is O
a O
direct O
TCF B
- I
1 I
target O
. O

TCF B
- I
1 I
deficiency O
resulted O
in O
the O
altered O
usage O
of O
additional O
Ly B
- I
49 I
receptors I
. O

Our O
findings O
rather O
suggest O
a O
TCF B
- I
1 I
- O
dependent O
, O
cell O
autonomous O
effect O
on O
the O
acquisition O
of O
multiple O
Ly B
- I
49 I
receptors I
. O

Therefore O
, O
besides O
TCF B
- I
1 I
binding O
to O
the O
proximal B
promoter I
, O
Ly O
- O
49 O
acquisition O
may O
also O
be O
regulated O
by O
TCF B
- I
1 I
binding O
to O
more O
distant O
cis B
- I
acting I
elements I
and O
/ O
or O
by O
regulating O
the O
expression O
of O
additional O
trans B
- I
acting I
factors I
. O

Therefore O
, O
besides O
TCF B
- I
1 I
binding O
to O
the O
proximal B
promoter I
, O
Ly O
- O
49 O
acquisition O
may O
also O
be O
regulated O
by O
TCF B
- I
1 I
binding O
to O
more O
distant O
cis B
- I
acting I
elements I
and O
/ O
or O
by O
regulating O
the O
expression O
of O
additional O
trans B
- I
acting I
factors I
. O

Consistent O
with O
the O
observed O
differential O
, O
positive O
or O
negative O
role O
of O
TCF B
- I
1 I
for O
Ly B
- I
49 I
receptor I
acquisition O
, O
reporter O
gene O
assays O
revealed O
the O
presence O
of O
an O
inducing O
as O
well O
as O
a O
repressing O
TCF B
site I
in O
certain O
proximal O
Ly B
- I
49 I
promoters I
. O

Consistent O
with O
the O
observed O
differential O
, O
positive O
or O
negative O
role O
of O
TCF B
- I
1 I
for O
Ly B
- I
49 I
receptor I
acquisition O
, O
reporter O
gene O
assays O
revealed O
the O
presence O
of O
an O
inducing O
as O
well O
as O
a O
repressing O
TCF B
site I
in O
certain O
proximal O
Ly B
- I
49 I
promoters I
. O

Ligation O
of O
CD11b B
and O
CD11c B
beta I
( I
2 I
) I
integrins B
by O
antibodies B
or O
soluble B
CD23 I
induces O
macrophage B
inflammatory I
protein I
1alpha I
( O
MIP B
- I
1alpha I
) O
and O
MIP B
- I
1beta I
production O
in O
primary O
human O
monocytes O
through O
a O
pathway O
dependent O
on O
nuclear B
factor I
- I
kappaB I
. O

Ligation O
of O
CD11b B
and O
CD11c B
beta I
( I
2 I
) I
integrins B
by O
antibodies B
or O
soluble B
CD23 I
induces O
macrophage B
inflammatory I
protein I
1alpha I
( O
MIP B
- I
1alpha I
) O
and O
MIP B
- I
1beta I
production O
in O
primary O
human O
monocytes O
through O
a O
pathway O
dependent O
on O
nuclear B
factor I
- I
kappaB I
. O

Because O
the O
promoters B
of O
these O
chemokine B
genes I
contain O
kappaB B
binding I
sites I
, O
we O
assessed O
the O
possible O
role O
of O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
in O
controlling O
induction O
of O
the O
genes O
through O
beta O
( O
2 O
) O
integrin O
engagement O
. O

Interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
, O
a O
cytokine B
that O
exerts O
many O
pro O
- O
atherosclerotic O
effects O
in O
vivo O
, O
causes O
up O
- O
regulation O
of O
ACAT B
- I
1 I
mRNA I
in O
human O
blood O
monocyte O
- O
derived O
macrophages O
and O
macrophage O
- O
like O
cells O
but O
not O
in O
other O
cell O
types O
. O

Additional O
experiments O
showed O
that O
all O
- O
trans O
- O
retinoic O
acid O
causes O
large O
induction O
of O
the O
transcription B
factor I
STAT1 I
, O
while O
IFN B
- I
gamma I
causes O
activation O
of O
STAT1 B
such O
that O
it O
binds O
to O
the O
GAS B
/ I
Sp1 I
site I
in O
the O
ACAT B
- I
1 I
P1 I
promoter I
. O

OBJECTIVE O
: O
To O
examine O
whether O
inhaled O
nitric O
oxide O
( O
NO O
) O
affected O
the O
intrapulmonary O
production O
of O
NO O
, O
reactive O
oxygen O
species O
, O
and O
nuclear B
factor I
- I
kappaB I
in O
a O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
model O
of O
acute O
lung O
injury O
. O

Inhaled O
NO O
also O
blocked O
the O
activities O
of O
reactive O
oxygen O
species O
and O
nuclear B
factor I
- I
kappaB I
binding O
to O
DNA O
in O
lavage O
cells O
and O
in O
alveolar O
macrophages O
. O

The O
mechanism O
of O
reducing O
NO O
production O
resulting O
from O
inhaled O
NO O
may O
involve O
, O
in O
part O
, O
the O
activities O
of O
reactive O
oxygen O
species O
and O
/ O
or O
nuclear B
factor I
- I
kappaB I
. O

METHODS O
AND O
RESULTS O
: O
BALB O
/ O
c O
mice O
, O
making O
a O
CD4 O
+ O
Th2 O
( O
IL O
- O
4 O
+ O
) O
cell O
response O
, O
express O
both O
MHC B
class I
II I
antigens I
( O
IA B
( I
d I
) I
, O
IE B
( I
d I
) I
) O
and O
are O
atherosclerosis O
- O
resistant O
. O

METHODS O
AND O
RESULTS O
: O
BALB O
/ O
c O
mice O
, O
making O
a O
CD4 O
+ O
Th2 O
( O
IL O
- O
4 O
+ O
) O
cell O
response O
, O
express O
both O
MHC B
class I
II I
antigens I
( O
IA B
( I
d I
) I
, O
IE B
( I
d I
) I
) O
and O
are O
atherosclerosis O
- O
resistant O
. O

METHODS O
AND O
RESULTS O
: O
BALB O
/ O
c O
mice O
, O
making O
a O
CD4 O
+ O
Th2 O
( O
IL O
- O
4 O
+ O
) O
cell O
response O
, O
express O
both O
MHC B
class I
II I
antigens I
( O
IA B
( I
d I
) I
, O
IE B
( I
d I
) I
) O
and O
are O
atherosclerosis O
- O
resistant O
. O

C57Bl O
/ O
6 O
mice O
produce O
a O
CD4 O
+ O
Th1 O
( O
interferon O
[ O
IFN O
] O
gamma O
+ O
) O
response O
, O
express O
IA B
( I
b I
) I
but O
no O
IE B
, O
and O
are O
atherosclerosis O
- O
prone O
. O

CONCLUSIONS O
: O
In O
mildly O
hypercholesterolemic O
C57Bl O
/ O
6 O
mice O
, O
presence O
of O
IA B
( I
b I
) I
and O
absence O
of O
IE B
regulated O
CD4 O
+ O
T O
helper O
- O
cell O
phenotype O
; O
fatty O
lesions O
were O
proportional O
to O
IFNgamma O
+ O
Th1 O
cells O
in O
both O
C57Bl O
/ O
6 O
and O
BALB O
/ O
c O
strains O
. O

Requirement O
for O
p38 B
and O
p44 B
/ I
p42 I
mitogen B
- I
activated I
protein I
kinases I
in O
RAGE B
- O
mediated O
nuclear B
factor I
- I
kappaB I
transcriptional O
activation O
and O
cytokine O
secretion O
. O

CML B
- I
modified I
albumin I
produced O
rapid O
transient O
activation O
of O
tyrosine O
phosphorylation O
, O
extracellular B
signal I
- I
regulated I
kinase I
1 I
and I
2 I
, O
and O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
, O
but O
not O
c B
- I
Jun I
NH I
( I
2 I
) I
- I
terminal I
kinase I
. O

Activation O
of O
NF B
- I
kappaB I
by O
CML B
- I
modified I
albumin I
increased O
secretion O
of O
proinflammatory B
cytokines I
( O
tumor B
necrosis I
factor I
- I
alpha I
, O
interleukin B
- I
1beta I
, O
and O
monocyte B
chemoattractant I
protein I
- I
1 I
) O
severalfold O
, O
and O
inhibition O
of O
p38 B
MAPK I
blocked O
these O
increases O
. O

Antigen O
- O
receptor O
cross O
- O
linking O
and O
lipopolysaccharide O
trigger O
distinct O
phosphoinositide B
3 I
- I
kinase I
- O
dependent O
pathways O
to O
NF O
- O
kappa O
B O
activation O
in O
primary O
B O
cells O
. O

Nuclear B
NF I
- I
kappaB I
is O
induced O
in O
B O
cells O
by O
engagement O
of O
either O
the O
BCR B
or O
CD40 B
or O
by O
stimulation O
with O
lipopolysaccharide O
( O
LPS O
) O
. O

In O
this O
report O
we O
address O
the O
role O
of O
phosphoinositide B
3 I
' I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
in O
BCR B
- O
and O
LPS O
- O
induced O
NF O
- O
kappaB O
activation O
using O
populations O
of O
primary O
murine O
resting O
B O
cells O
. O

Using O
the O
specific O
pharmacological O
inhibitors O
of O
PI B
3 I
- I
kinase I
, O
Wortmannin O
and O
LY294002 O
, O
we O
demonstrate O
that O
PI B
3 I
- I
kinase I
activity O
is O
vital O
for O
BCR B
- O
induced O
NF B
- I
kappaB I
DNA O
- O
binding O
activity O
. O

Using O
the O
specific O
pharmacological O
inhibitors O
of O
PI B
3 I
- I
kinase I
, O
Wortmannin O
and O
LY294002 O
, O
we O
demonstrate O
that O
PI B
3 I
- I
kinase I
activity O
is O
vital O
for O
BCR B
- O
induced O
NF B
- I
kappaB I
DNA O
- O
binding O
activity O
. O

Similar O
analyses O
reveal O
that O
PI B
3 I
- I
kinase I
is O
also O
critical O
in O
triggering O
NF B
- I
kappaB I
DNA O
- O
binding O
activity O
and O
IkappaBalpha B
degradation O
following O
LPS O
stimulation O
. O

Taken O
together O
, O
our O
results O
indicate O
the O
involvement O
of O
PI B
3 I
- I
kinase I
in O
at O
least O
two O
distinct O
signaling O
pathways O
leading O
to O
activation O
of O
NF B
- I
kappaB I
in O
B O
cells O
. O

In O
this O
report O
, O
we O
describe O
a O
new O
approach O
for O
direct O
identification O
of O
CD4 O
+ O
T O
cell O
epitopes O
of O
complex O
Ags B
that O
uses O
human B
class I
II I
tetramers I
to O
identify O
reactive O
cells O
. O

With O
a O
panel O
of O
60 O
overlapping O
peptides O
covering O
the O
entire O
sequence O
of O
the O
VP16 B
protein I
, O
a O
major O
Ag B
for O
HSV O
- O
2 O
, O
we O
generated O
a O
panel O
of O
class B
II I
MHC I
tetramers I
loaded O
with O
peptide O
pools O
that O
were O
used O
to O
stain O
peripheral O
lymphocytes O
of O
an O
HSV O
- O
2 O
infected O
individual O
. O

With O
this O
approach O
, O
we O
identified O
four O
new O
DRA1 O
* O
0101 O
/ O
DRB1 O
* O
0401 O
- O
and O
two O
DRA1 O
* O
0101 O
/ O
DRB1 O
* O
0404 O
- O
restricted O
, O
VP16 B
- I
specific I
epitopes I
. O

NF B
- I
kappaB I
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA O
expression O
of O
interleukin B
- I
6 I
, O
tumor B
necrosis I
factor I
- I
alpha I
, O
KC O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
and O
inducible B
nitric I
oxide I
synthase I
was O
assessed O
by O
semiquantitative O
RT O
- O
PCR O
. O

NF B
- I
kappaB I
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA O
expression O
of O
interleukin B
- I
6 I
, O
tumor B
necrosis I
factor I
- I
alpha I
, O
KC O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
and O
inducible B
nitric I
oxide I
synthase I
was O
assessed O
by O
semiquantitative O
RT O
- O
PCR O
. O

CD45 B
tyrosine I
phosphatase I
controls O
common O
gamma B
- I
chain I
cytokine I
- O
mediated O
STAT B
and O
extracellular O
signal O
- O
related O
kinase O
phosphorylation O
in O
activated O
human O
lymphoblasts O
: O
inhibition O
of O
proliferation O
without O
induction O
of O
apoptosis O
. O

To O
this O
end O
, O
we O
generated O
lymphoblasts O
which O
proliferate O
in O
response O
to O
common O
gamma B
- I
chain I
cytokines I
, O
but O
readily O
undergo O
apoptosis O
after O
cytokine O
withdrawal O
. O

Using O
RT O
- O
PCR O
, O
we O
found O
that O
CD45R0 O
signaling O
inhibited O
IL O
- O
2 O
mRNA O
production O
without O
major O
influence O
on O
IL B
- I
13 I
, O
IL B
- I
5 I
, O
or O
IFN B
- I
gamma I
mRNA I
levels O
. O

Pax5 B
thus O
functions O
both O
as O
a O
transcriptional O
repressor O
and O
activator O
, O
depending O
on O
its O
interactions O
with O
corepressors B
of O
the O
Groucho B
protein I
family I
or O
with O
positive O
regulators O
such O
as O
the O
TATA B
- I
binding I
protein I
. O

Concomitant O
induction O
of O
NFAT B
and O
AP B
- I
1 I
requires O
concerted O
activation O
of O
two O
different O
signaling O
pathways O
: O
calcium O
/ O
calcineurin O
, O
which O
promotes O
NFAT O
dephosphorylation O
, O
nuclear O
translocation O
and O
activation O
; O
and O
protein B
kinase I
C I
( I
PKC I
) I
/ I
Ras I
, O
which O
promotes O
the O
synthesis O
, O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Fos B
and I
Jun I
families I
of O
transcription B
factors I
. O

Electrophoretic O
mobility O
shift O
assays O
indicated O
plasmin B
- O
induced O
activation O
of O
NF B
- I
kappaB I
; O
DNA B
- I
binding I
complexes I
were O
composed O
of O
p50 B
, O
p65 B
, O
and O
c B
- I
Rel I
, O
as O
shown O
by O
supershift O
experiments O
. O

Mutation O
of O
either O
Tyr248 O
, O
Tyr357 O
, O
or O
Tyr462 O
to O
phenylalanine O
reduced O
transcription O
from O
a O
c B
- I
fos I
promoter I
relative O
to O
wild B
- I
type I
BAP I
/ I
TFII I
- I
I I
in O
transfected O
COS O
- O
7 O
cells O
, O
consistent O
with O
the O
interpretation O
that O
phosphorylation O
at O
these O
sites O
contributes O
to O
transcriptional O
activation O
. O

Mice O
deficient O
in O
the O
interferon B
consensus I
sequence I
binding I
protein I
( O
ICSBP B
) O
develop O
a O
disease O
resembling O
chronic O
myeloid O
leukemia O
( O
CML O
) O
, O
which O
in O
humans O
is O
caused O
by O
the O
BCR B
/ I
ABL I
oncoprotein I
. O

A O
transcriptional O
block O
in O
the O
IL B
- I
2 I
promoter I
at O
the O
- B
150 I
AP I
- I
1 I
site I
in O
effector O
CD8 O
+ O
T O
cells O
. O

To O
evaluate O
transcriptional O
regulation O
of O
the O
IL B
- I
2 I
gene I
in O
CD8 O
+ O
T O
cells O
, O
we O
stably O
transfected O
reporter B
genes I
into O
Ag B
- O
specific O
CD8 O
+ O
T O
cell O
clones O
. O

CD28 O
+ O
CD8 O
( O
+ O
) O
T O
cells O
unable O
to O
transcribe O
the O
IL B
- I
2 I
gene I
in O
response O
to O
antigenic O
stimulation O
had O
a O
block O
in O
transactivation O
of O
the O
- B
150 I
CD28 I
response I
element I
( I
CD28RE I
) I
/ I
AP I
- I
1 I
site I
of O
the O
IL B
- I
2 I
promoter I
, O
but O
did O
transactivate O
the O
composite O
NFAT B
/ I
AP I
- I
1 I
and I
OCT I
/ I
AP I
- I
1 I
sites I
, O
and O
a O
consensus B
AP I
- I
1 I
motif I
. O

CD28 O
+ O
CD8 O
( O
+ O
) O
T O
cells O
unable O
to O
transcribe O
the O
IL B
- I
2 I
gene I
in O
response O
to O
antigenic O
stimulation O
had O
a O
block O
in O
transactivation O
of O
the O
- B
150 I
CD28 I
response I
element I
( I
CD28RE I
) I
/ I
AP I
- I
1 I
site I
of O
the O
IL B
- I
2 I
promoter I
, O
but O
did O
transactivate O
the O
composite O
NFAT B
/ I
AP I
- I
1 I
and I
OCT I
/ I
AP I
- I
1 I
sites I
, O
and O
a O
consensus B
AP I
- I
1 I
motif I
. O

These O
results O
suggest O
that O
the O
defect O
at O
the O
- B
150 I
site I
may O
reflect O
the O
absence O
or O
inactivity O
of O
a O
required O
factor O
rather O
than O
repression O
of O
the O
IL B
- I
2 I
promoter I
. O

A O
m O
ultipotent O
immature O
myeloid O
cell O
population O
was O
produced O
from O
a O
basic B
fibroblast I
growth I
factor I
( O
bFGF B
) O
- O
dependent O
hematopoietic O
stem O
cell O
line O
, O
A O
- O
6 O
, O
when O
cultured O
with O
stem B
cell I
factor I
( O
SCF B
) O
replacing O
bFGF B
. O

Among O
various O
cytokines B
, O
interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
induced O
erythroid O
precursor O
cells O
that O
expressed O
the O
erythroid B
- I
specific I
GATA I
- I
1 I
and O
beta B
- I
major I
globin I
. O

We O
now O
show O
that O
while O
both O
purified O
recombinant B
gp350 I
( O
rgp350 B
) O
and O
EBV O
upregulate O
IL B
- I
6 I
mRNA I
synthesis O
in O
B O
cells O
, O
EBV O
- O
induced O
IL O
- O
6 O
gene O
activation O
occurs O
for O
a O
significantly O
longer O
period O
of O
time O
( O
i O
. O
e O
. O
12 O
hours O
for O
EBV O
as O
compared O
to O
6 O
hours O
for O
rgp350 B
) O
. O

Moreover O
, O
the O
half O
- O
life O
of O
EBV O
- O
induced O
IL B
- I
6 I
mRNA I
was O
also O
significantly O
longer O
( O
10 O
hours O
) O
than O
that O
of O
mRNA O
induced O
by O
rgp350 B
( O
about O
6 O
hours O
) O
. O

Gads B
is O
a O
SH2 B
and I
SH3 I
domain I
- O
containing O
, O
hematopoietic B
- I
specific I
adaptor I
protein I
that O
functions O
in O
signalling O
from O
the O
T B
cell I
receptor I
. O

Gads B
is O
distinguished O
from O
Grb2 B
and O
the O
closely O
related O
Grap B
protein I
by O
the O
presence O
of O
a O
120 B
amino I
acid I
unique I
region I
between O
the O
SH2 B
domain I
and O
the O
carboxy B
terminal I
SH3 I
domain I
. O

Targeting O
of O
p300 B
to O
the O
interleukin B
- I
2 I
promoter I
via O
CREB O
- O
Rel O
cross O
- O
talk O
during O
mitogen B
and O
oncogenic O
molecular O
signaling O
in O
activated O
T O
- O
cells O
. O

Recruitment O
of O
p300 B
by O
cAMP B
- I
responsive I
element I
- I
binding I
protein I
- I
Rel I
cross O
- O
talk O
at O
the O
composite B
CD28 I
response I
element I
( O
CD28RE B
) O
- O
TRE B
element I
of O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
promoter O
inducibility O
during O
T O
- O
cell O
activation O
, O
and O
CD28RE B
- I
TRE I
is O
the O
exclusive O
target O
of O
the O
human O
T O
- O
cell O
lymphotropic O
virus O
type O
I O
oncoprotein B
Tax I
. O

Recruitment O
of O
p300 B
by O
cAMP B
- I
responsive I
element I
- I
binding I
protein I
- I
Rel I
cross O
- O
talk O
at O
the O
composite B
CD28 I
response I
element I
( O
CD28RE B
) O
- O
TRE B
element I
of O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
promoter O
inducibility O
during O
T O
- O
cell O
activation O
, O
and O
CD28RE B
- I
TRE I
is O
the O
exclusive O
target O
of O
the O
human O
T O
- O
cell O
lymphotropic O
virus O
type O
I O
oncoprotein B
Tax I
. O

The O
intrinsic O
histone O
acetyltransferase O
activity O
of O
p300 B
is O
dispensable O
for O
activation O
of O
the O
IL B
- I
2 I
promoter I
, O
and O
the O
N B
- I
terminal I
743 I
residues I
contain O
the O
minimal O
structural O
requirements O
for O
synergistic O
transactivation O
of O
the O
CD28RE B
- I
TRE I
, O
the O
IL B
- I
2 I
promoter I
, O
and O
endogenous O
IL B
- I
2 I
gene I
expression O
. O

The O
intrinsic O
histone O
acetyltransferase O
activity O
of O
p300 B
is O
dispensable O
for O
activation O
of O
the O
IL B
- I
2 I
promoter I
, O
and O
the O
N B
- I
terminal I
743 I
residues I
contain O
the O
minimal O
structural O
requirements O
for O
synergistic O
transactivation O
of O
the O
CD28RE B
- I
TRE I
, O
the O
IL B
- I
2 I
promoter I
, O
and O
endogenous O
IL B
- I
2 I
gene I
expression O
. O

The O
intrinsic O
histone O
acetyltransferase O
activity O
of O
p300 B
is O
dispensable O
for O
activation O
of O
the O
IL B
- I
2 I
promoter I
, O
and O
the O
N B
- I
terminal I
743 I
residues I
contain O
the O
minimal O
structural O
requirements O
for O
synergistic O
transactivation O
of O
the O
CD28RE B
- I
TRE I
, O
the O
IL B
- I
2 I
promoter I
, O
and O
endogenous O
IL B
- I
2 I
gene I
expression O
. O

Mutational O
analysis O
of O
p300 B
reveals O
differential O
structural O
requirements O
for O
the O
N O
- O
terminal O
p300 O
module O
by O
individual O
cis B
- I
elements I
within O
the O
IL B
- I
2 I
promoter I
. O

These O
findings O
provide O
evidence O
that O
p300 B
assembles O
at O
the O
IL B
- I
2 I
promoter I
to O
form O
an O
enhanceosome O
- O
like O
signal O
transduction O
target O
that O
is O
centrally O
integrated O
at O
the O
CD28RE B
- I
TRE I
element I
of O
the O
IL B
- I
2 I
promoter I
through O
specific O
protein O
module O
- O
targeted O
associations O
in O
activated O
T O
- O
cells O
. O

These O
findings O
provide O
evidence O
that O
p300 B
assembles O
at O
the O
IL B
- I
2 I
promoter I
to O
form O
an O
enhanceosome O
- O
like O
signal O
transduction O
target O
that O
is O
centrally O
integrated O
at O
the O
CD28RE B
- I
TRE I
element I
of O
the O
IL B
- I
2 I
promoter I
through O
specific O
protein O
module O
- O
targeted O
associations O
in O
activated O
T O
- O
cells O
. O

These O
findings O
provide O
evidence O
that O
p300 B
assembles O
at O
the O
IL B
- I
2 I
promoter I
to O
form O
an O
enhanceosome O
- O
like O
signal O
transduction O
target O
that O
is O
centrally O
integrated O
at O
the O
CD28RE B
- I
TRE I
element I
of O
the O
IL B
- I
2 I
promoter I
through O
specific O
protein O
module O
- O
targeted O
associations O
in O
activated O
T O
- O
cells O
. O

METHODS O
: O
Cord O
blood O
mononuclear O
cells O
were O
Th1 O
- O
or O
Th2 O
- O
polarized O
by O
culture O
in O
IL O
- O
12 O
- O
or O
IL O
- O
4 O
- O
employing O
established O
methods O
; O
PBMC O
from O
house O
dust O
mite O
( O
HDM O
) O
- O
sensitive O
atopics O
and O
controls O
were O
stimulated O
overnight O
with O
HDM O
; O
cytokine O
production O
was O
measured O
by O
ELISA O
and O
GATA B
- I
3 I
mRNA I
expression O
by O
PCR O
. O

Homozygous O
disruption O
of O
either O
the O
Runx1 B
or I
Cbfb I
gene I
in O
mice O
results O
in O
embryonic O
lethality O
at O
midgestation O
due O
to O
hemorrhaging O
in O
the O
central O
nervous O
system O
, O
and O
severely O
impairs O
fetal O
liver O
hematopoiesis O
. O

In O
contrast O
, O
the O
CBFbeta B
- O
smooth B
muscle I
myosin I
heavy I
chain I
( I
SMMHC I
) I
fusion I
protein I
generated O
by O
the O
inv B
( I
16 I
) I
associated O
with O
acute O
myeloid O
leukemias O
( O
M4Eo O
) O
can O
not O
rescue O
definitive O
hematopoiesis O
by O
Cbfb O
- O
deficient O
ES O
cells O
. O

The O
implication O
of O
EBV O
in O
the O
skin O
lesions O
was O
determined O
by O
the O
presence O
of O
EBV B
- I
DNA I
, O
EBV B
- I
encoded I
nuclear I
RNA I
( O
EBER B
) O
and O
a O
clonality O
of O
EBV B
- I
DNA I
fragments I
containing O
the O
terminal B
repeats I
. O

Transcripts O
of O
EBV B
- I
encoded I
genes I
were O
screened O
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
, O
and O
confirmed O
by O
Southern O
blot O
hybridization O
. O

The O
expression O
of O
EBV B
- I
related I
antigens I
was O
examined O
by O
immunostaining O
using O
paraffin O
- O
embedded O
tissue O
sections O
and O
cell O
pellets O
of O
EBV O
- O
positive O
cell O
lines O
. O

Latent B
membrane I
protein I
- I
1 I
( I
LMP I
- I
1 I
) I
mRNA I
was O
detected O
in O
seven O
of O
eight O
patients O
and O
all O
cell O
lines O
, O
whereas O
EBNA B
- I
2 I
transcripts I
were O
found O
only O
in O
the O
cell O
lines O
. O

Latent B
BHRF1 I
transcripts I
encoding O
bcl B
- I
2 I
homologue I
and O
BCRF1 B
transcripts I
encoding O
viral B
interleukin I
( I
vIL I
) I
- I
10 I
were O
detected O
in O
one O
and O
two O
of O
eight O
patients O
, O
respectively O
. O

Oxidized B
low I
density I
lipoprotein I
( O
oxLDL B
) O
is O
inflammatory O
and O
signals O
through O
PPARs B
. O

[ O
( O
3 O
) O
H O
] O
azPC O
bound O
recombinant B
PPARgamma I
with O
an O
affinity O
( O
K O
( O
d O
) O
( O
( O
app O
) O
) O
approximately O
40 O
nm O
) O
that O
was O
equivalent O
to O
rosiglitazone O
( O
BRL49653 O
) O
, O
and O
competition O
with O
rosiglitazone O
showed O
that O
binding O
occurred O
in O
the O
ligand B
- I
binding I
pocket I
. O

The O
scavenger B
receptor I
CD36 I
is O
encoded O
by O
a O
PPRE B
- I
responsive I
gene I
, O
and O
azPC O
enhanced O
expression O
of O
CD36 B
in O
primary O
human O
monocytes O
. O

Down O
- O
regulation O
of O
the O
MAT B
II I
beta I
subunit I
expression O
causes O
a O
6 O
- O
10 O
- O
fold O
increase O
in O
intracellular O
AdoMet B
levels O
. O

Promoter B
deletion I
analysis I
defined O
a O
minimal B
promoter I
between O
positions B
+ I
52 I
and I
+ I
93 I
base O
pairs O
, O
a O
GC B
- I
rich I
region I
. O

Supershift O
assays O
showed O
no O
effect O
of O
the O
anti B
- I
Sp1 I
antibody I
on O
complex O
formation O
, O
whereas O
the O
anti B
- I
Sp3 I
antibody I
had O
a O
strong O
effect O
on O
protein O
. O
DNA O
complex O
formation O
, O
suggesting O
that O
Sp3 B
is O
one O
of O
the O
main O
factors O
binding O
to O
this O
Sp1 B
site I
. O

Supershift O
assays O
showed O
no O
effect O
of O
the O
anti B
- I
Sp1 I
antibody I
on O
complex O
formation O
, O
whereas O
the O
anti B
- I
Sp3 I
antibody I
had O
a O
strong O
effect O
on O
protein O
. O
DNA O
complex O
formation O
, O
suggesting O
that O
Sp3 B
is O
one O
of O
the O
main O
factors O
binding O
to O
this O
Sp1 B
site I
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES B
, O
MIP B
- I
1 I
alpha I
, O
MCP B
- I
1 I
, O
MCP B
- I
3 I
, O
and O
IP B
- I
10 I
) O
, O
pro O
- O
inflammatory O
( O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
18 I
, O
and O
TNF B
- I
alpha I
) O
, O
and O
antiviral B
( I
IFN I
- I
alpha I
/ I
beta I
) I
cytokines I
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES B
, O
MIP B
- I
1 I
alpha I
, O
MCP B
- I
1 I
, O
MCP B
- I
3 I
, O
and O
IP B
- I
10 I
) O
, O
pro O
- O
inflammatory O
( O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
18 I
, O
and O
TNF B
- I
alpha I
) O
, O
and O
antiviral B
( I
IFN I
- I
alpha I
/ I
beta I
) I
cytokines I
. O

Cytokine O
gene O
expression O
is O
associated O
with O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
AP B
- I
1 I
, O
STAT B
and O
IRF B
signal I
transducing I
molecules I
in O
influenza O
A O
virus O
- O
infected O
cells O
. O

Cytokine O
gene O
expression O
is O
associated O
with O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
AP B
- I
1 I
, O
STAT B
and O
IRF B
signal I
transducing I
molecules I
in O
influenza O
A O
virus O
- O
infected O
cells O
. O

In O
addition O
of O
upregulating O
cytokine B
gene I
expression O
, O
influenza O
A O
virus O
infection O
activates O
caspase B
- I
1 I
enzyme I
, O
which O
is O
involved O
in O
the O
proteolytic O
processing O
of O
proIL B
- I
1 I
beta I
and O
proIL B
- I
18 I
into O
their O
biologically O
active O
forms O
. O

In O
addition O
of O
upregulating O
cytokine B
gene I
expression O
, O
influenza O
A O
virus O
infection O
activates O
caspase B
- I
1 I
enzyme I
, O
which O
is O
involved O
in O
the O
proteolytic O
processing O
of O
proIL B
- I
1 I
beta I
and O
proIL B
- I
18 I
into O
their O
biologically O
active O
forms O
. O

Mutant O
frequencies O
were O
measured O
in O
the O
spleen B
lymphocyte I
hprt I
gene I
, O
and O
lacI O
mutant O
frequencies O
were O
determined O
in O
the O
liver O
and O
spleen O
lymphocytes O
. O

This O
proliferative O
defect O
is O
not O
reversed O
by O
addition O
of O
exogenous B
IL I
- I
2 I
and O
is O
p53 O
- O
independent O
. O

The O
growth O
inhibition O
caused O
by O
Mad1 B
is O
overcome O
by O
expression O
of O
active B
c I
- I
Myc I
. O

Benzene O
- O
extracted O
components O
are O
important O
for O
the O
major O
activity O
of O
diesel O
exhaust O
particles O
: O
effect O
on O
interleukin B
- I
8 I
gene I
expression O
in O
human O
bronchial O
epithelial O
cells O
. O

The O
nuclear B
receptor I
PPAR I
gamma I
is O
expressed O
by O
mouse O
T O
lymphocytes O
and O
PPAR O
gamma O
agonists O
induce O
apoptosis O
. O

Two O
cognate B
Sp1 I
binding I
sites I
located O
at O
- O
279 O
and O
- O
45 O
relative O
to O
the O
transcriptional B
start I
site I
proved O
crucial O
for O
Rta O
- O
mediated O
activation O
. O

During O
the O
lytic O
cycle O
, O
ZEBRA B
bound O
Rp B
near O
the O
Sp1 B
/ I
Sp3 I
site I
. O

To O
gain O
further O
insight O
into O
the O
relationship O
of O
Runx2 B
to O
other O
lymphomagenic O
pathways O
, O
we O
tested O
the O
effect O
of O
combining O
the O
CD2 B
- I
Runx2 I
transgene I
either O
with O
a O
Pim1 B
transgene I
( O
E B
( I
mu I
) I
- I
Pim1 I
) O
or O
with O
the O
p53 B
null O
genotype O
, O
as O
each O
of O
these O
displays O
independent O
synergy O
with O
Myc B
. O

Analysis O
of O
known O
Moloney B
MLV I
target I
genes I
in O
these O
lymphomas O
showed O
a O
high O
frequency O
of O
rearrangement O
at O
c B
- I
Myc I
or O
N B
- I
Myc I
( O
82 O
% O
) O
, O
and O
a O
significant O
number O
at O
Pim1 B
or O
Pim2 B
( O
23 O
% O
) O
, O
and O
at O
Pal1 B
/ I
Gfi1 I
( O
18 O
% O
) O
. O

T B
- I
cell I
factor I
- I
1 I
expression O
during O
human O
natural O
killer O
cell O
development O
and O
in O
circulating O
CD56 B
( I
+ I
) I
bright O
natural O
killer O
cells O
. O

Culture O
with O
the O
murine O
fetal O
liver O
cell O
line O
AFT024 O
and O
defined O
cytokines B
was O
capable O
of O
inducing O
TCF B
- I
1 I
mRNA I
. O

The O
TCF B
- I
1 I
isoform I
found O
in O
CD56 O
( O
+ O
bright O
) O
cells O
, O
which O
express O
lectin B
but O
not O
immunoglobulin B
class I
I I
recognizing O
inhibitory B
receptors I
, O
was O
identical O
to O
that O
induced O
in O
NK O
cell O
differentiation O
culture O
and O
was O
distinctly O
different O
from O
isoforms O
in O
T O
cells O
. O

These O
results O
suggest O
that O
TCF B
- I
1 I
does O
not O
target O
human B
killer I
immunoglobulin I
receptor I
genes I
, O
TCF B
- I
1 I
is O
uniquely O
expressed O
in O
circulating O
CD56 O
( O
+ O
bright O
) O
NK O
cells O
, O
and O
specific O
TCF B
- I
1 I
isoforms I
may O
play O
an O
important O
role O
in O
regulating O
NK O
differentiation O
from O
a O
common O
NK O
/ O
T O
- O
cell O
progenitor O
. O

The O
Bright B
DNA I
binding I
domain I
defined O
a O
new O
family O
, O
which O
includes O
SWI1 B
, O
a O
component O
of O
the O
SWI B
. I
SNF I
complex I
shown O
to O
have O
high O
mobility O
group O
- O
like O
DNA O
binding O
characteristics O
. O

The O
Bright B
DNA I
binding I
domain I
defined O
a O
new O
family O
, O
which O
includes O
SWI1 B
, O
a O
component O
of O
the O
SWI B
. I
SNF I
complex I
shown O
to O
have O
high O
mobility O
group O
- O
like O
DNA O
binding O
characteristics O
. O

Similar O
to O
one O
group O
of O
high B
mobility I
group I
box I
proteins I
, O
Bright B
distorts O
E B
mu I
binding I
site I
- O
containing O
DNA O
on O
binding O
, O
supporting O
the O
concept O
that O
it O
mediates O
E B
mu I
remodeling O
. O

The O
5 B
' I
- I
noncoding I
region I
of O
the O
BCL B
- I
6 I
gene I
is O
even O
a O
target O
for O
the O
mutation O
machinery O
. O

Translocations O
of O
the O
BCL B
- I
6 I
gene I
to O
heterologous B
promoters I
and O
mutations O
of O
its O
5 B
' I
- I
noncoding I
regulatory I
region I
were O
reported O
to O
be O
potential O
mechanisms O
for O
deregulating O
BCL B
- I
6 I
expression O
and O
for O
playing O
a O
role O
in O
the O
genesis O
of O
non O
- O
Hodgkin O
lymphoma O
. O

With O
only O
one O
exception O
, O
there O
were O
no O
lymphoma O
- O
specific O
recurrent O
BCL O
- O
6 O
mutations O
detected O
, O
and O
BCL B
- I
6 I
protein I
was O
absent O
from O
the O
HRS O
cells O
of O
most O
cases O
. O

In O
conclusion O
, O
( O
1 O
) O
somatic O
BCL O
- O
6 O
mutations O
are O
restricted O
to O
cHD O
cases O
of O
B O
- O
cell O
origin O
, O
and O
( O
2 O
) O
the O
BCL O
- O
6 O
mutations O
represent O
mostly O
irrelevant O
somatic O
base O
substitutions O
without O
consequences O
for O
BCL B
- I
6 I
protein I
expression O
and O
the O
pathogenesis O
of O
cHD O
. O

The O
staining O
was O
considered O
to O
be O
highly O
specific O
because O
it O
could O
be O
completely O
blocked O
by O
preabsorption O
with O
recombinant B
IFN I
- I
gamma I
. O

Regulation O
of O
activator B
protein I
- I
1 I
and O
NF B
- I
kappa I
B I
in O
CD8 O
+ O
T O
cells O
exposed O
to O
peripheral B
self I
- I
antigens I
. O

Regulation O
of O
activator B
protein I
- I
1 I
and O
NF B
- I
kappa I
B I
in O
CD8 O
+ O
T O
cells O
exposed O
to O
peripheral B
self I
- I
antigens I
. O

Regulation O
of O
activator B
protein I
- I
1 I
and O
NF B
- I
kappa I
B I
in O
CD8 O
+ O
T O
cells O
exposed O
to O
peripheral B
self I
- I
antigens I
. O

In O
this O
study O
, O
we O
analyzed O
the O
regulation O
of O
AP B
- I
1 I
- O
and O
NF B
- I
kappa I
B I
- O
mediated O
transcription O
during O
in O
vivo O
induction O
of O
tolerance O
to O
a O
self B
Ag I
expressed O
exclusively O
on O
hepatocytes O
. O

In O
contrast O
to O
CD8 O
( O
+ O
) O
Des O
( O
+ O
) O
T O
cells O
activated O
in O
vivo O
with O
APCs O
, O
which O
express O
high O
AP B
- I
1 I
and O
high O
NF B
- I
kappa I
B I
transcriptional O
activity O
, O
the O
unresponsive O
CD8 O
( O
+ O
) O
Des O
( O
+ O
) O
T O
cells O
expressed O
no O
AP B
- I
1 I
and O
only O
weak O
NF B
- I
kappa I
B I
transcriptional O
activity O
. O

In O
contrast O
to O
CD8 O
( O
+ O
) O
Des O
( O
+ O
) O
T O
cells O
activated O
in O
vivo O
with O
APCs O
, O
which O
express O
high O
AP B
- I
1 I
and O
high O
NF B
- I
kappa I
B I
transcriptional O
activity O
, O
the O
unresponsive O
CD8 O
( O
+ O
) O
Des O
( O
+ O
) O
T O
cells O
expressed O
no O
AP B
- I
1 I
and O
only O
weak O
NF B
- I
kappa I
B I
transcriptional O
activity O
. O

The O
differences O
in O
NF B
- I
kappa I
B I
transcriptional O
activity O
correlated O
with O
the O
generation O
of O
distinct O
NF B
- I
kappa I
B I
complexes I
. O

Indeed O
, O
in O
vivo O
primed O
T O
cells O
predominantly O
express O
p50 B
/ I
p50 I
and I
p65 I
/ I
p50 I
dimers I
, O
whereas O
these O
p50 B
- I
containing I
complexes I
are O
barely O
detectable O
in O
tolerant O
T O
cells O
that O
express O
p65 B
- I
and I
c I
- I
Rel I
- I
containing I
complexes I
. O

Existence O
of O
retinoic B
acid I
- I
receptor I
- O
independent O
retinoid B
X I
- I
receptor I
- O
dependent O
pathway O
in O
myeloid O
cell O
function O
. O

Existence O
of O
retinoic B
acid I
- I
receptor I
- O
independent O
retinoid B
X I
- I
receptor I
- O
dependent O
pathway O
in O
myeloid O
cell O
function O
. O

Its O
agonistic O
action O
on O
RXR B
/ I
RAR I
heterodimer I
, O
on O
the O
other O
hand O
, O
was O
neutralized O
by O
the O
RAR B
antagonist O
. O

The O
results O
indicate O
that O
the O
expression O
of O
Lck B
/ I
SHP I
- I
1 I
chimera I
inside O
lipid O
rafts O
profoundly O
inhibits O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
of O
CD3 B
zeta I
/ I
epsilon I
, O
IL O
- O
2 O
generation O
, O
and O
nuclear O
mobilization O
of O
NF B
- I
AT I
. O

In O
this O
study O
, O
T O
cell O
nuclear O
extracts O
from O
female O
lupus O
patients O
and O
normal O
donors O
were O
tested O
for O
biologically O
active O
ER B
proteins I
capable O
of O
binding O
to O
the O
human B
estrogen I
response I
element I
( O
hERE B
) O
by O
electrophoretic O
mobility O
shift O
assays O
. O

When O
peripheral O
blood O
T O
cells O
were O
stimulated O
with O
17beta O
- O
estradiol O
( O
E2 O
) O
, O
PMA O
and O
ionomycin O
, O
two O
major O
retarded O
bands O
in O
T O
cell O
nuclear O
extracts O
exhibited O
a O
migration O
pattern O
similar O
to O
slow O
migrating O
protein B
- I
ERE I
complexes I
in O
human O
breast O
cancer O
cell O
extracts O
. O

The O
formation O
of O
the O
complexes O
was O
inhibited O
by O
competition O
with O
the O
hERE O
cold O
oligonucleotide O
and O
partially O
with O
anti B
- I
ERalpha I
antibodies I
. O

There O
was O
no O
notable O
difference O
in O
the O
migration O
pattern O
of O
ERE B
- I
binding I
proteins I
between O
the O
SLE O
and O
normal O
T O
cell O
extracts O
. O

Mechanism O
of O
the O
inhibitory O
effect O
of O
protease O
inhibitor O
on O
tumor B
necrosis I
factor I
alpha I
production O
of O
monocytes O
. O

Monocytes O
are O
extremely O
important O
cells O
for O
regulating O
the O
cytokine O
network O
and O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
) O
and O
interleukin B
- I
( I
IL I
) I
10 I
, O
which O
are O
mainly O
synthesized O
by O
monocytes O
, O
are O
representative O
cytokines B
that O
play O
a O
central O
role O
in O
the O
cytokine O
network O
. O

The O
inhibitory O
effect O
of O
protease O
inhibitors O
on O
the O
activity O
of O
intracellular O
signal O
transduction O
pathways O
such O
as O
protein B
kinase I
C I
( O
PKC B
) O
and O
nuclear B
factor I
kappa I
B I
( O
NFkappaB B
) O
were O
also O
evaluated O
. O

The O
secretion O
of O
MCP B
- I
1 I
protein I
was O
significantly O
increased O
( O
195 O
% O
as O
compared O
to O
the O
control O
) O
in O
cells O
treated O
with O
pathological O
concentrations O
of O
homocysteine O
. O

Such O
effect O
was O
accompanied O
by O
an O
increased O
expression O
of O
MCP B
- I
1 I
mRNA I
( O
176 O
% O
as O
compared O
to O
the O
control O
) O
in O
endothelial O
cells O
which O
resulted O
in O
enhanced O
monocyte O
chemotaxis O
. O

Terminal O
effectors O
of O
B O
cell O
Fas B
- O
resistance O
include O
the O
known O
anti B
- I
apoptotic I
gene I
products I
, O
Bcl B
- I
xL I
and O
FLIP B
, O
and O
a O
novel O
anti B
- I
apoptotic I
gene I
that O
encodes O
FAIM B
( O
Fas B
Apoptosis I
Inhibitory I
Molecule I
) O
. O

Terminal O
effectors O
of O
B O
cell O
Fas B
- O
resistance O
include O
the O
known O
anti B
- I
apoptotic I
gene I
products I
, O
Bcl B
- I
xL I
and O
FLIP B
, O
and O
a O
novel O
anti B
- I
apoptotic I
gene I
that O
encodes O
FAIM B
( O
Fas B
Apoptosis I
Inhibitory I
Molecule I
) O
. O

Using O
triple O
transgenic O
mice O
expressing O
a O
TCR B
transgene I
, O
dominant B
negative I
ras I
/ I
Mek I
proteins I
and O
a O
reporter B
gene I
construct I
with O
AP B
- I
1 I
or I
NF I
- I
kappa I
B I
binding I
sites I
, O
we O
showed O
a O
complete O
lack O
of O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
but O
not O
AP B
- I
1 I
in O
DP O
thymocytes O
, O
whereas O
both O
were O
transcriptionally O
active O
in O
mature O
T O
cells O
after O
antigenic O
stimulation O
. O

Lack O
of O
NF B
- I
kappa I
B I
induction O
correlated O
with O
increased O
death O
in O
response O
to O
antigen B
. O

Taken O
together O
the O
results O
suggest O
that O
the O
lack O
of O
PKC B
epsilon I
in O
DP O
thymocytes O
could O
lead O
to O
the O
absence O
of O
NF B
- I
kappa I
B I
activity O
after O
antigenic O
stimulation O
contributing O
to O
negative O
selection O
. O

Although O
cytokine B
receptors I
are O
known O
to O
signal O
through O
STAT B
family I
transcription I
factors I
, O
the O
mechanisms O
by O
which O
other O
cell B
- I
surface I
molecules I
, O
such O
as O
CD2 B
, O
transduce O
signals O
is O
unclear O
. O

Although O
cytokine B
receptors I
are O
known O
to O
signal O
through O
STAT B
family I
transcription I
factors I
, O
the O
mechanisms O
by O
which O
other O
cell B
- I
surface I
molecules I
, O
such O
as O
CD2 B
, O
transduce O
signals O
is O
unclear O
. O

MATERIALS O
AND O
METHODS O
: O
T O
cells O
were O
treated O
with O
anti B
- I
CD2 I
antibodies I
or O
cells O
bearing O
the O
natural O
CD2 B
ligand I
CD58 I
, O
after O
which O
signaling O
through O
STAT B
transcription I
factors I
was O
assessed O
. O

CONCLUSION O
: O
Stimulation O
of O
T O
cells O
through O
cell B
- I
surface I
molecules I
such O
as O
CD2 B
involves O
activation O
of O
STAT B
transcription I
factors I
, O
thus O
recapitulating O
elements O
of O
cytokine O
signaling O
. O

Although O
the O
immediate B
- I
early I
proteins I
of O
both O
herpes O
simplex O
virus O
( O
HSV O
) O
and O
cytomegalovirus O
( O
CMV O
) O
are O
known O
to O
modify O
promyelocytic O
leukemia O
( O
PML O
) O
( O
ND10 O
) O
bodies O
in O
the O
nucleus O
of O
the O
host O
cell O
, O
it O
has O
been O
unclear O
whether O
lytic O
infection O
with O
gamma O
herpesviruses O
induces O
a O
similar O
effect O
. O

To O
examine O
whether O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
lytic O
replication O
interferes O
with O
PML O
bodies O
, O
we O
expressed O
the O
EBV B
immediate I
- I
early I
genes I
BZLF1 B
( I
Z I
) I
and O
BRLF1 B
( I
R I
) I
in O
EBV O
- O
positive O
cell O
lines O
and O
examined O
PML B
localization O
. O

To O
examine O
whether O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
lytic O
replication O
interferes O
with O
PML O
bodies O
, O
we O
expressed O
the O
EBV B
immediate I
- I
early I
genes I
BZLF1 B
( I
Z I
) I
and O
BRLF1 B
( I
R I
) I
in O
EBV O
- O
positive O
cell O
lines O
and O
examined O
PML B
localization O
. O

Suppression O
of O
nuclear B
factor I
- I
kappaB I
and O
stimulation O
of O
inhibitor B
kappaB I
by O
troglitazone O
: O
evidence O
for O
an O
anti O
- O
inflammatory O
effect O
and O
a O
potential O
antiatherosclerotic O
effect O
in O
the O
obese O
. O

Plasma B
tumor I
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
soluble B
intercellular I
adhesion I
molecule I
- I
1 I
( O
sICAM B
- I
1 I
) O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
, O
C B
- I
reactive I
protein I
( I
CRP I
) I
, O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
antiinflammatory B
cytokine I
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B
transcription I
factor I
NFkappaB I
. O

Tyrosine O
phosphorylation O
- O
dependent O
activation O
of O
NF B
- I
kappa I
B I
. O

Phosphorylation O
of O
the O
N B
- I
terminal I
domain I
of O
I B
kappa I
B I
inhibitory I
subunits I
induces O
activation O
of O
the O
transcription B
factor I
NF I
- I
kappa I
B I
. O

Although O
serine O
phosphorylation O
has O
been O
shown O
to O
induce O
ubiquitination O
and O
subsequent O
proteasome O
- O
mediated O
degradation O
of O
I B
kappa I
B I
- I
alpha I
, O
little O
is O
known O
about O
the O
mechanisms O
that O
lead O
to O
release O
of O
active O
NF B
- I
kappa I
B I
in O
T O
cells O
as O
a O
consequence O
of O
tyrosine O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
[ O
Imbert O
, O
V O
. O
, O
Rupec O
, O
R O
. O
A O
. O
, O
Livolsi O
, O
A O
. O
, O
Pahl O
, O
H O
. O
L O
. O
, O
Traenckner O
, O
B O
. O
M O
. O
, O
Mueller O
- O
Dieckmann O
, O
C O

The O
involvement O
of O
the O
tyrosine B
kinases I
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
in O
this O
reaction O
is O
demonstrated O
here O
using O
specific O
pharmacological O
inhibitors O
and O
Jurkat O
mutants O
unable O
to O
express O
these O
kinases B
. O

Although O
the O
inhibitors O
prevented O
both O
pervanadate O
- O
induced O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
on O
Tyr42 O
and O
NF B
- I
kappa I
B I
activation O
, O
we O
observed O
that O
, O
in O
p56 O
( O
lck O
) O
- O
deficient O
Jurkat O
mutants O
, O
NF B
- I
kappa I
B I
could O
still O
associate O
with O
I B
kappa I
B I
- I
alpha I
despite O
phosphorylation O
on O
Tyr42 O
. O

Although O
the O
inhibitors O
prevented O
both O
pervanadate O
- O
induced O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
on O
Tyr42 O
and O
NF B
- I
kappa I
B I
activation O
, O
we O
observed O
that O
, O
in O
p56 O
( O
lck O
) O
- O
deficient O
Jurkat O
mutants O
, O
NF B
- I
kappa I
B I
could O
still O
associate O
with O
I B
kappa I
B I
- I
alpha I
despite O
phosphorylation O
on O
Tyr42 O
. O

Furthermore O
, O
the O
SH2 B
domain I
of O
p56 B
( I
lck I
) I
appeared O
to O
be O
required O
for O
pervanadate O
- O
induced O
NF B
- I
kappa I
B I
activation O
but O
not O
for O
Tyr42 O
phosphorylation O
. O

Furthermore O
, O
the O
SH2 B
domain I
of O
p56 B
( I
lck I
) I
appeared O
to O
be O
required O
for O
pervanadate O
- O
induced O
NF B
- I
kappa I
B I
activation O
but O
not O
for O
Tyr42 O
phosphorylation O
. O

These O
results O
show O
that O
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
are O
key O
components O
of O
the O
signaling O
pathway O
that O
leads O
to O
phosphotyrosine O
- O
dependent O
NF B
- I
kappa I
B I
activation O
in O
T O
cells O
and O
confirm O
that O
tyrosine B
kinases I
must O
control O
at O
least O
two O
different O
steps O
to O
induce O
activation O
of O
NF B
- I
kappa I
B I
. O

These O
results O
show O
that O
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
are O
key O
components O
of O
the O
signaling O
pathway O
that O
leads O
to O
phosphotyrosine O
- O
dependent O
NF B
- I
kappa I
B I
activation O
in O
T O
cells O
and O
confirm O
that O
tyrosine B
kinases I
must O
control O
at O
least O
two O
different O
steps O
to O
induce O
activation O
of O
NF B
- I
kappa I
B I
. O

These O
results O
show O
that O
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
are O
key O
components O
of O
the O
signaling O
pathway O
that O
leads O
to O
phosphotyrosine O
- O
dependent O
NF B
- I
kappa I
B I
activation O
in O
T O
cells O
and O
confirm O
that O
tyrosine B
kinases I
must O
control O
at O
least O
two O
different O
steps O
to O
induce O
activation O
of O
NF B
- I
kappa I
B I
. O

Finally O
, O
we O
show O
that O
H O
( O
2 O
) O
O O
( O
2 O
) O
, O
which O
stimulates O
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
in O
T O
cells O
, O
is O
an O
activator O
of O
NF B
- I
kappa I
B I
through O
tyrosine O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
. O

Finally O
, O
we O
show O
that O
H O
( O
2 O
) O
O O
( O
2 O
) O
, O
which O
stimulates O
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
in O
T O
cells O
, O
is O
an O
activator O
of O
NF B
- I
kappa I
B I
through O
tyrosine O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
. O

These O
mutations O
prevent O
CD40 B
ligand I
( O
CD40L B
) O
- O
mediated O
degradation O
of O
inhibitor O
of O
NF B
- I
kappaB I
alpha I
( O
IkappaB B
- I
alpha I
) O
and O
account O
for O
the O
following O
observations O
: O
B O
cells O
from O
XHM O
- O
ED O
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class O
- O
switch O
recombination O
and O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF B
- I
kappaB I
- I
regulated I
cytokines I
interleukin B
12 I
( O
IL B
- I
12 I
) O
or O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
when O
stimulated O
with O

These O
mutations O
prevent O
CD40 B
ligand I
( O
CD40L B
) O
- O
mediated O
degradation O
of O
inhibitor O
of O
NF B
- I
kappaB I
alpha I
( O
IkappaB B
- I
alpha I
) O
and O
account O
for O
the O
following O
observations O
: O
B O
cells O
from O
XHM O
- O
ED O
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class O
- O
switch O
recombination O
and O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF B
- I
kappaB I
- I
regulated I
cytokines I
interleukin B
12 I
( O
IL B
- I
12 I
) O
or O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
when O
stimulated O
with O

In O
addition O
, O
nuclear O
body O
reorganization O
to O
macropunctated O
structures O
, O
as O
well O
as O
the O
degradation O
of O
PML B
- I
RAR I
alpha I
, O
was O
found O
to O
be O
similar O
for O
ATRA O
and O
all O
of O
its O
metabolites O
. O

The O
ATRA O
metabolites O
were O
found O
to O
exert O
their O
differentiation O
effects O
via O
the O
RAR B
alpha I
nuclear I
receptors I
, O
because O
the O
RAR O
alpha O
- O
specific O
antagonist O
BMS614 O
blocked O
metabolite O
- O
induced O
CD11c O
expression O
in O
NB4 O
cells O
. O

Expression O
of O
oestrogen B
and I
progesterone I
receptors I
by O
mast O
cells O
alone O
, O
but O
not O
lymphocytes O
, O
macrophages O
or O
other O
immune O
cells O
in O
human O
upper O
airways O
. O

RESULTS O
: O
Consistent O
with O
the O
known O
features O
of O
nasal O
polyps O
, O
CD4 O
+ O
( O
T O
helper O
/ O
inducer O
) O
, O
CD8 O
+ O
( O
cytotoxic O
/ O
suppressor O
) O
, O
CD68 O
+ O
( O
macrophages O
) O
, O
mast O
cells O
, O
eosinophils O
and O
neutrophils O
were O
all O
clearly O
detected O
by O
their O
relevant O
monoclonal B
antibodies I
or O
appropriate O
histochemical O
staining O
, O
but O
only O
mast O
cells O
tested O
positive O
for O
ER B
/ O
PR O
labelling O
with O
their O
polyclonal B
and I
monoclonal I
antibodies I
. O

Inhibition O
of O
PKC B
blocked O
I B
kappa I
B I
alpha I
degradation O
and O
p65 B
translocation O
in O
A O
/ O
R O
- O
challenged O
, O
but O
not O
redox O
- O
altered O
, O
endothelial O
cells O
. O

Given O
that O
C B
/ I
EBP I
proteins I
have O
been O
shown O
to O
interact O
with O
many O
other O
transcription B
factors I
including O
members O
of O
the O
ATF B
/ I
CREB I
family I
, O
we O
proceeded O
to O
determine O
whether O
an O
adjacent O
ATF B
/ I
CREB I
binding I
site I
could O
affect O
C B
/ I
EBP I
protein I
binding O
to O
C B
/ I
EBP I
site I
I I
. O

Given O
that O
C B
/ I
EBP I
proteins I
have O
been O
shown O
to O
interact O
with O
many O
other O
transcription B
factors I
including O
members O
of O
the O
ATF B
/ I
CREB I
family I
, O
we O
proceeded O
to O
determine O
whether O
an O
adjacent O
ATF B
/ I
CREB I
binding I
site I
could O
affect O
C B
/ I
EBP I
protein I
binding O
to O
C B
/ I
EBP I
site I
I I
. O

Given O
that O
C B
/ I
EBP I
proteins I
have O
been O
shown O
to O
interact O
with O
many O
other O
transcription B
factors I
including O
members O
of O
the O
ATF B
/ I
CREB I
family I
, O
we O
proceeded O
to O
determine O
whether O
an O
adjacent O
ATF B
/ I
CREB I
binding I
site I
could O
affect O
C B
/ I
EBP I
protein I
binding O
to O
C B
/ I
EBP I
site I
I I
. O

Electrophoretic O
mobility O
shift O
analyses O
indicated O
that O
selected O
ATF B
/ I
CREB I
site I
variants I
assisted O
in O
the O
recruitment O
of O
C B
/ I
EBP I
proteins I
to O
an O
adjacent O
, O
naturally O
occurring O
, O
low O
- O
affinity O
C B
/ I
EBP I
site I
. O

Electrophoretic O
mobility O
shift O
analyses O
indicated O
that O
selected O
ATF B
/ I
CREB I
site I
variants I
assisted O
in O
the O
recruitment O
of O
C B
/ I
EBP I
proteins I
to O
an O
adjacent O
, O
naturally O
occurring O
, O
low O
- O
affinity O
C B
/ I
EBP I
site I
. O

In O
addition O
, O
CREB B
- I
1 I
homodimers I
bind O
to O
the O
ATF B
/ I
CREB I
site I
and O
recruit O
C B
/ I
EBP I
dimers I
to O
their O
cognate O
weak B
binding I
sites I
. O

In O
addition O
, O
CREB B
- I
1 I
homodimers I
bind O
to O
the O
ATF B
/ I
CREB I
site I
and O
recruit O
C B
/ I
EBP I
dimers I
to O
their O
cognate O
weak B
binding I
sites I
. O

In O
addition O
, O
CREB B
- I
1 I
homodimers I
bind O
to O
the O
ATF B
/ I
CREB I
site I
and O
recruit O
C B
/ I
EBP I
dimers I
to O
their O
cognate O
weak B
binding I
sites I
. O

This O
interaction O
is O
reciprocal O
, O
since O
C B
/ I
EBP I
dimer I
binding O
to O
a O
strong O
C B
/ I
EBP I
site I
leads O
to O
enhanced O
CREB B
- I
1 I
recruitment O
to O
ATF B
/ I
CREB I
sites I
that O
are O
weakly O
bound O
by O
CREB B
. O

This O
interaction O
is O
reciprocal O
, O
since O
C B
/ I
EBP I
dimer I
binding O
to O
a O
strong O
C B
/ I
EBP I
site I
leads O
to O
enhanced O
CREB B
- I
1 I
recruitment O
to O
ATF B
/ I
CREB I
sites I
that O
are O
weakly O
bound O
by O
CREB B
. O

This O
interaction O
is O
reciprocal O
, O
since O
C B
/ I
EBP I
dimer I
binding O
to O
a O
strong O
C B
/ I
EBP I
site I
leads O
to O
enhanced O
CREB B
- I
1 I
recruitment O
to O
ATF B
/ I
CREB I
sites I
that O
are O
weakly O
bound O
by O
CREB B
. O

Thus O
, O
HIV B
- I
1 I
LTR I
ATF B
/ I
CREB I
binding I
site I
sequence O
variation O
may O
modulate O
cellular O
signaling O
at O
the O
viral B
promoter I
through O
the O
C O
/ O
EBP O
pathway O

OBJECTIVE O
: O
To O
examine O
the O
molecular O
and O
cellular O
mechanisms O
in O
a O
model O
of O
acute O
inflammatory O
monarticular O
arthritis O
induced O
by O
methylated B
bovine I
serum I
albumin I
( O
mBSA B
) O
and O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
. O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL O
- O
1 O
- O
dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger B
RNA I
( O
mRNA B
) O
for O
the O
chemokines B
monocyte B
chemoattractant I
protein I
1 I
, O
macrophage B
inhibitory I
protein I
2 I
( O
MIP B
- I
2 I
) O
, O
RANTES B
, O
MIP B
- I
1alpha I
, O
and O
MIP B
- I
1beta I
, O
in O
vivo O
and O
in O
vitro O
. O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL O
- O
1 O
- O
dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger B
RNA I
( O
mRNA B
) O
for O
the O
chemokines B
monocyte B
chemoattractant I
protein I
1 I
, O
macrophage B
inhibitory I
protein I
2 I
( O
MIP B
- I
2 I
) O
, O
RANTES B
, O
MIP B
- I
1alpha I
, O
and O
MIP B
- I
1beta I
, O
in O
vivo O
and O
in O
vitro O
. O

The O
Runt B
family I
transcription I
factor I
CBFalpha2 B
( O
AML1 B
, O
PEBP2alphaB B
, O
or O
Runx1 B
) O
is O
required O
by O
hematopoietic O
stem O
cells O
and O
expressed O
at O
high O
levels O
in O
T O
- O
lineage O
cells O
. O

Here O
, O
we O
report O
that O
both O
coding B
and I
noncoding I
sequences I
of O
the O
distal B
5 I
' I
end I
are O
highly O
conserved O
between O
the O
human B
and I
the I
murine I
genes I
, O
and O
the O
distal B
promoter I
is O
responsible O
for O
the O
overwhelming O
majority O
of O
CBFalpha2 O
expression O
in O
murine O
hematopoietic O
stem O
cells O
as O
well O
as O
in O
T O
cells O
. O

Here O
, O
we O
report O
that O
both O
coding B
and I
noncoding I
sequences I
of O
the O
distal B
5 I
' I
end I
are O
highly O
conserved O
between O
the O
human B
and I
the I
murine I
genes I
, O
and O
the O
distal B
promoter I
is O
responsible O
for O
the O
overwhelming O
majority O
of O
CBFalpha2 O
expression O
in O
murine O
hematopoietic O
stem O
cells O
as O
well O
as O
in O
T O
cells O
. O

Neither O
full B
- I
length I
isoform I
alters O
growth O
of O
a O
myeloid O
cell O
line O
under O
nondifferentiating O
conditions O
, O
but O
the O
proximal B
isoform I
selectively O
delays O
mitotic O
arrest O
of O
the O
cell O
line O
under O
differentiating O
conditions O
, O
resulting O
in O
the O
generation O
of O
greater O
numbers O
of O
neutrophils O
. O

However O
, O
other O
conserved B
sequence I
motifs I
, O
that O
differ O
between O
Ig B
variable I
gene I
families I
, O
are O
required O
for O
normal O
promoter O
function O
. O

The O
DNA B
binding I
domain I
of O
the O
Drosophila B
transcription I
factor I
( O
Antennapedia B
) O
, O
a O
60 B
amino I
acid I
protein I
, O
is O
rapidly O
taken O
up O
by O
cells O
and O
has O
been O
fused O
to O
selected O
antigens B
to O
enhance O
their O
immunogenicity O
. O

These O
CD3 O
+ O
cells O
also O
expressed O
increased O
levels O
of O
the O
TH2 B
associated I
receptor I
CCR3 I
. O

We O
show O
in O
this O
study O
that O
inhibition O
of O
NF B
- I
kappaB I
through O
the O
expression O
of O
an O
IkappaBalpha B
( O
inhibitory B
protein I
that O
dissociates O
from O
NF B
- I
kappaB I
) O
mutant O
refractory O
to O
signal O
- O
induced O
degradation O
( O
IkappaBalpha B
( I
DeltaN I
) I
) O
interfered O
with O
the O
acquisition O
of O
competence O
to O
proliferate O
in O
response O
to O
IL B
- I
4 I
as O
well O
as O
IL B
- I
2 I
. O

Thymocytes O
and O
T O
cells O
from O
IkappaBalpha B
( I
DeltaN I
) I
transgenic O
mice O
expressed O
normal O
levels O
of O
IL B
- I
2R I
subunits I
. O

Thymocytes O
and O
T O
cells O
from O
IkappaBalpha B
( I
DeltaN I
) I
transgenic O
mice O
expressed O
normal O
levels O
of O
IL B
- I
2R I
subunits I
. O

These O
results O
indicate O
that O
the O
NF O
- O
kappaB O
/ O
Rel O
/ O
IkappaBalpha O
system O
can O
regulate O
cytokine B
receptor I
capacitation O
through O
effects O
on O
the O
induction O
of O
downstream O
signaling O
by O
the O
Stat B
transcription I
factor I
family I
. O

METHODS O
/ O
RESULTS O
: O
Cells O
exposed O
to O
high O
D O
- O
glucose O
( O
30 O
mmol O
/ O
l O
) O
caused O
an O
increase O
in O
[ O
3H O
] O
- O
thymidine O
incorporation O
and O
cell O
numbers O
at O
24 O
and O
48 O
h O
and O
normalized O
at O
72 O
h O
( O
p O
< O
0 O
. O
05 O
) O
, O
whereas O
these O
changes O
were O
not O
found O
in O
high O
mannitol O
( O
30 O
mmol O
/ O
l O
) O
, O
IL B
- I
1 I
beta I
, O
or O
TNF B
alpha I
- O
stimulated O
mesangial O
cells O
. O

CONCLUSION O
/ O
INTERPRETATION O
: O
These O
results O
suggest O
that O
high O
glucose O
can O
upregulate O
intercellular B
adhesion I
molecule I
- I
1 I
protein O
and O
mRNA O
expression O
but O
not O
vascular O
adhesion O
molecule O
- O
1 O
expression O
in O
mesangial O
cells O
and O
promote O
leukocyte O
adhesion O
through O
up O
- O
regulation O
of O
intercellular B
adhesion I
molecule I
- I
1 I
through O
osmotic O
effect O
, O
possibly O
depending O
on O
the O
protein B
kinase I
C I
nuclear B
factor I
- I
kappa I
B I
( O
PKC B
- O
NF B
- I
kappa I
B I
) O
pathway O
. O

To O
address O
this O
issue O
, O
we O
studied O
a O
child O
with O
SCN O
who O
was O
totally O
unresponsive O
to O
G B
- I
CSF I
and O
had O
a O
novel O
point O
mutation O
in O
the O
extracellular B
domain I
of O
the O
G B
- I
CSF I
receptor I
( O
GCSF B
- I
R I
) O
. O

The O
in O
vitro O
effect O
of O
G B
- I
CSF I
and O
corticosteroids O
on O
granulopoiesis O
was O
evaluated O
in O
clonogenic O
assays O
of O
marrow O
mononuclear O
cells O
, O
by O
proliferation O
studies O
of O
the O
murine O
myeloid O
cell O
line O
32D O
expressing O
the O
patient O
' O
s O
mutated B
G I
- I
CSFR I
, O
and O
by O
measuring O
STAT5 O
activation O
in O
nuclear O
extracts O
from O
stimulated O
cells O
. O

When O
small O
daily O
doses O
of O
oral O
prednisone O
were O
then O
administered O
to O
the O
patient O
with O
conventional O
doses O
of O
subcutaneous B
G I
- I
CSF I
, O
the O
patient O
responded O
with O
increased O
neutrophil O
numbers O
and O
with O
a O
complete O
reversal O
of O
the O
infectious O
problems O
. O

All O
major O
RARs B
and I
RXRs I
isotypes I
were O
expressed O
in O
CHMC O
regardless O
of O
the O
presence O
or O
absence O
of O
9 O
- O
cRA O
. O

Gene O
regulation O
occurs O
via O
signal O
transduction O
pathways O
common O
to O
other O
innate O
immune O
responses O
, O
utilizing O
transcription B
factors I
such O
as O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
and O
NF B
interleukin I
- I
6 I
. O

Using O
a O
reporter O
system O
to O
detect O
interaction O
of O
CREB B
and O
CREB B
- I
binding I
protein I
( O
CBP B
) O
, O
in O
this O
study O
we O
found O
that O
CREB B
binds O
to O
CBP B
only O
by O
engagement O
of O
both O
CD3 B
and O
CD28 B
. O

Signaling O
through O
the O
TCR B
and O
costimulatory O
signals O
primarily O
control O
transcription O
of O
the O
IL B
- I
2 I
gene I
in O
naive O
T O
cells O
. O

The O
IL B
- I
2 I
gene I
can O
be O
induced O
by O
the O
AHR B
also O
in O
thymocytes O
in O
vivo O
after O
injection O
of O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
p O
- O
dioxin O
, O
a O
potent O
ligand O
of O
the O
AHR B
. O

However O
, O
in O
spleen O
cells O
in O
vitro O
costimulation O
via O
the O
TCR B
is O
necessary O
for O
optimal O
IL B
- I
2 I
gene I
induction O
. O

The O
cross O
- O
linking O
of O
the O
B B
cell I
Ag I
receptor I
( O
BCR B
) O
is O
coupled O
to O
the O
stimulation O
of O
multiple O
intracellular O
signal O
transduction O
cascades O
via O
receptor O
- O
associated O
, O
protein B
tyrosine I
kinases I
of O
both O
the O
Src B
and I
Syk I
families I
. O

The O
cross O
- O
linking O
of O
the O
B B
cell I
Ag I
receptor I
( O
BCR B
) O
is O
coupled O
to O
the O
stimulation O
of O
multiple O
intracellular O
signal O
transduction O
cascades O
via O
receptor O
- O
associated O
, O
protein B
tyrosine I
kinases I
of O
both O
the O
Src B
and I
Syk I
families I
. O

Treatment O
of O
these O
cells O
with O
anti B
- I
IgM I
Abs I
leads O
to O
the O
recruitment O
of O
the O
kinase B
from O
cytoplasmic O
and O
nuclear O
compartments O
to O
the O
site O
of O
the O
cross B
- I
linked I
receptor I
at O
the O
plasma O
membrane O
. O

Treatment O
of O
these O
cells O
with O
anti B
- I
IgM I
Abs I
leads O
to O
the O
recruitment O
of O
the O
kinase B
from O
cytoplasmic O
and O
nuclear O
compartments O
to O
the O
site O
of O
the O
cross B
- I
linked I
receptor I
at O
the O
plasma O
membrane O
. O

The O
Syk B
- I
receptor I
complexes I
aggregate O
into O
membrane O
patches O
that O
redistribute O
to O
form O
a O
cap O
at O
one O
pole O
of O
the O
cell O
. O

Catalytically O
active O
Syk B
promotes O
and O
stabilizes O
the O
formation O
of O
tightly B
capped I
BCR I
complexes I
at O
the O
plasma O
membrane O
. O

Lyn B
is O
not O
required O
for O
the O
recruitment O
of O
Syk B
to O
the O
cross B
- I
linked I
receptor I
, O
but O
is O
required O
for O
the O
internalization O
of O
the O
clustered O
BCR B
complexes I
. O

In O
the O
absence O
of O
Lyn B
, O
receptor B
- I
Syk I
complexes I
at O
the O
plasma O
membrane O
are O
long O
lived O
, O
and O
the O
receptor O
- O
mediated O
activation O
of O
the O
NF B
- I
AT I
transcription I
factor I
is O
enhanced O
. O

This O
study O
established O
a O
UUO O
model O
in O
angiotensin B
type I
1a I
receptor I
( O
AT1a B
) O
deficient O
( O
mutant O
) O
mice O
to O
elucidate O
the O
role O
of O
angiotensin B
II I
through O
AT1a B
on O
the O
fibrosis O
of O
the O
obstructed O
kidney O
( O
OBK O
) O
. O

Nuclear B
factor I
- I
kappaB I
activity O
was O
assessed O
by O
gel O
shift O
assay O
. O

Finally O
, O
UUO O
resulted O
in O
activation O
of O
nuclear B
factor I
- I
kappaB I
in O
wild O
mice O
but O
was O
inhibited O
in O
the O
OBK O
of O
mutant O
mice O
. O

HLA B
- I
DQ I
tetramers I
identify O
epitope O
- O
specific O
T O
cells O
in O
peripheral O
blood O
of O
herpes O
simplex O
virus O
type O
2 O
- O
infected O
individuals O
: O
direct O
detection O
of O
immunodominant O
antigen O
- O
responsive O
cells O
. O

MHC B
tetramers I
, O
which O
constitute O
a O
labeled B
MHC I
- I
peptide I
ligand I
suitable O
for O
binding O
to O
the O
Ag B
- I
specific I
receptor I
on O
T O
cells O
, O
provide O
a O
novel O
approach O
for O
the O
detection O
and O
characterization O
of O
such O
rare O
cells O
. O

Constitutive O
expression O
of O
NF B
- I
kappa I
B I
is O
a O
characteristic O
feature O
of O
mycosis O
fungoides O
: O
implications O
for O
apoptosis O
resistance O
and O
pathogenesis O
. O

Recently O
, O
members O
of O
the O
NF B
- I
kappaB I
family I
, O
including O
p65 B
( I
Rel I
A I
) I
, O
have O
been O
implicated O
in O
promoting O
survival O
of O
various O
hematopoeitic O
neoplasms O
, O
including O
T O
cell O
malignancies O
such O
as O
adult O
T O
cell O
leukemia O
- O
lymphoma O
. O

We O
investigated O
the O
expression O
of O
active B
NF I
- I
kappa I
B I
p65 I
( I
Rel I
A I
) I
in O
cases O
of O
mycosis O
fungoides O
( O
MF O
) O
and O
the O
effect O
of O
chemical O
inhibitors O
of O
NF B
- I
kappa I
B I
on O
apoptosis O
in O
cutaneous O
T O
cell O
lymphoma O
( O
CTCL O
) O
cell O
lines O
. O

In O
CTCL O
cell O
lines O
, O
the O
significant O
decrease O
in O
nuclear O
NF O
- O
kappa O
B O
expression O
and O
the O
marked O
increase O
in O
spontaneous O
apoptosis O
caused O
by O
chemical O
NF O
- O
kappa O
B O
inhibition O
suggest O
a O
critical O
role O
for O
NF B
- I
kappa I
B I
in O
the O
pathogenesis O
and O
tumor O
cell O
maintenance O
of O
CTCLs O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
tax B
protein I
activates O
transcription O
through O
AP B
- I
1 I
site I
by O
inducing O
DNA O
binding O
activity O
in O
T O
cells O
. O

We O
examined O
the O
activity O
of O
Tax B
in O
transcription O
through O
AP B
- I
1 I
- I
binding I
sites I
( O
AP B
- I
1 I
site I
) O
in O
T O
cells O
. O

Transient O
transfection O
studies O
showed O
that O
Tax B
activated O
the O
expression O
of O
a O
luciferase B
gene I
regulated O
by O
two O
copies O
of O
an O
AP B
- I
1 I
site I
in O
the O
human O
Jurkat O
T O
- O
cell O
line O
. O

Tax B
activates O
the O
expression O
of O
viral B
and I
cellular I
genes I
through O
two O
different O
enhancers O
: O
a O
cAMP B
- I
responsive I
( I
CRE I
) I
- I
like I
element I
and O
a O
kappaB B
element I
. O

Unlike O
the O
wild B
- I
type I
Tax I
, O
Tax703 B
and O
TaxM22 B
only O
weakly O
activated O
the O
AP B
- I
1 I
site I
in O
the O
T O
- O
cell O
line O
. O

Unlike O
the O
wild B
- I
type I
Tax I
, O
Tax703 B
and O
TaxM22 B
only O
weakly O
activated O
the O
AP B
- I
1 I
site I
in O
the O
T O
- O
cell O
line O
. O

Thus O
, O
Tax B
seems O
to O
activate O
the O
AP B
- I
1 I
site I
via O
mechanisms O
distinct O
from O
those O
of O
kappaB B
or I
CRE I
- I
like I
elements I
, O
and O
the O
activation O
of O
the O
AP B
- I
1 I
site I
is O
dispensable O
for O
IL O
- O
2 O
- O
independent O
growth O
of O
CTLL O
- O
2 O
. O

Thus O
, O
Tax B
seems O
to O
activate O
the O
AP B
- I
1 I
site I
via O
mechanisms O
distinct O
from O
those O
of O
kappaB B
or I
CRE I
- I
like I
elements I
, O
and O
the O
activation O
of O
the O
AP B
- I
1 I
site I
is O
dispensable O
for O
IL O
- O
2 O
- O
independent O
growth O
of O
CTLL O
- O
2 O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
Tax B
induced O
strong O
binding O
activity O
to O
an O
AP B
- I
1 I
site I
in O
CTLL O
- O
2 O
, O
whereas O
Tax703 B
did O
not O
, O
indicating O
that O
the O
induction O
of O
binding O
activity O
to O
the O
AP B
- I
1 I
site I
is O
essential O
for O
the O
transcriptional O
activation O
by O
Tax B
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
Tax B
induced O
strong O
binding O
activity O
to O
an O
AP B
- I
1 I
site I
in O
CTLL O
- O
2 O
, O
whereas O
Tax703 B
did O
not O
, O
indicating O
that O
the O
induction O
of O
binding O
activity O
to O
the O
AP B
- I
1 I
site I
is O
essential O
for O
the O
transcriptional O
activation O
by O
Tax B
. O

Other O
AP B
- I
1 I
proteins I
were O
undetectable O
. O

Activation O
of O
transcription O
through O
the O
AP B
- I
1 I
site I
in O
Jurkat O
cells O
by O
JunD B
and O
/ O
or O
Fra B
- I
2 I
was O
weak O
. O

Thus O
, O
the O
induction O
of O
AP B
- I
1 I
mRNA I
by O
Tax B
may O
not O
be O
sufficient O
for O
a O
complete O
activation O
of O
AP B
- I
1 I
site I
by O
Tax B
. O

Thus O
, O
the O
induction O
of O
AP B
- I
1 I
mRNA I
by O
Tax B
may O
not O
be O
sufficient O
for O
a O
complete O
activation O
of O
AP B
- I
1 I
site I
by O
Tax B
. O

Our O
results O
suggest O
that O
Tax B
activates O
the O
transcription O
of O
cellular B
genes I
with O
AP B
- I
1 I
sites I
by O
inducing O
the O
DNA O
- O
binding O
activity O
of O
AP B
- I
1 I
proteins I
in O
T O
cells O
, O
a O
mechanism O
distinct O
from O
those O
of O
CRE B
- I
like I
and I
kappaB I
elements I
. O

Our O
results O
suggest O
that O
Tax B
activates O
the O
transcription O
of O
cellular B
genes I
with O
AP B
- I
1 I
sites I
by O
inducing O
the O
DNA O
- O
binding O
activity O
of O
AP B
- I
1 I
proteins I
in O
T O
cells O
, O
a O
mechanism O
distinct O
from O
those O
of O
CRE B
- I
like I
and I
kappaB I
elements I
. O

We O
therefore O
designed O
HIV B
- I
1 I
genomes I
that O
replicate O
exclusively O
upon O
addition O
of O
the O
nontoxic O
effector O
doxycycline O
( O
dox O
) O
. O

Synovial O
fluid O
induced O
nuclear B
factor I
- I
kappaB I
DNA O
binding O
in O
a O
monocytic O
cell O
line O
. O

OBJECTIVE O
: O
To O
determine O
the O
effects O
of O
synovial O
fluids O
( O
SF O
) O
on O
DNA O
binding O
activity O
of O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
in O
the O
Mono O
Mac O
6 O
monocytic O
/ O
macrophage O
cell O
line O
as O
a O
model O
for O
the O
interaction O
between O
SF O
and O
synovial O
tissue O
macrophages O
in O
arthritis O
. O

The O
induction O
of O
this O
complex O
by O
SF O
was O
not O
affected O
by O
neutralization O
of O
TNF B
- I
alpha I
or O
IL B
- I
6 I
in O
SF O
, O
and O
the O
complex O
was O
not O
inducible O
by O
TNF B
- I
alpha I
, O
IL O
- O
1beta O
, O
TNF B
- I
alpha I
/ O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
platelet B
derived I
growth I
factor I
, O
lipopolysaccharide O
, O
or O
tetradecanoyl O
phorbol O
acetate O
. O

Normal O
mouse O
B O
cells O
and O
a O
variety O
of O
B O
lymphoma O
cells O
reflective O
of O
stages O
of O
B O
cell O
differentiation O
( O
e O
. O
g O
. O
, O
70Z O
/ O
3 O
, O
CH31 O
, O
WEHI O
- O
231 O
, O
CH12 O
, O
and O
J558 O
) O
express O
PPAR B
- I
gamma I
mRNA I
and O
, O
by O
Western O
blot O
analysis O
, O
the O
67 B
- I
kDa I
PPAR I
- I
gamma I
protein I
. O

Activated B
STAT3 I
was O
shown O
to O
bind O
an O
SIE B
- I
related I
element I
in O
the O
murine B
mcl I
- I
1 I
promoter I
. O

Using O
a O
luciferase O
reporter O
assay O
, O
we O
demonstrated O
that O
v O
- O
src O
overexpression O
in O
NIH3T3 O
induced O
STAT3 B
- O
dependent O
transcriptional O
activity O
from O
the O
mcl B
- I
1 I
promoter I
and O
increased O
endogenous O
Mcl O
- O
1 O
protein O
levels O
. O

To O
better O
define O
the O
role O
of O
ATF B
- I
2 I
in O
inflammation O
, O
adult O
mice O
expressing O
small O
amounts O
of O
a O
mutant B
ATF I
- I
2 I
protein I
were O
challenged O
with O
lipopolysaccharide O
( O
LPS O
) O
, O
anti B
- I
CD3 I
antibody I
or O
virus O
. O

Stimulation O
of O
T O
lymphocytes O
by O
anti B
- I
CD3 I
antibody I
also O
showed O
less O
induction O
of O
IL B
- I
1 I
and O
IL B
- I
6 I
in O
ATF O
- O
2 O
mutant O
tissues O
. O

ATF O
- O
2 O
mutant O
thymocytes O
treated O
with O
anti B
- I
CD3 I
antibody I
in O
vitro O
demonstrated O
reduced O
induction O
of O
c B
- I
Jun I
, O
JunB B
, O
JunD B
and O
Fra B
- I
2 I
. O

LIGHT B
, O
a O
TNF B
- I
like I
molecule I
, O
costimulates O
T O
cell O
proliferation O
and O
is O
required O
for O
dendritic O
cell O
- O
mediated O
allogeneic O
T O
cell O
response O
. O

This O
finding O
indicates O
that O
formation O
of O
a O
transcriptionaly B
active I
USF I
- I
1 I
/ I
Ets I
- I
1 I
complex I
is O
important O
in O
the O
productive O
infection O
of O
cells O
by O
HIV O
- O
1 O
, O
and O
suggests O
that O
inhibition O
of O
the O
interaction O
between O
USF B
- I
1 I
and O
Ets B
- I
1 I
with O
the O
HIV B
- I
1 I
LTR I
may O
provide O
a O
new O
target O
for O
anti O
- O
HIV O
- O
1 O
gene O
therapy O
. O

RESULTS O
: O
Both O
peripheral O
blood O
and O
bronchoalveolar O
lavage O
fluid O
eosinophils O
expressed O
NFATp B
and I
NFATc I
protein I
. O

B B
lymphocyte I
stimulator I
( O
BLyS B
) O
is O
a O
novel O
member O
of O
the O
TNF B
family I
of I
proteins I
expressed O
by O
myeloid O
cells O
as O
membrane O
- O
bound O
and O
soluble O
forms O
. O

In O
addition O
we O
report O
that O
BLyS B
binding O
to O
B O
cells O
results O
in O
the O
activation O
of O
NF B
- I
kappaB I
and O
the O
Ets B
family I
transcription I
factor I
, O
ELF B
- I
1 I
, O
and O
in O
the O
induction O
of O
mRNA O
for O
Polo B
- I
like I
kinase I
( O
PLK B
) O
. O

In O
addition O
we O
report O
that O
BLyS B
binding O
to O
B O
cells O
results O
in O
the O
activation O
of O
NF B
- I
kappaB I
and O
the O
Ets B
family I
transcription I
factor I
, O
ELF B
- I
1 I
, O
and O
in O
the O
induction O
of O
mRNA O
for O
Polo B
- I
like I
kinase I
( O
PLK B
) O
. O

It O
is O
composed O
of O
a O
fusion O
between O
full B
- I
length I
Nef I
and O
the O
estrogen B
receptor I
hormone I
- I
binding I
domain I
( O
Nef B
- I
ER I
) O
. O

By O
Northern O
analysis O
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
- I
2 I
mRNA I
in O
BAL O
cells O
increased O
markedly O
1 O
h O
after O
NaVO3 O
instillation O
and O
reduced O
a O
little O
bit O
at O
4 O
h O
, O
whereas O
MIP B
- I
1alpha I
mRNA I
in O
BAL O
cells O
was O
expressed O
relatively O
high O
1 O
h O
after O
NaVO3 O
instillation O
, O
although O
a O
basal O
expression O
was O
detected O
in O
control O
group O
, O
and O
returned O
rapidly O
nearly O
to O
control O
level O
at O
4 O
h O
. O

The O
facts O
that O
PMN O
influx O
was O
preceded O
by O
increased O
MIP O
- O
2 O
mRNA O
expression O
, O
suggesting O
that O
MIP B
- I
2 I
is O
involved O
in O
the O
development O
of O
NaVO3 O
- O
induced O
pulmonary O
inflammation O
, O
whereas O
increased O
MIP B
- I
1alpha I
mRNA I
expression O
was O
followed O
by O
decreased O
AMs O
in O
BAL O
cells O
, O
suggesting O
AMs O
might O
be O
activated O
by O
MIP B
- I
1alpha I
, O
adherent O
to O
the O
lining O
surface O
of O
the O
airways O
and O
then O
resistant O
to O
be O
washed O
out O
. O

To O
delineate O
the O
mechanisms O
of O
transcriptional O
activation O
, O
we O
recently O
cloned O
the O
5 B
' I
- I
flanking I
region I
of O
the O
MIP B
- I
2 I
gene I
. O

The O
promotor B
region I
contains O
consensus B
binding I
sites I
for O
transcription B
factor I
nuclear I
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
. O

Using O
electrophoretic O
mobility O
shift O
assay O
, O
increased O
nuclear O
NF B
- I
kappaB I
, O
not O
AP B
- I
1 I
, O
binding O
activity O
was O
detected O
1 O
h O
after O
NaVO3 O
instillation O
, O
which O
correlated O
with O
the O
induction O
of O
MIP B
- I
2 I
mRNA I
. O

In O
addition O
, O
elevated O
MIP B
- I
2 I
mRNA I
levels O
are O
accompanied O
by O
increased O
NF B
- I
kappaB I
binding O
activity O
in O
BAL O
cells O
, O
suggesting O
possible O
MIP B
- I
2 I
transcriptional O
regulation O
through O
NF B
- I
kappaB I
. O

In O
this O
study O
we O
analysed O
the O
induction O
of O
factors O
involved O
in O
cytokine O
signal O
transduction O
, O
such O
as O
STAT B
1 I
proteins I
and O
IRF B
- I
1 I
mRNA I
, O
in O
normal O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
exposed O
to O
HIV O
- O
infected O
cells O
, O
and O
the O
induction O
of O
apoptosis O
. O

Western O
blot O
analyses O
and O
reverse O
transcriptase O
- O
polymerase O
chain O
reaction O
results O
indicate O
that O
both O
cells O
infected O
with O
a O
X4 O
strain O
and O
cells O
infected O
with O
a O
R5 O
strain O
are O
able O
to O
increase O
intracellular O
levels O
of O
STAT B
1alpha I
and I
beta I
proteins O
as O
well O
as O
IRF B
- I
1 I
mRNA I
. O

Western O
blot O
analyses O
and O
reverse O
transcriptase O
- O
polymerase O
chain O
reaction O
results O
indicate O
that O
both O
cells O
infected O
with O
a O
X4 O
strain O
and O
cells O
infected O
with O
a O
R5 O
strain O
are O
able O
to O
increase O
intracellular O
levels O
of O
STAT B
1alpha I
and I
beta I
proteins O
as O
well O
as O
IRF B
- I
1 I
mRNA I
. O

The O
physical O
association O
of O
protein B
kinase I
C I
theta I
with O
a O
lipid O
raft O
- O
associated O
inhibitor O
of O
kappa B
B I
factor I
kinase I
( I
IKK I
) I
complex I
plays O
a O
role O
in O
the O
activation O
of O
the O
NF O
- O
kappa O
B O
cascade O
by O
TCR B
and O
CD28 B
. O

We O
investigated O
the O
role O
of O
protein B
kinase I
C I
theta I
( O
PKCtheta B
) O
in O
the O
activation O
of O
the O
NF B
- I
kappaB I
cascade O
in O
primary O
human O
CD4 O
( O
+ O
) O
lymphocytes O
. O

Constitutively O
active O
but O
not O
kinase B
- I
inactive I
PKCtheta I
activated O
IKKbeta B
in O
Jurkat O
T O
cells O
. O

Expression O
of O
dominant B
- I
active I
PKCtheta I
also O
had O
stimulatory O
effects O
on O
the O
CD28 B
response I
element I
of O
the O
IL B
- I
2 I
promoter I
. O

Expression O
of O
dominant B
- I
active I
PKCtheta I
also O
had O
stimulatory O
effects O
on O
the O
CD28 B
response I
element I
of O
the O
IL B
- I
2 I
promoter I
. O

However O
, O
it O
does O
induce O
chemotaxis O
, O
trans O
- O
Matrigel O
migration O
, O
and O
secretion O
of O
matrix O
metalloproteinase B
9 I
( O
MMP B
- I
9 I
) O
and O
vascular B
endothelial I
growth I
factor I
( O
VEGF B
) O
by O
these O
cells O
, O
and O
both O
SDF B
- I
1 I
and O
TPO B
increase O
the O
adhesion O
of O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
to O
fibrinogen B
and O
vitronectin B
. O

Investigating O
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF B
- I
1 I
and O
TPO B
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation O
/ O
activation O
( O
mitogen B
- I
activated I
protein I
kinase I
[ I
MAPK I
] I
p42 I
/ I
44 I
, O
MAPK B
p38 I
, O
and O
AKT B
[ I
protein I
kinase I
B I
] I
) O
and O
some O
that O
were O
distinct O
for O
TPO B
( O
eg O
, O
JAK B
- I
STAT I
) O
and O
for O
SDF B
- I
1 I
( O
eg O
, O
NF B
- I
kappa I
B I
) O
. O

It O
was O
also O
found O
that O
though O
inhibition O
of O
phosphatidyl B
- I
inositol I
3 I
- I
kinase I
( O
PI B
- I
3K I
) O
by O
LY294002 O
in O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
induced O
apoptosis O
and O
inhibited O
chemotaxis O
adhesion O
and O
the O
secretion O
of O
MMP B
- I
9 I
and O
VEGF B
, O
the O
inhibition O
of O
MAPK B
p42 I
/ I
44 I
( O
by O
the O
MEK O
inhibitor O
U0126 O
) O
had O
no O
effect O
on O
the O
survival O
, O
proliferation O
, O
and O
migration O
of O
these O
cells O
. O

Adhesion O
of O
immature O
and O
mature O
T O
cells O
induces O
in O
human O
thymic O
epithelial O
cells O
( O
TEC O
) O
activation O
of O
IL B
- I
6 I
gene I
trascription I
factors I
( O
NF B
- I
kappaB I
and O
NF B
- I
IL6 I
) O
and O
IL O
- O
6 O
gene O
expression O
: O
role O
of O
alpha3beta1 B
and I
alpha6beta4 I
integrins I
. O

We O
demonstrated O
that O
thymocytes O
adhere O
to O
TEC O
involving O
beta1 B
and I
beta4 I
integrins I
and O
induce O
the O
clustering O
of O
alpha3beta1 B
and I
alpha6beta4 I
heterodimers I
at O
the O
TEC O
surface O
. O

We O
demonstrated O
that O
thymocytes O
adhere O
to O
TEC O
involving O
beta1 B
and I
beta4 I
integrins I
and O
induce O
the O
clustering O
of O
alpha3beta1 B
and I
alpha6beta4 I
heterodimers I
at O
the O
TEC O
surface O
. O

The O
two O
latter O
phenomena O
were O
reproduced O
by O
the O
cross O
- O
linking O
of O
the O
alpha3 B
, O
alpha6 B
, O
beta1 B
and I
beta4 I
integrins I
, O
thus O
implying O
that O
the O
alpha3beta1 B
and I
alpha6beta4 I
heterodimers I
can O
signal O
during O
thymocyte O
adhesion O
. O

The O
two O
latter O
phenomena O
were O
reproduced O
by O
the O
cross O
- O
linking O
of O
the O
alpha3 B
, O
alpha6 B
, O
beta1 B
and I
beta4 I
integrins I
, O
thus O
implying O
that O
the O
alpha3beta1 B
and I
alpha6beta4 I
heterodimers I
can O
signal O
during O
thymocyte O
adhesion O
. O

We O
propose O
that O
alpha3beta1 B
and I
alpha6beta4 I
heterodimers I
are O
induced O
to O
cluster O
at O
the O
TEC O
surface O
recognizing O
yet O
unknown O
cellular B
ligands I
differentially O
expressed O
during O
T O
cell O
development O
. O

This O
result O
was O
confirmed O
using O
clones O
of O
EL4 O
cells O
stably O
expressing O
an O
inducible O
form O
of O
SKAT B
- I
2 I
, O
thus O
SKAT B
- I
2 I
is O
a O
novel O
Th2 B
- I
specific I
gene I
that O
may O
play O
a O
role O
in O
selective O
regulation O
of O
cytokine B
genes I
in O
T O
cells O
. O

hsp70 B
interacting I
protein I
Hip I
does O
not O
affect O
glucocorticoid B
receptor I
folding O
by O
the O
hsp90 O
- O
based O
chaperone O
machinery O
except O
to O
oppose O
the O
effect O
of O
BAG B
- I
1 I
. O

The O
hsp70 B
co I
- I
chaperone I
Hip I
has O
been O
recovered O
in O
receptor B
. I
hsp90 I
heterocomplexes I
at O
an O
intermediate O
stage O
of O
assembly O
in O
reticulocyte O
lysate O
, O
and O
Hip B
is O
also O
thought O
to O
be O
an O
intrinsic O
component O
of O
the O
assembly O
machinery O
. O

Despite O
the O
fact O
that O
Hip B
does O
not O
affect O
assembly O
, O
it O
is O
recovered O
in O
GR B
. I
hsp90 I
heterocomplexes I
assembled O
by O
both O
systems O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
ability O
of O
Tax B
to O
activate O
transcription O
through O
the O
AP B
- I
1 I
- I
binding I
site I
( O
AP B
- I
1 I
site I
) O
. O

A O
transient O
transfection O
study O
showed O
that O
Tax B
can O
activate O
transcription O
through O
the O
AP B
- I
1 I
- I
binding I
site I
in O
a O
human O
T O
cell O
line O
, O
whereas O
any O
combination O
of O
AP B
- I
1 I
proteins I
did O
so O
much O
less O
than O
Tax B
, O
indicating O
that O
the O
activation O
of O
the O
AP B
- I
1 I
site I
by O
Tax B
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP B
- I
1 I
mRNA I
. O

A O
transient O
transfection O
study O
showed O
that O
Tax B
can O
activate O
transcription O
through O
the O
AP B
- I
1 I
- I
binding I
site I
in O
a O
human O
T O
cell O
line O
, O
whereas O
any O
combination O
of O
AP B
- I
1 I
proteins I
did O
so O
much O
less O
than O
Tax B
, O
indicating O
that O
the O
activation O
of O
the O
AP B
- I
1 I
site I
by O
Tax B
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP B
- I
1 I
mRNA I
. O

A O
transient O
transfection O
study O
showed O
that O
Tax B
can O
activate O
transcription O
through O
the O
AP B
- I
1 I
- I
binding I
site I
in O
a O
human O
T O
cell O
line O
, O
whereas O
any O
combination O
of O
AP B
- I
1 I
proteins I
did O
so O
much O
less O
than O
Tax B
, O
indicating O
that O
the O
activation O
of O
the O
AP B
- I
1 I
site I
by O
Tax B
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP B
- I
1 I
mRNA I
. O

However O
, O
the O
HTLV B
- I
1 I
genes I
, O
including O
tax B
, O
are O
not O
significantly O
expressed O
in O
fresh O
leukemia O
cells O
from O
ATL O
patients O
. O

The O
conditionally O
active O
Raf B
proteins I
were O
regulated O
by O
beta O
- O
estradiol O
as O
cDNAs B
containing O
the O
Raf B
catalytic I
, O
but O
lacking O
negative B
- I
regulatory I
domains I
, O
were O
ligated O
to O
the O
hormone B
binding I
domain I
of O
the O
estrogen B
receptor I
( O
deltaRaf B
: I
ER I
) O
. O

In O
contrast O
when O
the O
Raf O
- O
responsive O
cells O
were O
induced O
to O
differentiate O
with O
PMA O
and O
GM B
- I
CSF I
, O
in O
the O
absence O
of O
deltaRaf B
: I
ER I
activation O
, O
increased O
levels O
of O
the O
CD11b B
and I
CD18 I
molecules I
were O
detected O
. O

Furthermore O
, O
we O
found O
that O
the O
Box1 B
region I
and O
the O
C B
- I
terminal I
tail I
of O
IL B
- I
13R I
alpha I
1 I
were O
critical O
for O
binding O
to O
Tyk2 B
, O
and O
activation O
of O
Jak1 B
, O
Tyk2 B
, O
the O
insulin B
receptor I
substrate I
- I
1 I
and O
STAT6 B
respectively O
. O

Here O
we O
show O
that O
site B
C I
binds O
members O
of O
the O
ubiquitously O
expressed O
RFX B
family I
of I
proteins I
, O
notably O
RFX1 B
, O
RFX3 B
, O
and O
the O
associated O
factor O
MIBP1 B
, O
whereas O
sites B
B I
and I
D I
both O
bind O
the O
B B
- I
cell I
- I
specific I
activator I
protein I
BSAP I
/ I
Pax5 I
. O

Here O
we O
show O
that O
site B
C I
binds O
members O
of O
the O
ubiquitously O
expressed O
RFX B
family I
of I
proteins I
, O
notably O
RFX1 B
, O
RFX3 B
, O
and O
the O
associated O
factor O
MIBP1 B
, O
whereas O
sites B
B I
and I
D I
both O
bind O
the O
B B
- I
cell I
- I
specific I
activator I
protein I
BSAP I
/ I
Pax5 I
. O

In O
reporter O
assays O
with O
mutant B
Wp I
constructs I
, O
the O
loss O
of O
factor O
binding O
to O
any O
one O
of O
these O
sites O
severely O
impaired O
promoter O
activity O
in O
B O
cells O
, O
while O
the O
wild B
- I
type I
promoter I
could O
be O
activated O
in O
non O
- O
B O
cells O
by O
ectopic O
BSAP O
expression O
. O

Activation O
of O
the O
Lck B
tyrosine I
protein I
kinase I
by O
the O
Herpesvirus O
saimiri O
tip B
protein I
involves O
two O
binding O
interactions O
. O

The O
Tip B
protein I
of O
Herpesvirus O
saimiri O
strain O
484C O
binds O
to O
and O
activates O
the O
Lck B
tyrosine I
protein I
kinase I
. O

A O
proline B
- I
rich I
region I
, O
residues O
132 O
- O
141 O
, O
binds O
to O
the O
SH3 B
domain I
of O
the O
Lck B
protein I
. O

We O
show O
here O
that O
the O
other O
Lck B
- I
binding I
domain I
, O
residues O
104 O
- O
113 O
, O
binds O
to O
the O
carboxyl B
- I
terminal I
half I
of O
Lck B
and O
that O
this O
binding O
does O
not O
require O
the O
Lck B
SH3 I
domain I
. O

We O
show O
here O
that O
the O
other O
Lck B
- I
binding I
domain I
, O
residues O
104 O
- O
113 O
, O
binds O
to O
the O
carboxyl B
- I
terminal I
half I
of O
Lck B
and O
that O
this O
binding O
does O
not O
require O
the O
Lck B
SH3 I
domain I
. O

Mutated O
Tip B
containing O
only O
one O
functional O
Lck B
- I
binding I
domain I
can O
bind O
stably O
to O
Lck B
, O
although O
not O
as O
strongly O
as O
wild B
- I
type I
Tip I
. O

Mutated O
Tip B
containing O
only O
one O
functional O
Lck B
- I
binding I
domain I
can O
bind O
stably O
to O
Lck B
, O
although O
not O
as O
strongly O
as O
wild B
- I
type I
Tip I
. O

Interaction O
of O
Tip B
with O
Lck B
through O
either O
Lck B
- I
binding I
domain I
increases O
the O
activity O
of O
Lck B
in O
vivo O
. O

Mutant O
forms O
of O
Tip B
lacking O
one O
or O
the O
other O
of O
the O
two O
Lck B
- I
binding I
domains I
retained O
the O
ability O
to O
stimulate O
Stat3 B
- O
dependent O
transcription O
. O

Tip B
lacking O
the O
proline O
- O
rich O
Lck B
- I
binding I
domain I
exhibited O
almost O
wild O
- O
type O
activity O
in O
this O
assay O
. O

In O
contrast O
, O
ablation O
of O
either O
Lck B
- I
binding I
domain I
abolished O
the O
ability O
of O
Tip B
to O
stimulate O
NF B
- I
AT I
- O
dependent O
transcription O
. O

Full O
biological O
activity O
of O
Tip B
, O
therefore O
, O
appears O
to O
require O
both O
Lck B
- I
binding I
domains I
. O

We O
have O
previously O
reported O
that O
the O
activation O
of O
resting O
human O
immature O
peripheral O
blood O
T O
( O
PBT O
) O
lymphocytes O
is O
associated O
with O
the O
loss O
of O
retinoid B
X I
receptor I
alpha I
( O
RXRalpha B
) O
expression O
. O

fNF B
- I
E2 I
mRNA I
was O
found O
to O
be O
more O
abundant O
in O
erythroid O
cells O
than O
megakaryocytic O
cells O
at O
day O
7 O
of O
culture O
. O

Although O
both O
isomers O
were O
expressed O
in O
human O
erythroid O
- O
megakaryocytic O
cell O
lines O
, O
megakaryocytic O
maturation O
with O
loss O
of O
erythroid O
phenotype O
induced O
by O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
resulted O
in O
exclusive O
downregulation O
of O
fNF B
- I
E2 I
, O
suggesting O
that O
fNF B
- I
E2 I
promoter I
is O
more O
erythroid O
specific O
. O

Functional O
analysis O
of O
fNF B
- I
E2 I
promoter I
showed O
that O
the O
promoter O
is O
active O
only O
in O
erythroid O
- O
megakaryocytic O
cells O
and O
that O
the O
double B
GATA I
sit I
e O
in O
the O
proximal O
region O
is O
necessary O
for O
its O
efficient O
activity O
. O

Transcriptional O
activation O
of O
heme B
oxygenase I
- I
1 I
and O
its O
functional O
significance O
in O
acetaminophen O
- O
induced O
hepatitis O
and O
hepatocellular O
injury O
in O
the O
rat O
. O

BACKGROUND O
/ O
AIM O
: O
Glutathione O
depletion O
contributes O
to O
acetaminophen O
hepatotoxicity O
and O
is O
known O
to O
induce O
the O
oxidative O
stress O
reactant O
heme B
oxygenase I
- I
1 I
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
cell O
- O
type O
specific O
expression O
of O
heme B
oxygenase I
- I
1 I
and O
its O
impact O
on O
liver O
injury O
and O
microcirculatory O
disturbances O
in O
a O
model O
of O
acetaminophen O
- O
induced O
hepatitis O
. O

METHODS O
: O
Gene O
expression O
of O
heme B
oxygenase I
- I
1 I
was O
studied O
by O
Northern O
- O
and O
Western O
analysis O
as O
well O
as O
immunohistochemistry O
. O

DNA O
- O
binding O
activity O
of O
nuclear B
factor I
- I
kappaB I
was O
determined O
by O
electrophoretic O
mobility O
shift O
assay O
. O

RESULTS O
: O
Acetaminophen O
caused O
a O
moderate O
sinusoidal O
perfusion O
failure O
( O
- O
15 O
% O
) O
and O
infiltration O
of O
neutrophils O
along O
with O
activation O
of O
nuclear B
factor I
- I
kappaB I
and O
intercellular B
adhesion I
molecule I
- I
1 I
and O
cytokine B
- I
induced I
neutrophil I
chemoattractant I
- I
1 I
mRNAs O
. O

Induction O
of O
heme B
oxygenase I
- I
1 I
mRNA O
and O
protein O
( O
approximately O
30 O
- O
fold O
) O
in O
hepatocytes O
and O
non O
- O
parenchymal O
cells O
paralleled O
the O
inflammatory O
response O
. O

Blockade O
of O
heme O
oxygenase O
activity O
with O
tin O
- O
protoporphyrin O
- O
IX O
abrogated O
acetaminophen O
- O
induced O
hepatic O
neutrophil O
accumulation O
and O
nuclear B
factor I
- I
kappaB I
activation O
, O
but O
failed O
to O
affect O
sinusoidal O
perfusion O
and O
liver O
injury O
. O

However O
, O
heme B
oxygenase I
- I
1 I
has O
no O
permissive O
effect O
on O
sinusoidal O
perfusion O
and O
does O
not O
affect O
liver O
injury O
in O
this O
model O
. O

These O
data O
argue O
against O
a O
central O
role O
of O
nuclear B
factor I
- I
kappaB I
activation O
and O
neutrophil O
infiltration O
as O
perpetuating O
factors O
of O
liver O
injury O
in O
acetaminophen O
toxicity O
. O

Supporting O
this O
notion O
, O
TNF B
- I
alpha I
- O
induced O
upregulation O
of O
GM B
- I
CSF I
mRNA I
levels O
and O
protein O
secretion O
in O
the O
TNF B
- I
alpha I
- O
proliferative O
, O
but O
not O
in O
the O
TNF O
- O
alpha O
- O
apoptotic O
cell O
lines O
. O

Transient O
expression O
of O
actively O
mutated O
Fyn B
, O
having O
Phe O
- O
528 O
instead O
of O
Tyr O
- O
528 O
or O
Thr O
- O
338 O
instead O
of O
Ile O
- O
338 O
, O
in O
Jurkat O
T O
- O
cells O
stimulated B
the I
serum I
response I
element I
( O
SRE B
) O
, O
12 B
- I
O I
- I
tetradecanoyl I
- I
phorbol I
- I
13 I
- I
acetate I
response I
element I
, O
cyclic B
AMP I
response I
element I
, O
and O
c B
- I
fos I
promoter I
. O

Transient O
expression O
of O
actively O
mutated O
Fyn B
, O
having O
Phe O
- O
528 O
instead O
of O
Tyr O
- O
528 O
or O
Thr O
- O
338 O
instead O
of O
Ile O
- O
338 O
, O
in O
Jurkat O
T O
- O
cells O
stimulated B
the I
serum I
response I
element I
( O
SRE B
) O
, O
12 B
- I
O I
- I
tetradecanoyl I
- I
phorbol I
- I
13 I
- I
acetate I
response I
element I
, O
cyclic B
AMP I
response I
element I
, O
and O
c B
- I
fos I
promoter I
. O

SRE B
was O
also O
stimulated O
by O
both O
normal B
and I
active I
Lck I
. O

Furthermore O
, O
normal B
and I
active I
Fyn I
stimulated O
transcription O
from O
the O
IL B
- I
2 I
gene I
promoter I
when O
transfected O
cells O
were O
stimulated O
by O
concanavalin B
A I
plus O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
. O

Under O
the O
same O
conditions O
, O
Lck B
did O
not O
stimulate O
IL B
- I
2 I
promoter I
unless O
it O
was O
activated O
by O
mutation O
. O

Csk B
, O
which O
phosphorylates O
tyrosine O
residues O
in O
the O
negative O
regulatory O
sites O
of O
Src B
family I
kinases I
, O
down O
- O
regulated O
Fyn O
- O
and O
Lck O
- O
mediated O
stimulation O
of O
the O
serum B
response I
element I
and O
Fyn O
- O
mediated O
enhancement O
of O
IL B
- I
2 I
promoter I
activity O
. O

Prior O
transfection O
studies O
have O
shown O
that O
when O
these O
p65 B
and I
p50 I
subunits I
are O
expressed O
independently O
as O
stable B
homodimers I
, O
p65 B
stimulates O
kappa O
B O
- O
directed O
transcription O
, O
whereas O
p50 B
functions O
as O
a O
kappa O
B O
- O
specific O
repressor O
. O

As O
with O
the O
prototypical O
NF B
- I
kappa I
B I
p50 I
- I
p65 I
heterodimer I
, O
this O
novel O
p65 B
homodimeric I
form I
of O
NF B
- I
kappa I
B I
is O
functionally O
sequestered O
in O
the O
cytoplasm O
but O
rapidly O
appears O
in O
the O
nuclear O
compartment O
following O
cellular O
stimulation O
. O

These O
later O
findings O
indicate O
that O
neither O
homo O
- O
nor O
heterodimer O
formation O
is O
an O
absolute O
prerequisite O
for O
I B
kappa I
B I
alpha I
recognition O
of O
p65 B
. O

Taken O
together O
with O
prior O
in O
vivo O
transcription O
studies O
, O
these O
results O
suggest O
that O
the O
biological O
activities O
of O
p65 B
and I
p50 I
homodimers I
are O
independently O
regulated O
, O
thereby O
providing O
an O
integrated O
and O
flexible O
control O
mechanism O
for O
the O
rapid O
activation O
and O
repression O
of O
NF B
- I
kappa I
B I
/ O
Rel B
- O
directed O
gene O
expression O
. O

Taken O
together O
with O
prior O
in O
vivo O
transcription O
studies O
, O
these O
results O
suggest O
that O
the O
biological O
activities O
of O
p65 B
and I
p50 I
homodimers I
are O
independently O
regulated O
, O
thereby O
providing O
an O
integrated O
and O
flexible O
control O
mechanism O
for O
the O
rapid O
activation O
and O
repression O
of O
NF B
- I
kappa I
B I
/ O
Rel B
- O
directed O
gene O
expression O
. O

Effects O
of O
IL B
- I
4 I
and O
Fc B
gamma I
receptor I
II I
engagement O
on O
Egr B
- I
1 I
expression O
during O
stimulation O
of O
B O
lymphocytes O
by O
membrane O
immunoglobulin O
crosslinking O
. O

We O
compared O
the O
expression O
of O
Egr B
- I
1 I
during O
B O
cell O
stimulation O
with O
Fab B
' I
2 I
and O
IgG B
anti I
- I
immunoglobulin I
( O
anti B
- I
Ig I
) O
, O
since O
it O
is O
known O
that O
Fab B
' I
2 I
anti I
- I
Ig I
is O
mitogenic O
while O
IgG B
anti I
- I
Ig I
is O
not O
, O
owing O
to O
a O
dominant O
inhibitory O
effect O
of O
crosslinking O
the O
B B
cell I
Fc I
gamma I
RII I
to O
membrane B
Ig I
. O

We O
compared O
the O
expression O
of O
Egr B
- I
1 I
during O
B O
cell O
stimulation O
with O
Fab B
' I
2 I
and O
IgG B
anti I
- I
immunoglobulin I
( O
anti B
- I
Ig I
) O
, O
since O
it O
is O
known O
that O
Fab B
' I
2 I
anti I
- I
Ig I
is O
mitogenic O
while O
IgG B
anti I
- I
Ig I
is O
not O
, O
owing O
to O
a O
dominant O
inhibitory O
effect O
of O
crosslinking O
the O
B B
cell I
Fc I
gamma I
RII I
to O
membrane B
Ig I
. O

While O
mitogenic O
doses O
of O
Fab B
' I
2 I
anti I
- I
Ig I
induce O
large O
and O
rapid O
increases O
in O
Egr O
- O
1 O
expression O
, O
IgG B
anti I
- I
Ig I
results O
in O
smaller O
increases O
in O
Egr B
- I
1 I
mRNA I
, O
comparable O
to O
that O
seen O
with O
submitogenic O
concentrations O
of O
Fab B
' I
2 I
anti I
- I
Ig I
. O

While O
mitogenic O
doses O
of O
Fab B
' I
2 I
anti I
- I
Ig I
induce O
large O
and O
rapid O
increases O
in O
Egr O
- O
1 O
expression O
, O
IgG B
anti I
- I
Ig I
results O
in O
smaller O
increases O
in O
Egr B
- I
1 I
mRNA I
, O
comparable O
to O
that O
seen O
with O
submitogenic O
concentrations O
of O
Fab B
' I
2 I
anti I
- I
Ig I
. O

However O
, O
the O
correlation O
between O
Egr O
- O
1 O
expression O
and O
B O
cell O
proliferation O
breaks O
down O
when O
IL B
- I
4 I
is O
added O
as O
a O
co O
- O
mitogen O
to O
induce O
B O
cell O
proliferation O
with O
IgG B
anti I
- I
Ig I
or O
submitogenic O
concentrations O
of O
Fab B
' I
2 I
anti I
- I
Ig I
. O

No O
corresponding O
increases O
in O
Egr B
- I
1 I
mRNA I
levels O
are O
observed O
when O
IL B
- I
4 I
is O
added O
. O

Therefore O
, O
IL B
- I
4 I
overcomes O
Fc O
receptor O
- O
mediated O
inhibition O
of O
B O
cell O
proliferation O
without O
affecting O
inhibition O
of O
Egr B
- I
1 I
mRNA I
induction O
, O
as O
demonstrated O
earlier O
for O
c B
- I
myc I
mRNA I
in O
this O
system O
. O

Therefore O
, O
IL B
- I
4 I
overcomes O
Fc O
receptor O
- O
mediated O
inhibition O
of O
B O
cell O
proliferation O
without O
affecting O
inhibition O
of O
Egr B
- I
1 I
mRNA I
induction O
, O
as O
demonstrated O
earlier O
for O
c B
- I
myc I
mRNA I
in O
this O
system O
. O

Identification O
of O
a O
novel O
cyclosporin B
- I
sensitive I
element I
in O
the O
human B
tumor I
necrosis I
factor I
alpha I
gene I
promoter I
. O

Tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
, O
a O
cytokine B
with O
pleiotropic O
biological O
effects O
, O
is O
produced O
by O
a O
variety O
of O
cell O
types O
in O
response O
to O
induction O
by O
diverse O
stimuli O
. O

In O
this O
paper O
, O
TNF B
- I
alpha I
mRNA I
is O
shown O
to O
be O
highly O
induced O
in O
a O
murine O
T O
cell O
clone O
by O
stimulation O
with O
T B
cell I
receptor I
( O
TCR B
) O
ligands O
or O
by O
calcium O
ionophores O
alone O
. O

Induction O
of O
the O
inducible O
nuclear B
complexes I
is O
rapid O
, O
independent O
of O
protein O
synthesis O
, O
and O
blocked O
by O
CsA O
, O
and O
thus O
, O
exactly O
parallels O
the O
induction O
of O
TNF B
- I
alpha I
mRNA I
by O
TCR O
ligands O
or O
by O
calcium O
ionophore O
. O

Our O
studies O
indicate O
that O
the O
kappa B
3 I
binding I
factor I
resembles O
the O
preexisting O
component O
of O
nuclear B
factor I
of O
activated O
T O
cells O
. O

Thus O
, O
the O
TNF B
- I
alpha I
gene I
is O
an O
immediate O
early O
gene O
in O
activated O
T O
cells O
and O
provides O
a O
new O
model O
system O
in O
which O
to O
study O
CsA B
- I
sensitive I
gene I
induction O
in O
activated O
T O
cells O
. O

Thus O
, O
the O
TNF B
- I
alpha I
gene I
is O
an O
immediate O
early O
gene O
in O
activated O
T O
cells O
and O
provides O
a O
new O
model O
system O
in O
which O
to O
study O
CsA B
- I
sensitive I
gene I
induction O
in O
activated O
T O
cells O
. O

Activation O
can O
be O
achieved O
in O
vitro O
by O
increased O
ionic O
strength O
, O
dilution O
or O
gel O
filtration O
and O
is O
manifested O
by O
an O
increased O
affinity O
of O
steroid B
- I
receptor I
complex I
for O
DNA B
and O
an O
altered O
elution O
profile O
from O
ion O
- O
exchange O
resins O
. O

We O
report O
here O
that O
DEAE O
- O
cellulose O
chromatography O
of O
steroid B
- I
receptor I
complexes I
from O
CEM O
- O
C7 O
, O
a O
cloned O
human O
leukaemic O
T O
- O
cell O
line O
sensitive O
to O
the O
cytolytic O
action O
of O
glucocorticoids O
, O
and O
its O
steroid O
- O
resistant O
subclone O
4R4 O
demonstrated O
that O
steroid B
receptors I
of O
clone O
4R4 O
can O
not O
form O
stable O
activated O
complexes O
. O

The O
mononuclear O
phagocytes O
contained O
approximately O
equal O
to O
4 O
- O
- O
10 O
X O
10 O
( O
3 O
) O
high B
affinity I
receptor I
sites I
per O
cell O
, O
with O
dissociation O
constants O
of O
approximately O
equal O
to O
2 O
- O
- O
8 O
nM O
dexamethasone O
. O

At O
37 O
degrees O
C O
the O
predominant O
form O
of O
the O
hormone B
- I
receptor I
complex I
was O
nuclear O
. O

In O
support O
of O
the O
existence O
of O
this O
pathway O
in O
whole O
cells O
, O
we O
found O
that O
the O
G O
protein O
inhibitor O
, O
GDP O
- O
beta O
- O
S O
, O
blocked O
NF B
- I
kappa I
B I
translocation O
induced O
by O
nitric O
oxide O
or O
LPS O
in O
permeabilized O
cells O
. O

Expression O
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
gene I
in O
T O
cells O
is O
activated O
by O
the O
combination O
of O
phorbol O
ester O
( O
phorbol O
myristate O
acetate O
) O
and O
calcium O
ionophore O
( O
A23187 O
) O
, O
which O
mimic O
antigen O
stimulation O
through O
the O
T B
- I
cell I
receptor I
. O

Here O
we O
use O
an O
in O
vitro O
transcription O
system O
to O
demonstrate O
that O
a O
cis B
- I
acting I
element I
( O
positions B
- I
54 I
to I
- I
40 I
) O
, O
referred O
to O
as O
CLE0 B
, O
is O
a O
target O
for O
the O
induction O
signals O
. O

We O
observed O
induction O
with O
templates O
containing O
intact O
CLE0 B
but O
not O
with O
templates O
with O
deleted B
or I
mutated I
CLE0 I
. O

Stimulation O
probably O
was O
mediated O
by O
CLE0 B
- I
binding I
proteins I
because O
depletion O
of O
these O
proteins O
specifically O
reduced O
GM B
- I
CSF I
transcription O
. O

The O
presence O
of O
CLE0 B
- I
like I
elements I
in O
the O
promoters B
of O
interleukin B
- I
3 I
( I
IL I
- I
3 I
) I
, I
IL I
- I
4 I
, I
IL I
- I
5 I
, I
GM I
- I
CSF I
, I
and I
NFAT I
sites I
in O
the O
IL B
- I
2 I
promoter I
suggests O
that O
the O
factors O
we O
detected O
, O
or O
related O
factors O
that O
recognize O
these O
sites O
, O
may O
account O
for O
the O
coordinate O
induction O
of O
these O
genes O
during O
T O
- O
cell O
activation O
. O

The O
presence O
of O
CLE0 B
- I
like I
elements I
in O
the O
promoters B
of O
interleukin B
- I
3 I
( I
IL I
- I
3 I
) I
, I
IL I
- I
4 I
, I
IL I
- I
5 I
, I
GM I
- I
CSF I
, I
and I
NFAT I
sites I
in O
the O
IL B
- I
2 I
promoter I
suggests O
that O
the O
factors O
we O
detected O
, O
or O
related O
factors O
that O
recognize O
these O
sites O
, O
may O
account O
for O
the O
coordinate O
induction O
of O
these O
genes O
during O
T O
- O
cell O
activation O
. O

Identification O
and O
characterization O
of O
an O
Alu B
- I
containing I
, I
T I
- I
cell I
- I
specific I
enhancer I
located O
in O
the O
last O
intron B
of O
the O
human B
CD8 I
alpha I
gene I
. O

Expression O
of O
the O
human B
CD8 I
alpha I
gene I
is O
restricted O
to O
cells O
of O
the O
lymphoid O
lineage O
and O
developmentally O
regulated O
during O
thymopoiesis O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
the O
human B
CD8 I
alpha I
gene I
is O
regulated O
by O
the O
interaction O
of O
multiple O
T B
- I
cell I
nuclear I
proteins I
with O
a O
transcriptional O
enhancer O
located O
in O
the O
last O
intron B
of O
the O
gene O
. O

Comparison O
of O
the O
CD8 B
alpha I
enhancer I
with O
other O
recently O
identified O
T B
- I
cell I
- I
specific I
regulatory I
elements I
suggests O
that O
a O
common O
set O
of O
transcription B
factors I
regulates O
several O
T B
- I
cell I
genes I
. O

We O
have O
now O
identified O
DNA B
sequences I
that O
are O
required O
for O
T O
cell O
- O
restricted O
IL B
- I
3 I
gene I
transcription O
. O

A O
series O
of O
transient O
transfections O
performed O
with O
human B
IL I
- I
3 I
- I
chloramphenicol I
acetyltransferase I
( I
CAT I
) I
reporter I
plasmids I
in O
T O
and O
non O
- O
T O
cells O
revealed O
that O
a O
plasmid B
containing O
319 O
bp O
of O
5 B
' I
flanking I
sequences I
was O
active O
exclusively O
in O
T O
cells O
. O

Deletion O
analysis O
revealed O
that O
T O
cell O
specificity O
was O
conferred O
by O
a O
49 B
- I
bp I
fragment I
( O
bp B
- I
319 I
to I
- I
270 I
) O
that O
included O
a O
potential B
binding I
site I
for O
AP B
- I
1 I
transcription I
factors I
6 O
bp O
upstream O
of O
a O
binding B
site I
for I
Elf I
- I
1 I
, O
a O
member O
of O
the O
Ets B
family I
of O
transcription B
factors I
. O

DNaseI B
footprint O
and O
electrophoretic O
mobility O
shift O
assay O
analyses O
performed O
with O
MLA O
- O
144 O
T O
cell O
nuclear O
extracts O
demonstrated O
that O
this O
49 B
- I
bp I
region I
contains O
a O
nuclear B
protein I
binding I
region I
that O
includes O
consensus B
AP I
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
. O

DNaseI B
footprint O
and O
electrophoretic O
mobility O
shift O
assay O
analyses O
performed O
with O
MLA O
- O
144 O
T O
cell O
nuclear O
extracts O
demonstrated O
that O
this O
49 B
- I
bp I
region I
contains O
a O
nuclear B
protein I
binding I
region I
that O
includes O
consensus B
AP I
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
. O

In O
vitro O
- O
transcribed O
and O
- O
translated O
Elf B
- I
1 I
protein I
bound O
specifically O
to O
the O
Elf B
- I
1 I
site I
, O
and O
Elf O
- O
1 O
antisera O
competed O
and O
super O
shifted O
nuclear O
protein O
complexes O
present O
in O
MLA O
- O
144 O
nuclear O
extracts O
. O

In O
vitro O
- O
transcribed O
and O
- O
translated O
Elf B
- I
1 I
protein I
bound O
specifically O
to O
the O
Elf B
- I
1 I
site I
, O
and O
Elf O
- O
1 O
antisera O
competed O
and O
super O
shifted O
nuclear O
protein O
complexes O
present O
in O
MLA O
- O
144 O
nuclear O
extracts O
. O

Transient O
transfection O
studies O
in O
MLA O
- O
144 O
T O
cells O
revealed O
that O
constructs O
containing O
mutations O
in O
the O
AP B
- I
1 I
site I
almost O
completely O
abolished O
CAT O
activity O
while O
mutation O
of O
the O
Elf B
- I
1 I
site I
or O
the O
NF B
- I
IL I
- I
3 I
site I
, O
a O
previously O
described O
nuclear B
protein I
binding I
site I
( O
bp B
. I
- I
155 I
to I
- I
148 I
) O
in O
the O
IL B
- I
3 I
promoter I
, O
reduced O
CAT O
activity O
to O
< O
25 O
% O
of O
the O
activity O
given O
by O
wild O
- O
type O
constructs O
. O

Transient O
transfection O
studies O
in O
MLA O
- O
144 O
T O
cells O
revealed O
that O
constructs O
containing O
mutations O
in O
the O
AP B
- I
1 I
site I
almost O
completely O
abolished O
CAT O
activity O
while O
mutation O
of O
the O
Elf B
- I
1 I
site I
or O
the O
NF B
- I
IL I
- I
3 I
site I
, O
a O
previously O
described O
nuclear B
protein I
binding I
site I
( O
bp B
. I
- I
155 I
to I
- I
148 I
) O
in O
the O
IL B
- I
3 I
promoter I
, O
reduced O
CAT O
activity O
to O
< O
25 O
% O
of O
the O
activity O
given O
by O
wild O
- O
type O
constructs O
. O

Transient O
transfection O
studies O
in O
MLA O
- O
144 O
T O
cells O
revealed O
that O
constructs O
containing O
mutations O
in O
the O
AP B
- I
1 I
site I
almost O
completely O
abolished O
CAT O
activity O
while O
mutation O
of O
the O
Elf B
- I
1 I
site I
or O
the O
NF B
- I
IL I
- I
3 I
site I
, O
a O
previously O
described O
nuclear B
protein I
binding I
site I
( O
bp B
. I
- I
155 I
to I
- I
148 I
) O
in O
the O
IL B
- I
3 I
promoter I
, O
reduced O
CAT O
activity O
to O
< O
25 O
% O
of O
the O
activity O
given O
by O
wild O
- O
type O
constructs O
. O

Transient O
transfection O
studies O
in O
MLA O
- O
144 O
T O
cells O
revealed O
that O
constructs O
containing O
mutations O
in O
the O
AP B
- I
1 I
site I
almost O
completely O
abolished O
CAT O
activity O
while O
mutation O
of O
the O
Elf B
- I
1 I
site I
or O
the O
NF B
- I
IL I
- I
3 I
site I
, O
a O
previously O
described O
nuclear B
protein I
binding I
site I
( O
bp B
. I
- I
155 I
to I
- I
148 I
) O
in O
the O
IL B
- I
3 I
promoter I
, O
reduced O
CAT O
activity O
to O
< O
25 O
% O
of O
the O
activity O
given O
by O
wild O
- O
type O
constructs O
. O

We O
conclude O
that O
expression O
of O
the O
human B
IL I
- I
3 I
gene I
requires O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
; O
however O
, O
unlike O
other O
previously O
characterized O
cytokine B
genes I
such O
as O
IL B
- I
2 I
, O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
factors I
can O
bind O
independently O
in O
the O
IL B
- I
3 I
gene I
. O

Characterization O
of O
the O
human B
CD4 I
gene I
promoter I
: O
transcription O
from O
the O
CD4 B
gene I
core I
promoter I
is O
tissue O
- O
specific O
and O
is O
activated O
by O
Ets B
proteins I
. O

Characterization O
of O
the O
human B
CD4 I
gene I
promoter I
: O
transcription O
from O
the O
CD4 B
gene I
core I
promoter I
is O
tissue O
- O
specific O
and O
is O
activated O
by O
Ets B
proteins I
. O

We O
located O
the O
transcription B
initiation I
site I
and O
showed O
that O
the O
CD4 B
core I
promoter I
( O
positions B
- I
40 I
to I
+ I
16 I
) O
lacks O
a O
classical O
` O
` O
TATA O
' O
' O
or O
initiator B
positioning I
consensus I
sequence I
but O
directs O
precise O
and O
efficient O
transcription O
when O
coupled O
to O
the O
ubiquitously O
active O
simian B
virus I
40 I
enhancer I
. O

We O
located O
the O
transcription B
initiation I
site I
and O
showed O
that O
the O
CD4 B
core I
promoter I
( O
positions B
- I
40 I
to I
+ I
16 I
) O
lacks O
a O
classical O
` O
` O
TATA O
' O
' O
or O
initiator B
positioning I
consensus I
sequence I
but O
directs O
precise O
and O
efficient O
transcription O
when O
coupled O
to O
the O
ubiquitously O
active O
simian B
virus I
40 I
enhancer I
. O

One O
of O
these O
sequences O
contains O
a O
perfect B
ETS I
consensus I
sequence I
. O

Electrophoretic O
- O
mobility O
- O
shift O
assays O
showed O
that O
the O
core O
promoter O
ETS O
motif O
binds O
an O
Ets B
- I
related I
protein I
specifically O
expressed O
at O
high O
levels O
in O
CD4 O
+ O
cells O
. O

Pyrrolidine O
dithiocarbamate O
inhibits O
NF B
- I
kappa I
B I
mobilization O
and O
TNF O
production O
in O
human O
monocytes O
. O

Stimulation O
of O
Mono O
Mac O
6 O
cells O
with O
LPS O
will O
increase O
complex B
II I
and O
will O
strongly O
induce O
a O
second O
specific O
complex O
( O
complex B
I I
) O
, O
which O
represents O
the O
p50 B
/ I
65 I
heterodimer I
. O

Kinetic O
analyses O
show O
that O
after O
LPS O
stimulation O
, O
NF B
- I
kappa I
B I
will O
peak O
at O
1 O
h O
, O
TNF O
transcript O
prevalence O
at O
2 O
h O
, O
and O
TNF B
protein I
at O
4 O
h O
. O

Analysis O
of O
freshly O
isolated O
, O
LPS O
- O
stimulated O
blood O
monocytes O
showed O
a O
similar O
blockade O
of O
NF B
- I
kappa I
B I
. O

These O
data O
show O
that O
dithiocarbamates O
can O
profoundly O
affect O
cytokine O
expression O
and O
suggest O
that O
NF B
- I
kappa I
B I
is O
involved O
in O
LPS O
- O
induced O
TNF O
gene O
expression O
in O
human O
monocytes O
. O

These O
regions O
are O
designated O
YI B
( O
amino B
acids I
[ I
aa I
] I
1 I
to I
25 I
) O
, O
YII B
( O
aa B
51 I
to I
102 I
) O
, O
and O
YIII B
( O
aa B
228 I
to I
245 I
) O
. O

These O
regions O
are O
designated O
YI B
( O
amino B
acids I
[ I
aa I
] I
1 I
to I
25 I
) O
, O
YII B
( O
aa B
51 I
to I
102 I
) O
, O
and O
YIII B
( O
aa B
228 I
to I
245 I
) O
. O

However O
, O
when O
fused O
to O
the O
DNA B
binding I
domain I
of O
GAL B
4 O
and O
assayed O
on O
GAL4 B
binding I
sites I
, O
regions B
YII I
and I
YIII I
were O
each O
sufficient O
to O
confer O
activation O
in O
S O
. O
cerevisiae O
. O

The O
amino B
- I
terminal I
region I
of O
ZEBRA B
( O
aa B
1 I
to I
98 I
) O
was O
required O
for O
activation O
both O
in O
S O
. O
cerevisiae O
and O
in O
human O
B O
cells O
; O
deletion O
of O
the O
carboxy B
- I
terminal I
18 I
aa I
also O
significantly O
reduced O
activation O
in O
both O
cell O
types O
. O

The O
amino B
- I
terminal I
region I
of O
ZEBRA B
( O
aa B
1 I
to I
98 I
) O
was O
required O
for O
activation O
both O
in O
S O
. O
cerevisiae O
and O
in O
human O
B O
cells O
; O
deletion O
of O
the O
carboxy B
- I
terminal I
18 I
aa I
also O
significantly O
reduced O
activation O
in O
both O
cell O
types O
. O

However O
, O
certain O
deletion B
mutants I
of O
ZEBRA B
containing O
mutations O
in O
the O
N B
- I
terminal I
region I
exhibited O
discordant O
behaviors O
in O
S O
. O
cerevisiae O
and O
in O
B O
cells O
. O

Functional O
interaction O
of O
the O
v B
- I
Rel I
and I
c I
- I
Rel I
oncoproteins I
with O
the O
TATA B
- I
binding I
protein I
and O
association O
with O
transcription B
factor I
IIB I
. O

Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation O
domain O
mapping O
to O
the O
unique O
C B
terminus I
of O
chicken B
c I
- I
Rel I
and O
the O
F9 B
cell I
- I
specific I
activation I
region I
common O
to O
both O
v B
- I
Rel I
and O
c B
- I
Rel I
interact O
with O
the O
TATA B
- I
binding I
protein I
( O
TBP B
) O
and O
transcription B
factor I
IIB I
( O
TFIIB B
) O
in O
vitro O
and O
in O
vivo O
. O

Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation O
domain O
mapping O
to O
the O
unique O
C B
terminus I
of O
chicken B
c I
- I
Rel I
and O
the O
F9 B
cell I
- I
specific I
activation I
region I
common O
to O
both O
v B
- I
Rel I
and O
c B
- I
Rel I
interact O
with O
the O
TATA B
- I
binding I
protein I
( O
TBP B
) O
and O
transcription B
factor I
IIB I
( O
TFIIB B
) O
in O
vitro O
and O
in O
vivo O
. O

In O
T O
lymphocytes O
, O
triggering O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
induces O
several O
signaling O
cascades O
which O
ultimately O
synergize O
to O
induce O
the O
activity O
of O
the O
nuclear B
factor I
of O
activated O
T O
cells O
( O
NFAT O
) O
, O
a O
DNA B
binding I
complex I
critical O
to O
the O
inducibility O
and O
T O
cell O
specificity O
of O
the O
T B
cell I
growth I
factor I
interleukin B
2 I
. O

A O
second O
important O
molecule O
in O
TCR O
signal O
transduction O
is O
the O
guanine B
nucleotide I
binding I
protein I
, O
p21ras B
, O
which O
is O
coupled O
to O
the O
TCR B
by O
a O
protein B
tyrosine I
kinase I
dependent O
mechanism O
. O

Expression O
of O
the O
chicken B
GATA I
factor I
family I
during O
early O
erythroid O
development O
and O
differentiation O
. O

The O
DNA O
motif O
WGATAR O
has O
been O
identified O
within O
transcriptional B
regulatory I
domains I
of O
globin B
and O
other O
erythroid B
- I
specific I
genes I
and O
the O
activator B
proteins I
that O
bind O
to O
this O
regulatory B
element I
, O
the O
GATA B
factors I
, O
belong O
to O
a O
multi B
- I
gene I
family I
that O
is O
expressed O
in O
chicken O
erythroid O
cells O
. O

The O
DNA O
motif O
WGATAR O
has O
been O
identified O
within O
transcriptional B
regulatory I
domains I
of O
globin B
and O
other O
erythroid B
- I
specific I
genes I
and O
the O
activator B
proteins I
that O
bind O
to O
this O
regulatory B
element I
, O
the O
GATA B
factors I
, O
belong O
to O
a O
multi B
- I
gene I
family I
that O
is O
expressed O
in O
chicken O
erythroid O
cells O
. O

IL B
- I
4 I
suppressed O
IL O
- O
2 O
and O
IFN O
- O
gamma O
mRNA O
levels O
in O
primary O
human O
T O
cells O
, O
and O
addition O
of O
anti B
- I
CD28 I
antibodies I
relieved O
this O
suppression O
. O

Using O
enhancer B
- I
reporter I
constructs I
, O
IL B
- I
4 I
specifically O
down O
- O
regulated O
the O
NFIL B
- I
2B I
element I
. O

Using O
enhancer B
- I
reporter I
constructs I
, O
IL B
- I
4 I
specifically O
down O
- O
regulated O
the O
NFIL B
- I
2B I
element I
. O

Electrophoretic O
mobility O
shift O
assays O
using O
a O
DNA O
oligomer O
containing O
the O
NFIL B
- I
2B I
binding I
site I
indicated O
that O
IL B
- I
4 I
inhibited O
the O
NFIL B
- I
2B I
complex I
and O
that O
the O
NFIL B
- I
2B I
DNA I
binding I
factor I
is O
distinct O
from O
AP B
- I
1 O
. O

Immunochemical O
differences O
between O
glucocorticoid B
receptors I
from O
corticoid O
- O
sensitive O
and O
- O
resistant O
malignant O
lymphocytes O
. O

For O
this O
purpose O
, O
purified B
immune I
immunoglobulin I
G I
was O
covalently O
linked O
to O
Sepharose B
CL I
- I
4B I
. O

For O
this O
purpose O
, O
purified B
immune I
immunoglobulin I
G I
was O
covalently O
linked O
to O
Sepharose B
CL I
- I
4B I
. O

Therefore O
, O
under O
appropriate O
experimental O
conditions O
, O
it O
was O
possible O
to O
demonstrate O
cross O
- O
reactivity O
between O
the O
antiserum O
against O
rat B
liver I
glucocorticoid I
receptor I
and O
the O
58 O
- O
to O
62 O
- O
A O
( O
Stokes O
radius O
) O
glucocorticoid B
receptor I
from O
species O
as O
diverse O
as O
mouse O
and O
humans O
. O

The O
cytoplasmic B
cortisol I
binding I
protein I
has O
a O
molecular O
weight O
95 O
000 O
and O
the O
soluble B
nuclear I
binding I
protein I
50 O
000 O
. O

The O
cytoplasmic B
cortisol I
binding I
protein I
has O
a O
molecular O
weight O
95 O
000 O
and O
the O
soluble B
nuclear I
binding I
protein I
50 O
000 O
. O

Inhibition O
of O
protein B
kinase I
A I
by O
H89 O
reduced O
IL B
- I
6 I
mRNA I
levels O
but O
did O
not O
detectably O
change O
IL O
- O
1 O
beta O
or O
TNF O
- O
alpha O
mRNA O
levels O
. O

In O
contrast O
, O
LPS O
did O
not O
increase O
leukemia B
inhibitory I
factor I
mRNA I
, O
which O
was O
constitutively O
expressed O
and O
not O
significantly O
reduced O
by O
these O
inhibitors O
. O

Both O
PTK O
inhibitors O
also O
reduced O
the O
LPS O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
which O
is O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
cytokine B
genes I
such O
as O
IL B
- I
6 I
and O
TNF B
- I
alpha I
. O

The O
activation O
of O
NF B
- I
kappa I
B I
was O
also O
reduced O
by O
H89 O
, O
whereas O
staurosporine O
had O
no O
effect O
on O
this O
response O
. O

In O
summary O
, O
these O
findings O
suggest O
that O
protein B
kinase I
C I
and O
protein B
kinase I
A I
appear O
to O
have O
selective O
effects O
in O
the O
LPS O
induction O
of O
cytokines B
, O
whereas O
PTK B
is O
required O
for O
LPS O
induction O
of O
a O
broad O
spectrum O
of O
cytokines B
and O
NF B
- I
kappa I
B I
activation O
in O
monocytes O
. O

In O
vivo O
control O
of O
NF B
- I
kappa I
B I
activation O
by O
I B
kappa I
B I
alpha I
. O

In O
vivo O
control O
of O
NF B
- I
kappa I
B I
activation O
by O
I B
kappa I
B I
alpha I
. O

The O
transcription B
factor I
NF B
- I
kappa I
B I
is O
stored O
in O
the O
cytoplasm O
in O
complexes O
with O
the O
inhibitor B
protein I
I I
kappa I
B I
alpha I
. O

It O
has O
been O
shown O
in O
vitro O
that O
dissociation O
of O
I B
kappa I
B I
alpha I
from O
these O
complexes O
results O
in O
active B
NF I
- I
kappa I
B I
. O

In O
this O
report O
we O
show O
that O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
activation O
of O
B O
or O
pre O
- O
B O
cells O
results O
in O
loss O
of O
I B
kappa I
B I
alpha I
from O
NF B
- I
kappa I
B I
complexes I
in O
vivo O
. O

Some O
liberated B
dimers I
were O
retained O
in O
the O
cytoplasm O
, O
however O
, O
through O
binding O
to O
newly O
synthesized O
I B
kappa I
B I
alpha I
, O
a O
finding O
which O
strongly O
suggests O
( O
i O
) O
that O
the O
LPS O
- O
induced O
signal O
causes O
dissociation O
of O
complexes O
rather O
than O
preventing O
their O
association O
and O
( O
ii O
) O
that O
dissociation O
results O
from O
modification O
of O
I B
kappa I
B I
alpha I
and O
not O
of O
c B
- I
rel I
or O
p65 B
. O

Some O
liberated B
dimers I
were O
retained O
in O
the O
cytoplasm O
, O
however O
, O
through O
binding O
to O
newly O
synthesized O
I B
kappa I
B I
alpha I
, O
a O
finding O
which O
strongly O
suggests O
( O
i O
) O
that O
the O
LPS O
- O
induced O
signal O
causes O
dissociation O
of O
complexes O
rather O
than O
preventing O
their O
association O
and O
( O
ii O
) O
that O
dissociation O
results O
from O
modification O
of O
I B
kappa I
B I
alpha I
and O
not O
of O
c B
- I
rel I
or O
p65 B
. O

We O
propose O
that O
this O
turnover O
results O
in O
the O
low O
level O
of O
active B
NF I
- I
kappa I
B I
presumably O
necessary O
even O
in O
the O
unstimulated O
cell O
, O
and O
that O
the O
high O
rate O
of O
synthesis O
of O
I B
kappa I
B I
alpha I
provides O
the O
ability O
to O
turn O
off O
NF B
- I
kappa I
B I
activity O
rapidly O
as O
soon O
as O
the O
activating O
signal O
ceases O
. O

We O
propose O
that O
this O
turnover O
results O
in O
the O
low O
level O
of O
active B
NF I
- I
kappa I
B I
presumably O
necessary O
even O
in O
the O
unstimulated O
cell O
, O
and O
that O
the O
high O
rate O
of O
synthesis O
of O
I B
kappa I
B I
alpha I
provides O
the O
ability O
to O
turn O
off O
NF B
- I
kappa I
B I
activity O
rapidly O
as O
soon O
as O
the O
activating O
signal O
ceases O
. O

Identification O
of O
a O
killer B
cell I
- I
specific I
regulatory I
element I
of O
the O
mouse B
perforin I
gene I
: O
an O
Ets O
- O
binding O
site O
- O
homologous O
motif O
that O
interacts O
with O
Ets B
- I
related I
proteins I
. O

Electrophoretic O
mobility O
shift O
assay O
and O
UV O
cross O
- O
linking O
experiments O
revealed O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
may O
possess O
common O
DNA B
- I
binding I
subunits I
. O

In O
view O
of O
the O
homology O
between O
the O
NF B
- I
P I
motif I
and O
other O
Ets B
proto I
- I
oncoprotein I
- I
binding I
sites I
, O
it O
is O
postulated O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
belong O
to O
the O
Ets B
protein I
family I
. O

To O
evaluate O
the O
role O
of O
NF B
- I
kappa I
B I
in O
human O
peripheral O
blood O
T O
- O
lymphocytes O
, O
we O
previously O
analyzed O
the O
activation O
of O
NF B
- I
kappa I
B I
- I
related I
complexes I
in O
response O
to O
CD2 O
+ O
CD28 O
costimulation O
. O

We O
demonstrated O
a O
long O
- O
term O
induction O
of O
p50 B
/ I
p65 I
heterodimer I
, O
a O
putative B
p65 I
/ I
c I
- I
Rel I
heterodimer I
, O
and O
a O
constitutive O
nuclear O
expression O
of O
KBF1 B
/ I
p50 I
homodimers I
. I

As O
the O
role O
of O
p50 B
remains O
unclear O
, O
we O
focused O
our O
present O
study O
on O
NF B
- I
kappa I
B1 I
( O
p50 B
/ I
p105 I
) O
gene O
regulation O
. O

Partial O
inhibition O
of O
p50 O
and O
p105 O
expression O
by O
NF B
- I
kappa I
B1 I
antisense O
oligonucleotides O
significantly O
reduced O
T O
- O
cell O
proliferation O
and O
CD25 B
/ I
IL I
- I
2R I
alpha I
cell O
surface O
expression O
. O

Reactive O
oxygen O
intermediates O
activate O
NF B
- I
kappa I
B I
in O
a O
tyrosine O
kinase O
- O
dependent O
mechanism O
and O
in O
combination O
with O
vanadate O
activate O
the O
p56lck B
and I
p59fyn I
tyrosine I
kinases I
in O
human O
lymphocytes O
. O

We O
now O
provide O
evidence O
that O
the O
tyrosine O
kinase O
inhibitor O
herbimycin O
A O
and O
the O
free O
radical O
scavenger O
N O
- O
acetyl O
- O
cysteine O
inhibit O
both O
radiation O
- O
induced O
and O
H2O2 O
- O
induced O
activation O
of O
NF B
- I
kappa I
B I
, O
indicating O
that O
activation O
triggered O
by O
ROI O
is O
dependent O
on O
tyrosine O
kinase O
activity O
. O

The O
influence O
of O
human B
serum I
albumin I
and O
sex B
hormone I
binding I
globulin I
( O
SHBG B
) O
on O
the O
enzymic O
conversion O
of O
androstenedione O
to O
testosterone O
in O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O

A O
reliable O
procedure O
is O
described O
for O
isolating O
3H B
- I
triamcinolone I
acetonide I
( I
3H I
- I
TA I
) I
receptor I
complexes I
from O
purified O
chronic O
lymphatic O
leukemia O
( O
CLL O
) O
lymphocyte O
nuclei O
, O
based O
on O
the O
use O
of O
carbobenzoxy O
- O
L O
- O
phenylalanine O
( O
CBZ O
- O
L O
- O
phe O
) O
to O
prevent O
breakdown O
of O
hormone B
- I
receptor I
complexes I
during O
extraction O
of O
nuclei O
with O
0 O
. O
6M O
KCl O
. O

Among O
them O
are O
four O
purine O
boxes O
which O
have O
been O
described O
to O
be O
important O
sequence O
motifs O
of O
the O
Il B
- I
2 I
promoter I
. O

Several O
purine O
boxes O
and O
an O
AT B
- I
rich I
protein I
- I
binding I
site I
of O
the O
Il O
- O
4 O
promoter O
are O
also O
recognized O
by O
the O
high B
mobility I
group I
protein I
HMG B
I I
( I
Y I
) O
. O

Several O
purine O
boxes O
and O
an O
AT B
- I
rich I
protein I
- I
binding I
site I
of O
the O
Il O
- O
4 O
promoter O
are O
also O
recognized O
by O
the O
high B
mobility I
group I
protein I
HMG B
I I
( I
Y I
) O
. O

Whereas O
the O
binding O
of O
NFAT B
- I
1 I
and O
Octamer B
factors I
enhance O
the O
activity O
of O
the O
Il B
- I
4 I
promoter I
, O
the O
binding O
of O
HMG O
I O
( O
Y O
) O
suppresses O
its O
activity O
and O
, O
therefore O
, O
appears O
to O
be O
involved O
in O
the O
suppression O
of O
Il B
- I
4 I
transcription O
in O
resting O
T O
lymphocytes O
. O

Phosphatidylcholine O
hydrolysis O
activates O
NF B
- I
kappa I
B I
and O
increases O
human O
immunodeficiency O
virus O
replication O
in O
human O
monocytes O
and O
T O
lymphocytes O
. O

We O
have O
tested O
whether O
breakdown O
of O
phosphatidylcholine O
( O
PC O
) O
initiated O
by O
exogenous O
addition O
of O
a O
PC B
- I
specific I
phospholipase I
C I
( O
PC B
- I
PLC I
) O
from O
Bacillus O
cereus O
or O
by O
endogenous O
overexpression O
of O
PC B
- I
PLC I
induces O
functional O
activation O
of O
NF B
- I
kappa I
B I
and O
increases O
human B
immunodeficiency I
virus I
( I
HIV I
) I
enhancer I
activity O
. O

Induction O
of O
NF B
- I
kappa I
B I
by O
PC B
- I
PLC I
did O
not O
depend O
on O
de O
novo O
synthesis O
of O
proteins O
or O
autocrine O
secretion O
of O
either O
tumor B
necrosis I
factor I
or O
interleukin B
1 I
. O

In O
human O
monocytic O
and O
lymphoblastoid O
T O
- O
cell O
lines O
, O
induction O
of O
NF B
- I
kappa I
B I
by O
PC B
- I
PLC I
resulted O
in O
clear O
induction O
of O
luciferase B
expression O
vectors O
placed O
under O
the O
control O
of O
synthetic B
kappa I
B I
enhancers I
or O
wild O
type O
, O
but O
not O
kappa O
B O
- O
mutated O
, O
HIV B
long I
terminal I
repeat I
constructs I
. O

In O
human O
monocytic O
and O
lymphoblastoid O
T O
- O
cell O
lines O
, O
induction O
of O
NF B
- I
kappa I
B I
by O
PC B
- I
PLC I
resulted O
in O
clear O
induction O
of O
luciferase B
expression O
vectors O
placed O
under O
the O
control O
of O
synthetic B
kappa I
B I
enhancers I
or O
wild O
type O
, O
but O
not O
kappa O
B O
- O
mutated O
, O
HIV B
long I
terminal I
repeat I
constructs I
. O

NF O
- O
kappa O
B O
activation O
promoted O
by O
addition O
of O
exogenous B
PC I
- I
PLC I
correlated O
with O
an O
intense O
production O
of O
diacylglycerol O
. O

However O
, O
addition O
of O
a O
phosphatidylinositol B
- I
specific I
PLC I
from O
B O
. O
cereus O
also O
induced O
diacylglycerol O
but O
did O
not O
activate O
kappa B
B I
enhancer I
- I
directed I
vectors I
. O

Glucocorticoids O
inhibit O
signal O
transduction O
through O
IL B
- I
2 I
receptor I
. O

Inhibition O
of O
T O
cell O
proliferation O
by O
Dex O
was O
associated O
with O
decreased O
IL O
- O
2 O
- O
dependent O
tyrosine O
phosphorylation O
of O
several O
intracellular B
proteins I
and O
decreased O
phosphorylation O
of O
the O
retinoblastoma B
gene I
product I
Rb I
, O
a O
protein O
essential O
for O
controlling O
the O
progression O
of O
cells O
through O
the O
cell O
cycle O
. O

PLB O
- O
IIIB O
cells O
displayed O
a O
constitutive O
NF O
- O
kappa O
B O
- O
like O
binding O
activity O
that O
was O
distinct O
from O
that O
induced O
by O
tumor B
necrosis I
factor I
alpha I
or O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
treatment O
of O
the O
parental O
PLB O
- O
985 O
cell O
line O
. O

The O
70 B
- I
kDa I
protein I
corresponds O
to O
the O
NF B
- I
kappa I
B I
RelA I
( I
p65 I
) I
subunit I
, O
which O
is O
activated O
in O
response O
to O
an O
acute O
paramyxovirus O
infection O
or O
a O
chronic O
HIV O
- O
1 O
infection O
. O

Virus O
infection O
does O
not O
appear O
to O
alter O
the O
amount O
of O
RelA B
( O
p65 B
) O
or O
NFKB1 B
( O
p50 B
) O
but O
rather O
affects O
the O
capacity O
of O
I B
kappa I
B I
alpha I
to O
sequester O
RelA B
( I
p65 I
) I
, O
therefore O
leading O
to O
constitutive O
levels O
of O
RelA O
DNA O
binding O
activity O
and O
to O
increased O
levels O
of O
NF O
- O
kappa O
B O
- O
dependent O
gene O
activity O
. O

Virus O
infection O
does O
not O
appear O
to O
alter O
the O
amount O
of O
RelA B
( O
p65 B
) O
or O
NFKB1 B
( O
p50 B
) O
but O
rather O
affects O
the O
capacity O
of O
I B
kappa I
B I
alpha I
to O
sequester O
RelA B
( I
p65 I
) I
, O
therefore O
leading O
to O
constitutive O
levels O
of O
RelA O
DNA O
binding O
activity O
and O
to O
increased O
levels O
of O
NF O
- O
kappa O
B O
- O
dependent O
gene O
activity O
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

To O
determine O
what O
type O
of O
synovial O
cell O
was O
positive O
for O
EBS O
, O
cryosections O
of O
synovial O
tissues O
were O
immunostained O
with O
a O
specific O
monoclonal B
anti I
- I
estrogen I
receptor I
antibody I
( O
anti B
- I
ER I
MAb I
) O
using O
both O
immunofluorescence O
and O
immunoperoxidase O
techniques O
. O

Double O
immunostaining O
with O
the O
anti B
- I
ER I
MAb I
and O
with O
specific B
MAb I
to O
detect O
different O
macrophage B
antigens I
( O
Ber B
- I
MAC3 I
, O
MAC387 B
, O
CD68 B
) O
and O
CD8 O
+ O
T O
cell O
subsets O
( O
CD29 O
+ O
, O
CD45RO O
+ O
and O
CD29 O
- O
, O
CD45RO O
- O
) O
was O
performed O
. O

